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Aldosterone influences the kidney’s normal regulation of blood pressure (BP), but if 
consistently elevated, aldosterone may contribute to hypertension. BP is decreased
with aerobic exercise training (AEX), but the extent to which plasma aldosterone 
(PA) levels change is unclear. The CYP11B2 -344C/T polymorphism has been 
associated with hypertension and may contribute to the change in BP and PA with 
AEX. The purpose of this tudy was to determine if 6 months of AEX changed PA 
levels, 24-hour Na+ excretion and BP in middle-aged to older prehypertensives, and 
whether the -344C/T polymorphism was associated with changes in these primary 
outcome variables. Forty (23 Caucasians, 14 African descents (AD), 2 Asian/Pacific 
Islanders and 1 of other ethnicity) disease free sedentary prehypertensives completed 
AEX. All participants followed the AHA Step I diet. Blood samples were collected 
under fasting and supine conditions and PA was measured by RIA. In the total 
sample, PA levels decreased after AEX (p=0.04). The reduction in PA levels in 
Caucasians (-37±15 pg/ml, p=0.02) tended to be greater (p=0.07) than the reduction 
in PA levels in AD (-2±8 pg/ml, p=0.77). Among AD, PA levels tended to decrease 
when controlling for baseline PA levels (p=0.09). The change in systolic BP(SBP) in 
Caucasians (-3±1 mm Hg, p=0.05) was significantly different (p=0.03) than the 
change in SBP in AD (4±3, p=0.28). In the AD, 24-hour Na+ excretion tended to 
increase when controlling for baseline 24-hour Na+ excretion (p=0.06). Among the 
Caucasians, the TC+CC genotype group tended to decrease PA levels (-39±21 pg/ml, 
p=0.09) and significantly decreased SBP (-4±2 pg/ml, p=0.03). Among AD, the TT 
genotype group significantly decreased PA levels when controlling for baseline PA 
levels (-17±7 pg/ml, p=0.04). The AD TC+CC genotype group tended to increase 
SBP when controlling for the change in 24-hour Na+ excretion (1±2 mm Hg, 
p=0.09) and 24-hour Na+ excretion significantly increased when controlling for the 
change in BMI (14±11 mmol/d, p=0.03). BP and PA levels appear to be more 
responsive to AEX in Caucasians compared to AD. The CYP11B2 -344C/T gene 
appears to influence the responses of hypertensive phenotypes to AEX.
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Essential hypertension is a chronic disease in which the etiology is considered 
to be multifactoral and polygenic. Due to the complex pathology and the polygenic 
nature of hypertension, research has necessarily focused on multiple physiological 
mechanisms and candidate g nes to better understand the factors involved in the 
etiology of hypertension. The renin-angiotensin-aldosterone system (RAAS) has 
received significant attention because of its role in the kidney’s regulation of blood 
pressure. Components of the RAAS, such as aldosterone, have been shown to have a 
substantial influence on sodium (Na+) reabsorption within the kidney, which can lead 
to an increase in blood pressure (54). Specifically, aldosterone is released from the 
zona glomerulosa region of the adrenal cortex and acts on the collecting tubules in the 
kidney to increase Na+ reabsorption (54).
Given that aldosterone affects renal Na+ handling and consequently blood 
pressure, alterations in aldosterone biosynthesis may contribute to the development of 
hypertension. This reasoning has prompted investigation into genes that might 
influence aldosterone biosynthesis. Recently, the aldosterone synthase (AS) gene,
CYP11B2, which is expressed in the zona glomerulosa of the adrenal cortex, has been 
identified as a possible contributor to the development of hypertension because it 
codes for the enzyme AS (P450c11AS), which synthesizes aldosterone (20; 54; 161).
Polymorphisms within the CYP11B2 gene, such as the –344C/T single 
nucleotide polymorphism (SNP), may be responsible for the interindividual variation 
in aldosterone levels and may affect an individual’s susceptibility to hypertension. 
The –344C/T polymorphism is a promoter mutation that consists of a C to T 
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nucleotide substitution –344 nucleotides upstream from the start of translation (155).
The SNP resides in the Ad4 sequence, a nuclear receptor half-site that is required for 
the development and function of the adrenal glands and the region where the 
transcription factor, steroidogenic transcription factor (SF-1) binds (10; 104). It has 
been suggested that the –344C/T polymorphism may affect SF-1 binding (155), but 
there is continued debate on whether this affects gene expression (10; 20).
Recently, Henderson et al. reported that the risk of hypertension was 
associated with the T allele of the -344 C/T polymorphism in hypertensives of 
African descent (66). Similarly, Brand and colleagues found that the T allele was 
more frequent in hypertensive Caucasians compared to normotensive Caucasians (14; 
29). The T allele has also been linked to the age-associated increase in diastolic blood 
pressure (DBP) in Caucasian males (127). Despite these positive findings, other 
studies have reported no association between the -344C/T polymorphism and 
hypertension in individuals of African descent, Caucasians and Japanese (79; 150; 
163). 
In regards to ethnicity, there appears to be some differences in the –344C/T 
allele frequency. It has been reported that among those of African descent, the T 
allele has a much higher frequency than the C allele (163). In Caucasians, the 
frequency of both the T and C allele has been reported to be approximately 50%
(163). 
Based on the available evidence, the –344C/T allele association with 
aldosterone levels in the plasma and urine may differ between normotensive and 
hypertensive individuals. For example, in hypertensives, the C allele was associated 
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with greater plasma aldosterone levels and the CC genotype was associated with a 
lack of reduction in serum aldosterone levels after one week of oral Na+ loading (31; 
114). Counter to these findings, Davies et al. and Brand et al. have reported that in 
normotensives, the T allele was associated with increased urinary aldosterone 
excretion and plasma aldosterone levels (14; 29). 
Aerobic exercise training is effective in reducing blood pressure in 
hypertensive individuals (58; 59; 84; 87; 125). One possible mechanism for exercise 
training-induced reductions in blood pressure is an increase in Na+ excretion (16; 84), 
and it is possible that a reduction in plasma aldosterone levels with exercise training 
could contribute to the increase in Na+ excretion (13; 67; 86). 
Despite controlling for variables known to affect the blood pressure response 
to aerobic exercise training, there continues to be hypertensive i di iduals who 
change and other individuals who d not change their blood pressure and other 
hypertension-related phenotypes with aerobic exercise training.  Based on the 
observed interindividual variability in the blood pressure response to aerobic exercis  
training, studies have been conducted to determine the influence of common gene 
variants on the responses of hypertension-related phenotypes to aerobic exercise 
training. 
The purpose of the current study was to determine whether 6 months of 
aerobic exercise training reduced plasma aldosterone levels, increased 24-hour Na+
excretion and reduced blood pressure in middle-ag d to older prehypertensives. 
Additionally, because the CYP11B2 –344C/T polymorphism has been related to 
plasma aldosterone, Na+ handling and blood pressure it was important to investigate 
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 Participants between the ages of 50-75 years were recruited from the College 
Park, Maryland and the District of Columbia metropolitan area, via advertisements in 
newspapers, radio public service announcements, direct mail and health fairs. The 
Institutional Review Board of the University of Maryland, College Park approved the 
study. Participants underwent an initial telephone screening and were excluded from 
the study if they had a body mass index (BMI) greater than 37 kg/m2, any form of 
cardiovascular disease (CVD), liver disease, diabetes, pulmonary disease, or 
orthopedic conditions that would impair their ability to exercise. Females were 
excluded if they were not post-menopausal for more than 2 years. For who that were 
post-menopausal, they were asked to maintain their hormone replacement status for 
the entirety of the study. Potential participants on more than 2 antihypertensive 
medications were excluded. Participants in the study were required to be sedentary, 
therefore those exercising more than 2 times per week for more than 20 minutes were 
considered active and were excluded. 
Participants who met the initial study inclusion criteria provided written
informed consent and were scheduled for two screening visits. The first screening 
visit involved a 2-hour post-prandial glucose tolerance test and blood samples were 
obtained for chemistries and DNA analysis. Participants were excluded if they 
exhibited a fasting blood glucose > 126 mg/dl, or a blood glucose greater than 200 
mg/dl at 2 hours. Participants were excluded if they had a glomerular filtration rate
(GFR) < 60 ml/min/1.73 m2, which was estimated by use of the Modification of Diet 
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in Renal Disease (MDRD) equation, and serum creatinine levels >1.5 mg/dl, both 
ensured that they did not have evidence of renal disease. BMI was verified and three 
casual blood pressure measurements were taken on each arm using standard 
sphygmomanometer. Participants with an average systolic blood pressure (SBP) < 
120 or >159 mm Hg and/or diastolic blood pressure (DBP) <80 or >99 mm Hg were 
excluded from the study.
During the second screening visits, participants performed a physician 
supervised graded exercise test (Bruce protocol) to screen for CVD. ECG, blood 
pressure, and heart rate were measured before the treadmill test, at the end of each 
stage, and during the 6 minutes after the test. The test was terminated upon the onset 
of cardiovascular signs and/or symptoms, or when the participants could no longer 
continue. Subjects were included in the study if they did not exhibit any 
cardiovascular signs or symptoms and had less than 2mV ST segment depression (2). 
Dietary Stabilization/Medication Tapering
Dietary and weight changes are known to independently contribute to the 
reduction in blood pressure (9; 42; 49). In order to control for such effects, all 
participants were required to be weight stable and follow a controlled diet in order to 
determine the independent effects of aerobic exercise training on plasma aldosterone 
levels, Na+ excretion, and blood pressure. Participants attended a 6-week dietary class 
taught by a Registered Dietician two times per week. The participants followed the 
American Heart Association (AHA) Step I diet (50- 5% of calories from 
carbohydrates, 30-35 % from fat, 20-25% from protein, 350 mmol/day of cholesterol, 
and 3g/day of salt) for the entirety of the study. The participants were required to stay 
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within 5% of their study entry body weight throughout the study. The participants 
completed a 7-day food record to ensure that they adhered to the diet. Participant’s 
diet records were analyzed by the dietician using the Nutritionist IV software. 
Participants using antihypertensive medications were tapered off of their 
medications during the 6-week dietary period with written approval from their 
personal physician. Participants needed to maintain their blood pressure between 120-
159/80-99 mm Hg to be included in the study. Participants with SBP < 120 or >159 
mm Hg and/or DBP <80 or >99 mm Hg consistently during the 6-week dietary period 
were excluded from the study.
Baseline Testing
Casual Blood Pressure Measurement: Casual blood pressure was measured in 
all participants on three separate days ccording to the JNC VII guidelines (19). The 
average of the casual blood pressure measurements recorded on separate baseline 
testing days was the primary outcome variable used in the data analysis. In the event 
that casual blood pressure measurements were only obtained on two separate baseline 
testing days, these values were averaged and used as the primary outcome variable in 
the data analysis. 
24-hour Urine Collection: Participants underwent urine collection to measure 
24-hour Na+ and potassium (K+) excretion. The participants were given 2 urine 
collection bottles in which to collect their urine over the 24-hour period, starting the 
morning they picked up the containers (7am-9am) and ending after their first 
urination of the morning. They were also given a cooler filled with ice to keep the 
urine cold. Participants returned the urine containers the following morning. The 
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urine was processed at the University of Maryland, College Park, Hypertension and 
Exercise Physiology Laboratory and sent to Quest Diagnostic Laboratories for 
analysis of  Na+ and K+  excretion (CLIA L icense 21D0218877 ).  
Maximal Oxygen Consumption (VO2max): To develop an exercise 
prescription specific for each participant and to assess their cardiovascular fitness, 
participants performed a physician supervised VO2max test. Participants began 
exercising on a treadmill at an intensity equivalent to 70% of the peak heart rate they 
achieved during their screening exercise test. Participants were fitted with a 
mouthpiece and a nose clip in order to collect the expired air necessary to measure 
oxygen consumption. The grade was increased 2% every 2 minutes, and ECG, heart 
rate and blood pressure was measured every 2 minutes and after the test. The test was 
stopped when participants could no longer continue or upon onset of cardiovascular 
signs and/or symptoms (2). Oxygen uptake was measured using a computerized on-
line VO2 system including a gas analyzer (Mass Spectrometer MGA-1100, Marquette 
Electronics Inc., Milwaukee, WI) and a bi-directional turbine flow meter (Ventilation 
Measurement Module VMM-2, Interface Associates, Aliso Viejo, CA). VO2maxwas 
measured continuously, and in order to ensure that a true VO2max two of the three 
criteriawere met (RER > 1.1, HR > [220-age], and <150 ml/min increase in VO2
during the last two minutes of the test).    
Body composition: Changes in percent body fat may act as a confounding 
variable when measuring the independent effect of exercise training on blood 
pressure, plasma aldosterone andNa+ excretion (9; 46-49; 78; 129). Therefore, dual 
energy X-ray absorptiometry (DEXA) was used to assess any body composition 
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changes that occurred during the 6-month aerobic exercise training period. Fat mass 
and fat free mass were measured. Participants were instructed to fast for 12 hours 
prior to the start of the test.
Measurement of Aldosterone:  Blood samples for the measurement of plasma 
aldosterone were collected before the start of the oral glucose tolerance test (OGTT). 
Participants were instructed to undergo a 12-hour fast prior to blood sample collection 
and to exclude all ibuprofen and antihistamines 48 hours before the OGTT (17). The 
aldosterone samples were collected while the participant was supine for 15-20 
minutes (142). Blood samples were collected in EDTA tubes and centrifuged at 3000 
rpm for 20 minutes at 4°C, and the plasma was aliquoted into 1.5 ml microtubes and 
stored at –20°C (85) . Radioimmunoassay was u ed to measure plasma aldosterone 
levels (125I Coat-A-Count Aldosterone kit, Diagnostic Products Corporation).
Genotyping: Genotyping was performed at the Functional Genomics 
Laboratory in the Department of Kinesiology at the University of Maryland. DNA 
was extracted from whole blood samples using techniques described by Miller (101). 
DNA amplification was performed by polymerase chain reaction (PCR), with the use 
of the CYP11B2 (-344C/T) forward primer 5’- AGG-GTG-TAC- CTG- TGT-CAG-
GGC A-3’ and the CYP11B2 (344C/T) reverse primer 5’-CCT-CTC-CTT-TCT-
CCA-GGG-CTG A-3’. The PCR was performed at a denaturing temperature of 95°C 
for 5 minutes, followed by 35 cycles at 95°C for 30 seconds, 53°C for 30 seconds, 
72°C for 30 seconds and 72°C for 5 minutes. Digestion was performed with the Hae 
III enzyme, and TT homozygotes were detected at 186 base pairs (bp), CT 
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heterozygotes were detected at 186, 115, and 71 bp, and CC homozygotes were 
detected at 115 and 71 bp.
Exercise Training
Participants underwent a 6 month supervised aerobic exercise training 
intervention, which was held at the University of Maryland Wellness Research 
Laboratory. Participants exercised 3 times per week and were given a wrist heart rate 
monitor (Model 6124, Polar Electro, Canada) to monitor their prescribed heart rate. 
During the first week of exercise training, the participants exercised for 20 minutes at 
50% of heart rate reserve (HRR). Exercise duration was increased gradually by 5 
minutes per week until the participants were exercising for 40 minutes. At the 6th
week, exercise intensity was increased by 5% of their HRR every week until they 
were exercising at 70% of HRR. Seated blood pressures were measured at the 
beginning and end of each exercise session. The participants recorded their blood 
pressure, heart rate, weight, exercise intensity and duration in a logbook provided for 
them. These log books were analyzed to ensure that the participants were adhering to 
their exercise prescription. Once the participants completed the 10th week of exercise 
training, they were required to add an extra day of unsupervised exercise for 45-60 
minutes at <70% of HRR to their current exercise prescription. 
Final Testing  
Upon completion of the 6-month exercise training protocol, participants 
repeated all tests performed at baseline. This included casual blood pressure 
measurement, 24-hour urine collection, VO2max, body composition, and aldosterone 
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measurement. The participants continued exercising until all final tests were 
completed. In addition, the final tests were performed after participants provided a 7-
day food record to ensure dietary compliance, and 24-36 hours after their regular 
exercise session. 
Data Analysis
Statistical analyses were performed using SPSS (Version 11.0). A dependent
samples t-test was used to determine whether there were significant changes in 
subject characteristics with aerobic exercise training in the total study population. 
ANCOVA was performed in the total sample to determine if significant changes
occurred in the primary outcome variables (plasma aldosterone levels, 24-hour Na+
excretion and casual blood pressure) with aerobic exercise training. Variables known 
to influence the primary outcome variables were used as covariates. ANCOVA was 
also performed when ethnicity and gender were entered separately as grouping 
variables. Linear regression analyses were conducted to determine if there were 
relationships between the change values for plasma aldosterone levels, 24-hour Na+
excretion, and blood pressure.
An independentsamples t-test was performed to compare subject 
characteristics between the two ethnicities (Caucasians and individuals of African 
descent) and a dependent -test was performed within each ethnic group. ANCOVA
was performed within each ethnic group. Linear regression analyses were also 
conducted within each ethnic group to determine if there were relationships between 
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the change values for plasma aldosterone levels and 24-hour Na+ excretion, and 
casual blood pressure.
The literature has reported that the CYP11B2 -344C/T genotype and allele 
frequencies differ between Caucasians and individuals of African descent (14; 66; 
147; 163). Therefore, genetic analyses were performed separately within each ethnic 
group. A Chi-Square test was performed within each ethnic group to determine if the 
genotype distribution of the CYP11B2 –344C/T polymorphism was in Hardy-
Weinberg equilibrium. An independent t-test was performed to compare the subject 
characteristics between the TT and TC+CC genotype groups before and after aerobic 
exercise training. A dependent samples  t-test was performed within each genotype 
group to determine whether there were changes in subject characteristics with aerobic 
exercise training. ANCOVA was perfomed within each genotype group to compare 
differences in the primary outcome variables. Linear regression analyses were also 
conducted within each genotype group to determine if there were relationships 
between the change values for plasma aldosterone levels and 24-hour Na+ excretion, 
and casual blood pressure. All values are reported as means ± SE. ANCOVA results 
were reported as adjusted means. A p-value of ≤ 0.05 was considered statistically 
significant.
The variables gender, age, BMI, Na+ and K+ excretion are known to have an 
influence on plasma ldosterone levels; therefore they were used as covariates when 
measuring the effect of exercise training on plasma aldosterone levels. The variables 
plasma aldosterone, Na+ excretion and BMI are known to influence blood pressure; 
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therefore they were used as covariates when measuring the effect of exercise training 
on blood pressure. Additionally, BMI and plasma aldosterone can influence Na+
excretion, therefore they were used as covariates when investigating the effect of 
exercise on 24-hour Na+ excretion
Four separate assays were completed to measure plasma aldosterone levels in 
all of the samples. The intra-assay coefficient was 24.9% and the inter-assay 




Sixty-six participants (37 females and 29 males) with a mean age of 58±1 
years were enrolled in this study, in which 50% (n=33) were Caucasian, 42% (n=28) 
were of African descent, 3% (n=2) were Asian/Pacific Islander and 5% (n=3) were 
categorized as other thnicity. The participants were prehypertensive (SBP 131±1 
mm Hg, DBP 85±1 mm Hg), had plasma aldosterone levels (82±7 pg/ml) within the 
normal range (20-230 pg/ml) and had 24-hour Na+ excretion (112±7 mmol/d) within 
the normal range (52-380 mmol/d). Serum creatinine (1.0±0.0 mg/dl) and GFR (76±2 
ml/min/1.73 m2) were less than 1.5 mg/dl and greater than 60ml/min/1.73 m2, 
respectively, indicating normal renal function. Additionally, the participants were 
overweight (BMI 28.7±0.5 kg/m2) and unfit (VO2 max 23.9±0.6 ml/kg/min).
Of the 66 participants, 40 (22 males and 18 females) completed the 6 month 
aerobic exercise training intervention. Of those completing the aerobic exercise 
training intervention, 23 were Caucasian, 14 were individuals of African descent, 2 
were Asian/Pacific Islanders and 1 individual was categorized as other ethnicity. In 
this total group, SBP, DBP, and 24-hour Na+ excretion did not significantly change 
with aerobic exercise training, but there was a significant reduction in plasma 
aldosterone levels with aerobic exercise training (p=0.04) (Table 1). There was no 
significant change in 24-hour K+ excretion, but there was a significant reduction in 
BMI, total body fat, and body weight, and a significant increase in VO2 max with 
aerobic exercise training (Table 1). The change in plasma aldosterone levels were not 
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independently related with the training-induced changes in SBP, DBP, or 24-hour 
Na+ excretion.
Ethnicity
Both ethnic groups (African descent and Caucasian) were prehypertensive and
had normal baseline plasma aldosterone levels and 24-hour Na+ excretion (Table 2). 
The BMI and VO2 max values for each ethnic group indicated that they were 
overweight and unfit (Table 2). Individuals of African descent had baseline plasma 
aldosterone levels that were 42% lower than Caucasians (p=0.002) and baseline 24-
hour K+ excretion that was 28% lower (p=0.002) compared to Caucasians (Table 2).  
The change in plasma aldosterone levels (final vs. baseline) with aerobic 
exercise training tended to be different between the two ethnic groups (p=0.07) 
(Table 3). Final plasma aldosterone levels after aerobic exercise training also tended 
to be different between the two ethnic groups (p=0.08)(Table 2). Additionally, after 
separately controlling for final BMI and final 24-hour K+ excretion after aerobic 
exercise training, final plasma aldosterone levels after aerobic exercise training were 
significantly different between the two ethnic groups. Adjusted means for final  
plasma aldosterone levels in the two ethnic groups after aerobic exercise training, and 
after controlling for final BMI were 80±7 pg/ml in the Caucasian groupand 60±9 
pg/ml in the African descent group (p=0.03). The adjusted means for final plasma 
aldosterone levels in the two ethnic groups after aerobic exercise training, and after 
controlling for final 24-hour K+ excretion were 82±7 pg/ml in the Caucasian group
and 58±8 pg/ml in the African descent group (p=0.01). There was no difference in the 
change in 24-hour Na+ excretion between the two ethnic groups (Table 3). The 
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change in SBP was significantly different between Caucasians and individuals of 
African descent (Caucasians -3±1 mm Hg; African descent 4±3 mm Hg, p=0.03). 
After aerobic exercise training, body weight was significantly lower (p=0.02) among 
individuals of African descent compared to Caucasians (Table 2). 
Caucasian Group: The Caucasians significantly increased VO2 max and 
reduced total body fat, body weight, and BMI after 6 months of aerobic exercise 
training (Table 4). Aerobic exercise training significantly reduced plasma aldosterone 
levels and SBP (Table 4). Baseline plasma aldosterone levels were a strong predictor 
of the change in plasma aldosterone levels with aerobic exercise training (r= -0.90, 
p<0.001), with those who had the highest baseline plasma aldosterone levels 
experienced the greatest reduction in plasma aldosterone levels (Figure 1). After 
accounting for baseline plasma aldosterone levels, the reduction in plasma 
aldosterone levels with aerobic exercise training remained significant. The adjusted 
mean for the change in plasma aldosterone levels when controlling for baseline 
plasma aldosterone levels was -39±8 pg/ml (p<0.001).
Baseline SBP was a strong predictor of the change in SBP with aerobic 
exercise training (r= -0.60, p=0.01). Those with the greatest SBP at baseline had the 
greatest reduction in SBP with aerobic exercise training. There was no significant 
change in 24-hour Na+ and K+ excretion with aerobic exercise training (Table 4). The 
change in plasma aldosterone levels with aerobic exercise training were not 
independently related with the change in SBP, DBP, or 24-hour Na+ excretion in 
Caucasians.
17
African Descent Group: The individuals of African descent significantly 
increased their VO2 max with aerobic exercise training (Table 5). There was no 
significant change in total body fat, and BMI, and body weight tended to decrease 
after aerobic exercise training in individuals of African descent (Table 5). There were 
no significant changes in SBP, DBP and plasma aldosterone levels with aerobic 
exercise training (Table 5). After accounting for baseline plasma aldosterone levels, 
there was a tendency for plasma aldosterone levels to decrease with aerobic exercise 
training. The adjusted mean for the change in plasma aldosterone levels when 
controlling for baseline plasma aldosterone levels was -2±7 pg/ml (p=0.09). There 
was also a tendency for baseline plasma aldosterone levels to be negatively related to 
the change in plasma aldosterone levels with aerobic exercise training (r= -0.50, 
p=0.09) (Figure 2). There was a tendency for 24-hour Na+ excretion to increase after 
aerobic exercise training when accounting for baseline 24-hour Na+ excretion 
(p=0.06). There was a tendency for a negative relationship between baseline 24-hour 
Na+ excretion and the change in 24-hour Na+ excretion with aerobic exercise training 
(r= -0.53, p=0.06). Additionally, the change in DBP was statistically significant fter
accounting for the change in 24-hour Na+ excretion (p=0.05).This did not occur with 
SBP. It was found that the change in plasma aldosterone levels with aerobic exercise 




CYP11B2 -344C/T genotype and allele frequencies differ between Caucasians 
and individuals of African descent (14; 66; 147; 163), therefore the frequencies were 
determined separately in each ethnic group. Due to the small number of individuals 
who were either Asian/Pacific Islander or categorized as other et nicity, genotype 
frequency was not determined in these two groups.
Caucasian Group: The CYP11B2 -344C/T genotype frequencies for 
Caucasians were 0.41, 0.39 and 0.20 for the TT, TC and CC genotypes, respectively 
(Table 6). The T and C allele frequencies were 0.61 and 0.39, similar to what has 
been found in other Caucasian populations (14; 163). The distribution of the 
CYP11B2 -344C/T genotype frequencies were in Hardy-Weinberg equilibrium
 (χ 2=1.05, p=0.61). The TT genotype group tended (p=0.06) to be younger than the 
TC+CC genotype group (Table 7), but there were no other differences in baseline 
subject characteristics between the two genotype groups. 
There were 9 participants in the TT genotype group and 13 in the TC+CC 
genotype group who completed the study. The change in plasma aldosterone levels 
with aerobic exercise training was significantly different between the two genotype 
groups after accounting for baseline plasma aldosterone levels. The adjusted means 
for change in plasma aldosterone levels in the two genotype groups when controlling 
for baseline plasma aldosterone levels were -23±10 pg/ml for the TT genotype group 
and -47±8 pg/ml for the TC+CC genotype group (p<0.001). Other variables known to 
affect plasma aldosterone levels did not affect the change in plasma aldosterone levels 
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between the two genotype groups when used as covariates. Final values for plasma 
aldosterone levels after aerobic exercise training were significantly lower among the 
TC+CC genotype group compared to the TT genotype group (Table 8). The change in 
SBP was significantly different between the two genotype groups when accounting 
for baseline SBP. The adjusted means for the change in SBP in the two genotype 
groups when controlling for baseline SBP were-2±2 mm Hg for the TT genotype 
group and -4±1 mm Hg for the TC+CC genotype group (p=0.02). The change in DBP 
was significantly different between the two genotype groups (p=0.04) (Table 8).
In the TC+CC genotype group there was a significant reduction in SBP, MI,
total body fat, and body weight and a trend toward a reduction in plasma aldosterone 
levels (Table 9). The change in plasma aldosterone levels with aerobic exercise 
training was not independently related to the change in SBP and 24-hour Na+
excretion within any genotype group. There were no significantchanges in the 
plasma aldosterone, 24-hour Na+ excretion and blood pressure in the TT genotype 
group (Table 10).
African Descent Group: The CYP11B2 -344 T and C allele frequencies for 
individuals of African descent were 0.75 and 0.25, respectively (Table 11). These 
frequencies are similar to previous studies that have included individuals of African 
descent (66; 163).  The genotype frequencies were 0.54, 0.42, and 0.04 for the TT, 
TC and CC genotype groups, respectively (Table 11). The distribution of the 
genotype frequencies was in Hardy-Weinberg equilibrium (χ 2=0.427, p=0.75). At 
baseline, there was a tendency for the TC+CC genotype group to have a greater 
percent body fat (p=0.07) compared to the TT genotype group (Table 12). There were 
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no other differences in baseline subject characteristics between the two genotype 
groups.  
There were 6 participants in the TT genotype group and 8 in the TC+CC 
genotype group who completed the study.After controlling for baseline plasma 
aldosterone levels, there was a difference in the change in plasma aldosterone lev ls 
with aerobic exercise training between the two genotype groups. The adjusted means 
for the change in plasma aldosterone levels in the two genotype groups when 
controlling for baseline plasma aldosterone levels were-22±9 pg/mlin the TT 
genotype group and 12±8 pg/ml in the TC+CC genotype group (p=0.01). Final 
plasma aldosterone levels after aerobic exercis  training were significantly greater 
(p=0.01) among the TC+CC genotype group compared to the TT genotype group 
(Table 13). The change in SBP was also significantly (p=0.05) different between the 
two genotype groups (Table 13), with  the TT genotype having a non-significant 
reduction in SBP (Table 14) and the TC+CC genotype group tending to increase in 
SBP with aerobic exercise training (Table 15). There was no significant difference 
between the two genotype groups in the changes in DBP or 24-hour Na+ excretion 
with aerobic exercise training. 
After accounting for baseline plasma aldosterone levels, the change in plasma 
aldosterone levels was significant in the TT genotype group. The adjusted mean for 
the change in plasma aldosterone levels in the TT genotype group when controlling 
for baseline plasma aldosterone levels was -17±7 pg/ml (p=0.04). Adjusting for 
baseline plasma aldosterone levels, the change in plasma aldosterone levels was not 
significant in the TC+CC genotype group. Among the TC+CC genotype group, there 
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was a tendency (p=0.10) to increase SBP with aerobic exercise training (Table 15). 
SBP tended to increase with aerobic exercise training when accounting for the change 
in 24-hour Na+ excretion in the TC+CC genotype group. The adjusted mean for the 
change in SBP in the TC+CC genotype group when accounting for the change in 24-
hour Na+ excretion was 11±2 mm Hg (p=0.09). Adjusting for the change in 24-hour 
Na+ excretion, the change in SBP was not significant in the TT genotype group. There 
was a significant increase in 24-hour Na+ excretion after accounting for the change in 
BMI among the TC+CC genotype group. The adjusted mean for the change in 24-
hour Na+ excretion in the TC+CC genotype group when controlling for the change in 
BMI was 14±11 mmol/d (p=0.03). Adjusting for the change in BMI, the change in 
24-hour Na+ was significant in the TT genotype group. In both genotype groups, the 
change in plasma aldosterone levels with aerobic exercise training was not 
independently related to the change in SBP, DBP and 24-hour Na+ excretion. 
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Table 1. Subject characteristics before and after aerobic exercise training in the total 
sample.
Values are unadjusted means ± SE.
Samples sizes vary because of missing data.
Variable N Before After P-value
BMI (kg/m2) 39 28.3±0.6 27.8±0.6 0.002
Weight (kg) 39 84.2±2.2 82.4±2.1 0.001
Total Body Fat (%) 29 37±2 35±2 0.001
VO2 max (ml/kg/min) 38 24.6±0.8 28.1±0.9 <0.001
Na+ excretion (mmol/d) 37 119±9 124±10 0.43
K+ excretion (mmol/d) 37 66±4 68±4 0.56
Total Urine Volume (ml/d) 37 2104±143 2197±144 0.40
Systolic BP (mm Hg) 34 132±2 131±2 0.54
Diastolic BP (mm Hg) 33 84±1 84±1 0.86
Plasma Aldosterone (pg/ml)37 95±10 75±5 0.04
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Table 2.  Comparison of subject characteristics between the African descent and 
Caucasian groups before and after aerobic exercise training.
                African descent            Caucasians
Variable Baseline Final Baseline Final
Age (years) 57±1 (n=28) 58±1 (n=33)
Height (cm) 167±2 (n=28) 173±2 (n=33)
Weight (kg) 81.7±2.3  (n=25) 76.6±3.0 (n=13)** 85.9±2.8 (n=31) 86.9±2.8 (n=23)
BMI (kg/m2) 29.2±0.7 (n=25) 26.9±0.8 (n=13) 28.6±0.7 (n=31) 28.7±0.7 (n=23)
SCr (mg/dl) 1.1±0.0 (n=26) 1.0±0.0 (n=31)
GFR (ml/min/1.73m2) 77±3 (n=26) 75±2 (n=31)
Total Body Fat (%) 40±2 (n=20) 40±3 (n=11) 36±2 (n=32) 34±2 (n=16)
VO2 max (ml/kg/min) 22.2±0.6 (n=24)* 25.9±1.6 (n=13)** 24.8±0.9 (n=30) 29.2±1.1 (n=22)
Na+ excretion (mmol/d) 109±11 (n=25) 118±11 (n=13) 114±±10 (n=31) 132±15 (n=22)
K+ excretion (mmol/d) 51±4 (n=25)* 69±8 (n=13) 70±4 (n=31) 69±4 (n=22)
Total Urine Volume 
(ml/d) 1828±151 (n=25) 1957±206 (n=13) 2154±150 (n=31) 2395±191 (n=22)
Systolic BP (mm Hg) 129±2 (n=21) 134±4 (n=10) 132±2 (n=31) 131±2 (n=21)
Diastolic BP (mm Hg) 86±1 (n=20) 84±2 (n=9) 85±1 (n=28) 84±2 (n=21)
Plasma Aldosterone 
(pg/ml) 62±7 (n=28)* 61±9 (n=14) 107±12 (n=28) 81±7 (n=20)
SCr, serum creatinine; GFR, glomerular filtration rate. Values are unadjusted means ± 
SE.  * p≤0.05 Baseline ethnic differences; ** p≤0.05 Final ethnic differences. 
These are not within ethnic group comparison sample sizes. Within ethnic group 
comparisons are shown in Tables 4 & 5. 
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Table 3. Change values for primary outcome variables and 24-hour K+ excretion for 
individuals of African descent and Caucasians.
Values are unadjusted means ± SE. * Significant difference at p≤0.05.
Variable African Descent Caucasians
Change Na+ excretion (mmol/d) 4±12 (n=13) 9±8 (n=22)
Change K+ excretion (mmol/d) 12±8 (n=13) -2 ±5 (n=22)
Change  Systolic BP (mm Hg) 4±3 (n=10) -3±1 (n=21)*
Change  Diastolic BP (mm Hg) -1±2 (n=9) 0±1 (n=21)
Change plasma aldosterone (pg/ml)-2±8 (n=14) -37±15 (n=20)
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Table 4. Subject characteristics before and after aerobic exercise training in 
Caucasians.
Values are unadjusted means ± SE. 
Variable N Before After P-value
BMI (kg/m2) 23 29.1±0.8 28.7±0.7 0.01
Weight (kg) 23 88.2±2.9 86.9±2.8 0.01
Total Body Fat (%) 16 36±2 34±2 0.001
VO2 max (ml/kg/min) 22 25.4±1.1 29.2±1.1 <0.001
Na+ excretion (mmol/d) 22 123±14 132±15 0.29
K+ excretion (mmol/d) 22 71±5 69±4 0.67
Total Urine Volume (ml/d) 22 2227±201 2395±191 0.36
Systolic BP (mm Hg) 21 133±2 131±2 0.05
Diastolic BP(mm Hg) 21 84±2 84±2 0.83
Plasma Aldosterone (pg/ml) 20 119±16 81±7 0.02
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Table 5. Subject characteristics before and after aerobic exercise training in 
individuals of African descent.
Values are unadjusted means ± SE. 
Variable N Before After P-value
BMI (kg/m2) 13 28.0±1.0 26.9±0.8 0.06
Weight (kg) 13 79.5±3.4 76.6 ±3.0 0.06
Total Body Fat (%) 11 40±3 40±3 0.56
VO2 max (ml/kg/min) 13 22.3±1.0 25.9±1.6 <0.001
Na+ excretion (mmol/d) 13 114±10 118±11 0.77
K+ excretion (mmol/d) 13 57±8 69±8 0.16
Total Urine Volume (ml/d) 13 2002±215 1957±206 0.79
Systolic BP (mm Hg) 10 130±3 134±4 0.28
Diastolic BP (mm Hg) 9 85±2 84±2 0.50
Plasma Aldosterone (pg/ml)14 64±9 61±9 0.77
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Allele Frequencies T C
38(0.61) 24(0.39)
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 Table 7. Baseline subject characteristics for TT and TC+CC genotype groups in 
Caucasians.
SCr, serum creatinine; GFR, glomerular filtration rate. Values are unadjusted
 means ± SE.
There were no significant differences.
Variable TT TC+CC
Age (years) 56±1 (n=13) 60±2 (n=18)
SCr  (mg/dl) 1.0±0.1 (n=12) 1.0±0.4 (n=17)
GFR (ml/min/1.73m2) 75±4 (n=12) 75±2 (n=17)
Weight (kg) 86.3±5.0 (n=13) 87.5±3.4 (n=16)
BMI (kg/m2) 28.9±1.3 (n=13) 28.4±1.0 (n=16)
Total Body Fat (%) 37±3 (n=12) 34±2 (n=18)
VO2 max (ml/kg/min) 24.4±1.3 (n=13) 25.7±1.4 (n=15)
Na+ excretion (mmol/d) 123±19 (n=12) 108±14 (n=17)
K+ excretion (mmol/d) 75±6 (n=12) 66±6 (n=17)
Total Urine Volume (ml/d) 2371±228 (n=12) 1984±215 (n=17)
Systolic BP (mm Hg) 130±3 (n=12) 134±3 (n=17)
Diastolic BP (mm Hg) 83±3 (n=11) 86±1 (n=16)
Plasma Aldosterone (pg/ml) 119±19 (n=11) 99±17 (n=16)
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Table 8. Subject characteristics in the Caucasian TT and TC+CC genotype groups 
after aerobic exercise training.
Values are unadjusted means ± SE. * Significant difference at p≤0.05.
Variable TT TC+CC
BMI (kg/m2) 29.1±0.8 (n=9) 28.4±1.2 (n=13)
Weight (kg) 89.7±4.2 (n=9) 86.4±3.7 (n=13)
Total Body Fat (%) 35±2 (n=7) 
 
30±3 (n=8)
VO2 max (ml/kg/min) 29.1±1.6 (n=9) 29.7±1.6 (n=12)
Na+ excretion (mmol/d) 157±31 (n=8) 123±15 (n=13)
K+ excretion (mmol/d) 74±8 (n=8) 68±5 (n=13)
Total Urine Volume (ml/d) 2401±149 (n=8) 2369±314 (n=13)
Systolic BP (mm Hg) 130±4 (n=8) 130±2 (n=12)
Diastolic BP (mm Hg) 86±3 (n=8) 83±2 (n=12)
Plasma Aldosterone (pg/ml) 98±8 (n=8) 70±9 (n=12)*
Change plasma aldosterone (pg/ml)-36±20 (n=8) -39±21 (n=12)
Change Na+ excretion (mmol/d) 20±16 (n=8) 6±9 (n=13)
Change K+ excretion (mmol/d) -8±10 (n=8) 4±5 (n=13)
Change  Systolic BP (mm Hg) -2±2 (n=8) -4±2 (n=12)
Change  Diastolic BP (mm Hg) 3±2 (n=8) -2±1 (n=12)*
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 Table 9. Subject characteristics before and after aerobic exercise training in the 
Caucasian TC+CC genotype group.
Values are unadjusted means ± S.E.
Variable N Before After P-value
BMI (kg/m2) 13 28.8±1.2 28.4±1.2 0.01
Weight (kg) 13 87.6±3.7 86.4±3.7 0.01
Total Body Fat (%) 8 33±3 30±3 0.004
VO2 max (ml/kg/min) 12 25.2±1.7 29.7±1.6 <0.001
Na+ excretion (mmol/d) 13 116±17 123±15 0.47
K+ excretion (mmol/d) 13 64±7 68±5 0.35
Total Urine Volume (ml/d) 13 1966±278 2369±314 0.03
Systolic BP (mm Hg) 12 135±3 130±2 0.03
Diastolic BP (mm Hg) 12 85±2 83±2 0.15
Plasma Aldosterone (pg/ml)12 109±21 70±9 0.09
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Table 10. Subject characteristics before and after aerobic exercise training in the
Caucasian TT genotype group.
Values are unadjusted means ± S.E. 
Variable N Before After P-value
BMI (kg/m2) 9 29.6±0.9 29.1±0.8 0.17
Weight (kg) 9 91.1±4.7 89.7±4.3 0.16
Total Body Fat (%) 7 37±3 35±2 0.15
VO2 max (ml/kg/min) 9 26.1±1.4 29.1±1.6 0.02
Na+ excretion (mmol/d) 8 137±26 157±31 0.25
K+ excretion (mmol/d) 8 82±6 74±8 0.46
Total Urine Volume (ml/d) 8 2680±271 2401±149 0.31
Systolic BP (mm Hg) 8 132±5 130±4 0.49
Diastolic BP (mm Hg) 8 83±4 86±3 0.18
Plasma Aldosterone (pg/ml)8 134±24 98±8 0.12
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Table 12. Baseline subject characteristics for TT and TC+CC genotype groups in 
individuals of African descent.
SCr, serum creatinine; GFR, glomerular filtration rate. There were no significant 
differences between the two genotype groups.
Variable TT TC+CC
Age (years) 58±1 (n=14) 57±2 (n=12)
SCr  (mg/dl) 1.1±0.0 (n=13) 1.0±0.1 (n=11)
GFR (ml/min/1.73m2) 74±3 (n=13) 82±7 (n=11)
Weight (kg) 78.1±2.5 (n=12) 83.6±3.6 (n=12)
BMI (kg/m2) 28.1±0.9 (n=12) 30.0±1.1 (n=12)
Total Body Fat (%) 37±2 (n=11) 44±3 (n=8)
VO2 max (ml/kg/min) 22.1±0.8 (n=12) 22.4±1.0 (n=12)
Na+ excretion (mmol/d) 126±18 (n=13) 89±13 (n=11)
K+ excretion (mmol/d) 47±3 (n=13) 55±9 (n=11)
Total Urine Volume (ml/d) 1823±168 (n=13) 1903±279 (n=11)
Systolic BP (mm Hg) 129±3 (n=12) 130±4 (n=8)
Diastolic BP (mm Hg) 85±2 (n=11) 87±2 (n=8)
Plasma Aldosterone (pg/ml) 64±11 (n=14) 59±10 (n=12)
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Table 13. Subject characteristics for TT and TC+CC genotype groups in individuals 
of African descent after aerobic exercise training.
Values are unadjusted means ± SE. * Significant difference at p≤0.05.
Variable TT TC+CC
BMI (kg/m2) 25.6±0.8 (n=6) 28.1±1.3 (n=7)
Weight (kg) 71.5±2.8 (n=6) 80.9±4.6 (n=7)
Total Body Fat (%) 35±4 (n=6) 46±5 (n=5)
VO2 max (ml/kg/min) 25.6±1.7 (n=6) 26.1±2.7 (n=7)
Na+ excretion (mmol/d) 110±21 (n=6) 124±12 (n=7)
K+ excretion (mmol/d) 52±5 (n=6) 83±13(n=7)
Total Urine Volume (ml/d) 1622±223 (n=6) 2245±305 (n=7)
Systolic BP (mm Hg) 128±5 (n=6) 143±6 (n=4)
Diastolic BP (mm Hg) 81±2 (n=5) 87±3 (n=4)
Plasma Aldosterone (pg/ml) 37±8 (n=6) 79±11 (n=8)*
Change Plasma aldosterone (pg/ml)-17±12 (n=6) 8±10 (n=8)
Change Na+ excretion (mmol/d) -9±17 (n=6) 14±17 (n=7)
Change K+ excretion (mmol/d) 5±8 (n=6) 18±13 (n=7)
Change  Systolic BP (mm Hg) -1±3 (n=6) 11±5 (n=4)*
Change  Diastolic BP (mm Hg) -3±2 (n=5) 1±3 (n=4)
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Table 14. Subject characteristics before and after aerobic exercise training in the 
African descent TT genotype group.
Values are unadjusted means ± S.E.
Variable N Before After P-value
BMI (kg/m2) 6 25.9±0.9 25.6±0.8 0.32
Weight (kg) 6 72.5±3.1 71.5±2.7 0.31
Total Body Fat (%) 6 35±3 35±4 
 
0.91
VO2 max (ml/kg/min) 6 22.1±0.9 25.6±1.7 0.02
Na+ excretion (mmol/d) 6 119±18 110±21 0.62
K+ excretion (mmol/d) 6 48±6.1 52±5.2 0.55
Total Urine Volume (ml/d) 6 1669±157 1622±223 0.86
Systolic BP (mm Hg) 6 129±4 128±5 0.70
Diastolic BP (mm Hg) 5 85±2 81±2 0.22
Plasma Aldosterone (pg/ml) 6 54±15 37±8 0.24 
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Table 15. Subject characteristics before and after aerobic exer ise training in the 
African descent TC+CC genotype group.
Values are means ± S.E. Significant difference at p≤0.05. 
Variable N Before After P-value
BMI (kg/m2) 7 29.7±1.4 28.1±1.3 0.11
Weight (kg) 7 85.5±4.7 80.9±4.6 0.11
Total Body Fat (%) 5 46±5 46±5 0.28
VO2 max (ml/kg/min) 7 22.5±1.7 26.1±2.7 0.02
Na+ excretion (mmol/d) 7 109±13 124±12 0.44
K+ excretion (mmol/d) 7 66±13 83±13 0.23
Total Urine Volume (ml/d) 7 2288±352 2245±305 0.86
Systolic BP (mm Hg) 4 132±6 143±6 0.10
Diastolic BP (mm Hg) 4 86±3 87±3 0.66
Plasma Aldosterone (pg/ml)8 71±12 79±11 0.43
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Figure 1. Relationship between baseline plasma aldosterone levels and the change in 
plasma aldosterone with aerobic exercise training in Caucasians.





























Figure 2.  Relationship between baseline plasma aldosterone levels and the change in 
plasma aldosterone levels with aerobic exercise training in individuals of African 
descent.
































The purpose of the current study was to determine whether 6 months of 
aerobic exercise training reduced plasma aldosterone levels, increased 24-hour Na+
excretion and reduced blood pressure in middle-ag d to older prehypertensives. 
Additionally, the study determined whether the CYP11B2 -344C/T polymorphism 
influenced the change in these primary outcome variables with aerobic exercise 
training. This was the first study to investigate the effect of aerobic exercise training 
on plasma aldosterone levels in a prehypertensive population in both Caucasians and 
individuals of African descent, as well as the first to determine whether the -344C/T 
polymorphism identified prehypertensives who changed plasma aldosterone levels 
and blood pressure with aerobic exercise training.
 The current study was not designed to investigate ethnic differences in the 
responses of the primary outcome variables to aerobic exercise training, but it was 
found that the Caucasians and individuals of African descent responded differently to 
the aerobic exercise training. In light of these ethnicity-dependent responses, 
presenting the results without accounting for these ethnic differences would provide 
an inaccurate interpretation of how aerobic exercise training affected the primary 
outcome variables. 
Aerobic exercise training reduced plasma aldosterone levels in the
prehypertensive Caucasian population. There are no studies that have reported a 
reduction in plasma aldosterone levels with aerobic exercise training in a 
prehypertensive population, and very few that have done so in a normotensive or 
hypertensive population (13; 67). Hespel et al. were one of the first to report that in a 
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normotensive population, greater reductions in plasma aldosterone levels were 
associated with an increase in physical work capacity with aerobic exercise training 
(67). Braith et al. demonstrated that among heart failure patients, plasma aldosterone 
levels significantly decreased by 50 pg/ml after 16 weeks of aerobic exercise training 
(13). The reduction in plasma aldosterone levels among the Caucasians in the current 
study were approximately 12-13 pg/ml smaller than the plasma aldosterone reduction 
in the Braith et al. study. The larger plasma aldosterone reduction among the Braith et 
al. participants may have been because their participants were less healthy and had
greater baseline plasma aldosterone levels than the Caucasian group in the current 
study.
In the current study, baseline plasma aldosterone levels did contribute to the 
change in plasma aldosterone levels with aerobic exercise training in the Caucasian 
group, but after controlling for its small influence, the change in plasma aldosterone 
levels remained significant. This finding highlights the effectiveness of aerobic 
exercise training in reducing plasma aldosterone levels in Caucasian 
prehypertensives. Severalmechanisms may explain the exercise training-induced 
reduction in plasma aldosterone levels. Aerobic exercise training has been shown to 
suppress plasma renin activity (PRA) in normotensive and hypertensive individuals 
(34; 67; 86; 98). The reduction in PRA can result in the reduction in angiotensin II 
(ang II) leading to a decrease in aldosterone biosynthesis (13; 54; 67). Subsequently, 
Braith et al. also reported a reduction in ang II levels in heart failure patients with 
aerobic exercise training (13). Sympathetic stimulation, which is known to activate 
renin release leading to the release of ang II (33; 54), has been shown to decrease 
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with aerobic exercise training in hypert nsive individuals (34; 86). Therefore, it can 
be suggested that the reduction in sympathetic stimulation with aerobic exercise 
training may be a mechanism by which aldosterone biosynthesis decreases (67). 
Though the evidence is limited, there is also the possibility of an exercise-induced 
reduction in adrenal stimulation contributing to the reduction in plasma aldosterone 
levels (67; 146).                                                                                                                     
After 6 months of aerobic exercise training, the Caucasian participants also 
experienced a small, but significant reduction in SBP and no reduction in DBP. 
Larger reductions in SBP and DBP have been reported with similar aerobic exercis  
training programs (58; 59; 82; 135). In the current study, the prehypertensive status of 
the participants may have contributed to the small reduction in SBP. In previous 
aerobic exercise training studies that included hypertensive participants, baseline 
blood pressures were at hypertensive levels (58; 59; 82; 135). The baseline blood 
pressures for the Caucasians in the current study were below hypertensive levels, 
possibly allowing for less of a reduction in SBP with aerobic exercise training. There 
have been previous aerobic exercise training studies in which the population had 
blood pressures at prehypertensive levels (22; 45). In these previous studies, there 
was either a small reduction or no significant reduction in blood pressure (22; 45). 
Therefore, there is evidence to support that prehypertensives may reduce their blood 
pressure with aerobic exercise training, but the magnitude of the reductions may be 
less than in hypertensives. 
It was found that there was no change in 24-hour Na+ excretion among the 
Caucasians. Very few studies have investigated to what extent 24-hour Na+ excretion 
42
changes with aerobic exercise training in Caucasians, and of those studies that have, 
there were no significant changes (34; 58; 136). The significant increases in 24-hour 
Na+ excretion that have been reported mainly occurred with aerobic exercise training 
in hypertensive Japanese (84) or hypertensives of African descent (16). In both of 
these populations, it has been suggested that Na+ retention may contribute to their 
hypertension. Therefore, it is possible that in Caucasian populations, there may not be 
a change in Na+ excretion with aerobic exercise training.
 The change in plasma aldosterone levels with exercise training were not 
related to the change in blood pressure or 24-hour Na+ excretion in the Caucasian 
participants. This does not necessarily mean that the reduction in plasma aldosterone 
levels did not contribute to the reduction in SBP or thatpl sma aldosterone’s 
reduction is not by itself beneficial. Garcia et al., reported that the normal relationship 
between plasma aldosterone and Na+ excretion is not observed among hypertensives 
(73). It is very possible that those that are prehypertensive also experience the same 
phenomenon, and because blood pressure i  indirectly affected by aldosterone, a 
correlation between plasma aldosterone and blood pressure may not be observed. 
There is also the possibility that aldosterone’s influence on the development of 
hypertension in Caucasians is through a pathway other than renal Na+ handling. 
Recently, a review by Oberleither reported that vascular endothelial cells can 
synthesize aldosterone, express mineralocorticoid receptors and contain epithelial Na+
channels (108). Therefore, the action of aldosterone on the vascular endothelial cell is 
similar to what occurs in the renal collecting duct (108). It has been suggested that 
when aldosterone is present, there is an influx of water leading to the swelling of the 
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endothelial cells (108). This swelling is thought to lead to endothelial cell dysfunction 
(108). There is also evidence to suggest that aldosterone can alter renal and peripheral 
vascular vasoconstrictor and vasodilator dysfunction, which could ultimately 
contribute to the development of hypertension (7; 8; 37; 134). Therefore, aldosterone 
appears to have different pathways by which it can contribute to the development and 
maintenance of hypertension. In the present study, aerobic exercise training reduced 
plasma aldosterone levels in prehypertensive Caucasians, possibly slowing the further 
progression of hypertension.
The individuals of African descent who were included in the present study 
were also prehypertensive and had baseline plasma aldosterone levels that were 
within the normal range. After aerobic exercise training, plasma aldosterone levels 
did not significantly change for the individuals of African descent, but after 
accounting for baseline plasma aldosterone levels, there was a tendency for plasma 
aldosterone levels to be reduced with aerobic exercise training. Those with baseline 
plasma aldosterone levels less than 75 pg/ml were more likely to increase plasma 
aldosterone levels with aerobic exercise training and those who had baseline plasma 
aldosterone levels greater than 75 pg/ml, decreased plasma aldosterone levels with 
aerobic exercise training. Therefore, the lack of a significant average change in 
plasma aldosterone levels in the individuals of African descent may have been a 
result of these differential changes based on the baseline plasma aldosterone levels. 
The differential change in plasma aldosterone levels that occurred in the 
African descent group may have revealed a larger and more important finding in that 
the directional change in plasma aldosterone levels with aerobic exercise training is
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dependent on whether or not individuals of African descent have suppressed plasma 
aldosterone levels at baseline. The low plasma aldosterone levels at baseline may 
support findings that Na+ retention in some individuals of African descent suppresses 
plasma aldosterone levels and other components of the RAAS (40; 64; 96; 97; 128). 
Na+ retention was not measured in the current study, but based on the findings it 
appears that some of the individuals of African descent may have experienced som
Na+ retention. For example, 24-hour Na+ excretion tended to increase when removing 
the effect of baseline 24-hour Na+ excretion. Additionally, baseline 24-hour Na+
excretion tended to contribute to the change in 24-hour Na+ excretion with exercise 
training, and exhibited a similar relationship pattern that occurred between baseline 
plasma aldosterone levels and the change in plasma aldosterone levels. This suggests 
that the individuals that suppressed baseline Na+ excretion were more likely to 
increase 24-hour Na+ excretion after aerobic exercise training. On a larger scale, the 
similarity in plasma aldosterone and 24-hour Na+ excretion relationship patterns may 
further support evidence that among individuals of African descent, Na+ handling 
influences their plasma aldosterone levels and the response of plasma aldosterone to 
aerobic exercise training is influenced by the response of Na+ excretion to aerobic 
exercise training.
Among the individuals of African descent, 24-hour Na+ excretion after 
aerobic exercise training was negatively related to DBP with aerobic exercise 
training. In which as 24-hour Na+ excretion increased there was reduction in DBP. 
Even though 24-hour Na+ excretion did not change significantly with aerobic exercise 
training, it is possible that the slight increase in 24-hour Na+ excretion contributed to 
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the reduction in blood pressure. Guyton clearly states that due to the sensitivity of the 
pressure natriuresis mechanism in the kidney, onlyslight changes in the level ofNa+
output are necessary to cause shifts in the level of blood pressure (55). 
There was no association between plasma aldosterone and 24-hour Na+
excretion, SBP and DBP among the individuals of African descent. This lack of 
relationship may have been due to Na+ retention-related suppression of the RAAS 
that has been suggested to occur in some individuals of African descent (40; 64; 96; 
97; 128). If this is true, then it is unlikely that aldosterone is driving Na+ re bsorption 
and blood pressure. Rather, it is the Na+ retention that is drivng plasma aldosterone 
suppression and therefore blood pressure is probably not likely to be completely 
influenced by plasma aldosterone following exercise training. Unfortunately, the 
present study did not find a relationship between the change in 24-hour Na+ excretion 
and the change in plasma aldosterone following exercise training. This may have 
been due to the lack of uniform changes in plasma aldosterone and 24-hour Na+
excretion. The individuals of African descent appeared to havesubstantial within-
group heterogeneity in the change in plasma aldosterone levels and 24-hour Na+
excretion with exercise training. A larger sample size may have allowed for a clearer 
separation between those individuals who had low levels of Na+ excretion and 
suppressed plasma aldosterone levels, and those that did not. This may have made it 
easier to determine to what extent aerobic exercise training affected these variables in 
individuals of African descent.
There were no significant changes in SBP or DBP with aerobic exercise 
training among the individuals of African descent. These findings differ from studies 
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that have reported blood pressure reductions in individuals of African descent (34; 
87) and differ from the findings in the Caucasian participants in the current study.
Again, a difference between the current study and other studies in individuals of 
African descent is that the baseline blood pressures were much lower than the studies 
that reported reductions in blood pressure (34; 87). The ethnic differences in blood 
pressure response to aerobic exercise training may have resulted from 
pathophysiological differences in the mechanism of hypertension development that 
are reported between individuals of African descent and Caucasians (40; 64; 96).
 The results of the presnt study indicated that there were distinct differences 
between the individuals of African descent and Caucasians before and after aerobic 
exercise training. The baseline plasma aldosterone levels of the individuals of African 
descent were 42% lower than Caucasians. Additionally, plasma aldosterone levels 
after aerobic exercise training were significantly lower in individuals of African 
descent than Caucasians after accounting for BMI and 24-hour K+ excretion after 
aerobic exercise training. The prevalence of lower plasma aldosterone levels among 
individuals of African descent compared to Caucasians has been a topic of much 
debate (40; 64; 96; 115; 116). Some studies have not found basal plasma aldosterone 
levels to be different between individuals of African descent and Caucasians (35; 40; 
41; 64; 96), whereas other studies have found that in individuals of African descent 
basal plasma aldosterone levels are suppressed (115; 116) or have an attenuated 
response to RAAS stimulation (40; 41; 64). Therefore, evn though the evidence is 
mixed, there is some support that plasma aldosterone levels can be suppressed in both 
normotensive and hypertensive individuals of African descent.
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K+ is known to be an important stimulus of aldosterone biosynthesis (20; 54)
and lower potassium intake among individuals of African descent has been found to 
be one factor that accounts for the differences in plasma aldosterone levels between 
the two ethnic groups (91; 115). Langford et al. reported that ethnic differences in 
plasma aldosterone levels were eliminated when normotensives of African descent 
and normotensive Caucasians were placed on a 10 week homogenous K+ diet (91). A 
limitation of the present study was that K+ intake was not controlled. This may have 
accounted for significantly lower baseline 24-hour K+ excretion among individuals of 
African descent. Contrary to this, when controlling for 24-hour K+ excretion before 
and after aerobic exercise training, plasma aldosterone levels continued to be 
significantly lower among the individuals of African descent. These findings are 
supportive of a study by Pratt et al. who showed that ethnic differences in K+ intake 
did not solely account for the ethnic differences in plasma aldosterone levels (115).
The individuals in the current study were not obese, but were considered to be 
overweight. BMI was slightly lower and body weight was significantly lower among 
individuals of African descent compared to Caucasians. Obese individuals have been 
shown to have greater plasma aldosterone lev ls than non-obese individuals (46-48; 
124). When controlling for BMI after aerobic exercise training, plasma aldosterone 
levels after aerobic exercise training were still lower in individuals of African 
descent. This is the first study to demonstrate that the plasma aldosterone response to 
aerobic exercise training is different between these two ethnic groups. These 
differences in exercise training induced-responses do not appear to be attributed to 
differences in K+ intake or body composition. Therefore, the ethnic differences in 
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plasma aldosterone levels may be due to differences in RAAS regulation that have 
been suggested by previous research (40; 64; 128).
Among the Caucasians, for the primary outcome variables plasma aldosterone 
and SBP the sample sizes were not sufficient to meet 80% power. Regardless, after 6-
months of aerobic exercise training the TC+CC genotype group was more responsive 
in that they significantly reduced SBP and tended to reduce plasma aldosterone 
levels, while the TT homozygotes did not. Rankinen et al. reported strong linkage 
between the 8q21 region, the location of CYP11B2, and the change in SBP during 
cycle ergometry at 50 W following 20 weeks of aerobic exercise trainingamong 
Caucasians (118). The findings of Rankinen et al. combined with the findings from 
the current study indicate that the CYP11B2 -344C/T gene polymorphism or a 
polymorphism that is in linkage with the -344C/T polymorphism, may influence the 
change in plasma aldosterone levels and SBP with aerobic exercise training.
The phenomenon of the genotypes with the dominate allele being associated 
with the change in hypertension phenotypes has been demonstrated in gene-exercise 
studies involving other RAAS gene polymorphisms, such as the ACE I/D and the 
AGT M235T (57; 119; 120; 161). Hagberg et al. and Zhang et al. reported that the 
ACE I allele was associated with a reduction in blood pressure with aerobic exercise 
training (57; 161). Rankinen et al. and Rauramaa et al. found that the AGT 235M 
allele was associated with a reduction in blood pressure with aerobic exercise training 
(119; 120). The results of the aforementioned studies combined with the results of the 
present study suggest that RAAS genes may have a significant influence on the blood 
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pressure response to aerobic exercise training in prehypertensive and hypertensive 
Caucasians. 
The previous gene- xercise studies did not measure RAAS intermediate 
phenotypes and this has prevented them from making a stronger physiological link 
between the gene polymorphism and the blood pressure reduction with aerobic 
exercise training (59; 119; 120). In the current study, the measurement of plasma 
aldosterone enhanced the study’s ability to determine a potential physiological link 
between the gene and the endpoint phenotype, blood pressure. There was not a 
significant relationship between blood pressure and plasma aldosterone levels in any 
of the genotype or ethnic groups.
Final plasma aldosterone levels were lower after aerobic exercise training 
among the Caucasian TC+CC genotype group compared to the Caucasian TT 
genotype group. Additionally, after controlling for baseline plasma aldosterone levels, 
the TC+CC genotype group had a greater reduction in plasma aldosterone levels 
compared to the TT genotype group with exercise training. The genotype-associated 
differences in plasma aldosterone levels after aerobic exercise training may have been 
the result of molecular differences between the T and C alleles. Compared to the -
344T allele, the -344C allele has been associated with tig ter binding of the 
transcription factor SF-1 to the non-essential regulatory sequence Ad4 (10; 20; 155). 
It has been suggested that the tighter binding of SF-1 to Ad- 4 makes SF-1 unavailable 
to bind to other functional CYP11B2 gene regulatory sites (14; 93; 147). Hence, it is 
suggested that the -344C allele is associated with less CYP11B2 gene transcription 
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and aldosterone biosynthesis (14; 94; 147). The lower aldosterone biosynthesis 
associated with the 
-344C allele possibly enabled those in the current study with the TC+CC genotype to 
be more responsive to the exercise training-induced mechanisms that contribute to the 
reduction in plasma aldosterone levels. Alternatively, the -344T allele has been 
associated with less binding of SF-1 to Ad- 4, making SF-1 more available to bind to 
other functional regulatory sites resulting in increased CYP11B2 gene transcription 
and aldosterone biosynthesis (14; 94; 147). The greater aldosterone biosynthesis 
associated with the -344T allele may have caused those in the TT genotype group to 
experience more resistance to the exercise training-induced mechanisms that 
contribute to the reduction in plasma aldosterone levels. 
When controlling for baseline SBP, the Caucasian TC+CC genotype group 
had a significantly greater reduction in SBP compared to the Caucasian TT genotype 
group. Additionally, the reduction in DBP among the TC+CC genotype group was 
significantly different compared to the TT genotype group. The reduction in blood 
pressure among the TC+CC genotype group mayhave been partly due to their 
reduction in plasma aldosterone levels. As discussed earlier, aldosterone can cause 
peripheral vasoconstriction, affecting resting vascular tone (7; 8; 134). The reduction 
in plasma aldosterone levels with aerobic exercise training may have lead to greater 
exercise training-induced resting vasodilation among the TC+CC genotype group 
leading to their reduction in blood pressure (93; 118). However, there was no 
significant association between the change in plasma aldosterone levels and the 
changes in SBP and DBP to support this. In future research, it may be necessary to 
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measure vascular endothelial function to determine whether the -344C/T 
polymorphism is associated with the change in resting vascular tone.
Among the Caucasians,for the primary outcome variable 24-hour Na+
excretion the sample size was sufficient to meet the requirements of 80% power. The 
lack of a genotype-associated reduction in 24-hour Na+ excretion and the lack of a 
relationship between the change in plasma aldosterone levels and the change in 24-
hour Na+ excretion may indicate that among Caucasians, the contribution of 
aldosterone to elevated blood pressure is more associated with endothelial function 
than renal Na+ handling.
Among the individuals of African descent, for all of the primary outcome 
variables the sample size was not sufficient to meet 80% power. Despite this lack of 
statistical power, after controlling for baseline plasma aldosterone levels, the change 
in plasma aldosterone levels was significantly different between the two genotype 
groups. Also, the TT genotype group tended to have lower final plasma aldosterone 
levels after aerobic exercise training compared to the TC+CC genotype group. The 
genotype associations with the change in plasma aldosterone levels among the 
individuals of African descent were opposite to what was found among the 
Caucasians. Therefore, it is difficult to determine whether the molecular differences 
between the T and C allele, which were discussed above, provide a sufficient 
explanation for thegenotype associations with the change in plasma aldosterone 
levels for both ethnic groups. Among the individuals of African descent, both 
genotype groups had similar baseline plasma aldosterone levels, and as stated earlier, 
these levels were suppressed compared to the Caucasians. Therefore, it was 
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interesting that the TT genotype group experienced a -17 pg/ml reduction in plasma 
aldosterone levels with aerobic exercise training when controlling for baseline plasma 
aldosterone levels. Their plasma aldosterone concentration after aerobic exercise 
training was 37 pg/ml, which is suggestive of further aldosterone suppression after 
aerobic exercise training. It appears that the TT genotype may be less advantageous 
for individuals of African descent, a population known to experience RAAS 
suppression. The TC+CC genotype group experienced a non-significant increase in 
plasma aldosterone levels with aerobic exercise training. This may suggest that the 
TC or the CC genotype may be more advantageous among individuals of African 
descent because it is less likely to lead to further suppression of plasma aldosterone 
levels with aerobic exercise training.
After aerobic exercise training, the African descent TT genotype group 
experienced a non-significant reduction in 24-hour Na+ excretion and the TC+CC 
genotype group experienced a significant increase in 24-hour Na+ excretion, after 
controlling for the change in BMI. These findings may indicate that in individuals of 
African descent with the TT genotype, aerobic exercise training does not increase Na+
excretion and this may contribute to the further suppression of plasma aldosterone 
levels with aerobic exercise training. The exercise training-induced increase in 24-
hour Na+ excretion that was observed in the TC+CC genotype group may prevent the 
further suppression of plasma aldosterone levels with aerobic exercise training. A 
larger sample size will be necessary to confirm these suggestions. 
The African descent TC+CC genotype group tended to increase SBP with 
aerobic exercise training. For SBP, there were only 4 individuals of African descent 
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with the TC+CC genotype, and all four individuals increased their SBP with aerobic 
exercise training. Therefore, it is difficult to discern whether this finding is due to 
chance or if it provides some initial evidence that the TC+CC genotype is associated 
with an adverse SBP response to aerobic exercise training. 
In conclusion, the results from the current study indicated that Caucasians and 
individuals of African descent differ in their responses of plasma aldosterone levels, 
24-hour Na+ excretion and blood pressure to aerobic exercise training. Ethnic 
differences in the regulation of the RAAS may have contributed to the differences in 
the responses of these primary outcome variables. The findings also revealed that the 
CYP11B2 -344C/T polymorphism may influence the responses of plasma 
aldosterone, 24-hour Na+ excretion and blood pressure to aerobic exercise training, 
but the allele-associated responses differed between individuals of African descent 
and Caucasians. It is unlikely that the -344C/T polymorphism alone influenced the 
responses of these primary outcome variables, therefore further investigation is 
needed to determine whether other CYP11B2 polymorphisms that are in linkage 
disequilibrium with the -344C/T polymorphism, may in conjunction with the 
–344C/T polymorphism contribute o the exercise-training induced responses.
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Appendix A ─ Statement of Research Purpose
Purpose of the Study 
The purpose of the current study was to determine whether 6 months of 
aerobic exercise training reduced plasma aldosterone levels, increased 24-hour Na+
excretion and reduced blood pressure in middle-aged to older prehypertensives. 
Additionally, whether the CYP11B2 –344C/T polymorphism influenced the 
responses of these primary outcome variables to aerobic exercise training.
Significance of Study 
Hypertension continues to be an indiscriminate chronic disease that places 
older individuals at increased risk for the development of potentially fatal conditions 
such as cardiovascular and renal disease (19). Aerobic exercise training is considered 
a life style modification that can aid in the reduction and control of blood pressure in 
hypertensive individuals (1; 19) and has proven to effectively reduce blood pressure 
in hypertensive individuals (58; 59; 82; 84; 87). There is an ongoing effort to 
elucidate the physiological mechanisms involved in the reduction of blood pressure 
with aerobic exercise training, and one system that may have great influence but has 
not been adequately researched, is the RAAS. Therefore, the current study determined 
if plasma aldosterone levels changed with aerobic exercise training, and if the change 
in plasma aldosterone influenced Na+ handling and blood pressure response in a 
prehypertensive population. Thus, the current study is contributing to the 
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understanding of the mechanisms involved in the reduction of blood pressure with 
aerobic exercise training.
In recent years, there have been a few gene-exercise research studies that 
found that the ACE I/D and AGT M235T polymorphisms were associated with blood 
pressure changes with aerobic exercise training (57; 119; 120; 16). Because these 
RAAS genes appear to influence blood pressure responses to aerobic exercise 
training, it is important to investigate whether other important RAAS genes also 
influence blood pressure responses to aerobic exercise training. The CYP11B2
-344C/T polymorphism may be a likely candidate due to the evidence demonstrating 
that it is related to blood pressure, Na+ h ndling and aldosterone levels (29; 31; 66; 
114). Therefore, the second objective of this study was to determine whether the 
-344C/T polymorphism was associated with changes in plasma aldosterone levels, 
24-hour Na+ excretion and blood pressure response to aerobic exercise training. The 
current study was also important because the aforementioned gene-ex rcise studies 
lacked the measurement of the intermediate phenotype associated with the genes that 
were investigated. This has prevented the previous studies from making a strong 
physiological link between the gene polymorphism and the reduction in blood 
pressure with aerobic exercise training. Therefore, by measuring plasma aldosterone, 
the current study had the potential to better understand the role that the -344C/T 
polymorphism had in the reduction of blood pressure with aerobic exercise training.
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Research Hypotheses
1. Due to limited research on the response of plasma aldosterone and Na+
excretion to aerobic exercise training, long-term aerobic exercise training will 
reduce plasma aldosterone levels, increase 24-hour Na+ excretion, and reduce 
blood pressure in middle-aged to older prehypertensives. 
2. The change in plasma aldosterone levels will be associated with the change in 
24-hour Na+ excretion and the change in blood pressure.
3. The majority of CYP11B2 -344C/T association studies have reported that the 
presence of the mutant T allele was ssociated with elevated blood pressure 
(14; 29; 66; 141; 147). Traditionally, in gene-exercise training studies that 
have included RAAS gene polymorphisms, such as the ACE I/D and the 
M235T, the presence of the mutant allele is associated with a lack of exercise-
induced changes in blood pressure (57; 119; 120; 161). Therefore, in the 
present study it was hypothesized that participants with the TC+CC genotype 
would have a greater reduction in the intermediate phenotype, plasma 
aldosterone levels, a greater increase in the intermediate phenotype, 24-hour 
Na+ excretion, and a greater reduction in the endpoint phenotype, blood 
pressure, after aerobic exercise training compared to those with the TT 
genotype. The changes in phenotypes associated with the TT genotype group 
would not be different from zero. 
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Delimitations
The following were delimitations of the study: 
1. The study population consisted of prehypertensive men and women between 
the ages of 50-75 years on 2 or less antihypertensive medications. Theywere 
void of diabetes, kidney. liver and cardiovascular disease. 
2. The study focused on plasma aldosterone levels, and therefore was not able to 
assess urinary aldosterone changes with aerobic exercise training.
3. The women in the study were post-menopausal and were required to maintain 
their hormone replacement status. This was necessary because changes in 
hormone replacement could affect plasma aldosterone levels. 
4. A gene-exercise association was exclusively studied in the –344C/T 
polymorphism. Therefore, it was not possible to determine if there were 
interactions between –344C/T and other polymorphisms of the CYP11B2 
gene or other genes of the RAAS.
Limitations
The following factors were limitations of the study:
1. During the initial screening, participants were asked to report any health 
problems, their current fitness level, and any medications being taken. It was 
possible that there was inaccurate reporting by participants, which lead to the 
inclusion of participants with unreported health problems. This could have 
negatively impacted the data. 
2. Participants were asked to self-report dietary intake throughout the study to 
ensure they were meeting AHA Step I guidelines. There was the possibility 
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that inaccurate reporting of dietary intake affected plasma aldosterone levels, 
24-hour Na+ excretion and blood pressure measurements.
3. A total of 40 participants completed the study, of which 14 were of African 
descent and 23 were Caucasian. The small sample size within each ethnic 
group, reduced the power to detect genotype-dependent aerobic exercise 
training-induced changes in plasma aldosterone levels, 24-hour Na+ excretion 
and blood pressure.
4. There was no control group included in the current study. 
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Definition of Terms
Adrenal Gland: Endocrine and neuroendocrine gland that lies superior to the 
kidneys. It has two distinct parts, the adrenal medulla is the inner portion that 
produces catecholamines and adrenal cortex is the outer portion that produces steroid 
hormones.
CYP11B2 Cis-regulatory Element: responsible for the transcriptional regulation of 
the CYP11B2 gene.
Cytochrome P450: monooxygenases which catalyze many reactions involved in 
drug metabolism, synthesis of cholesterol, steroid hormones and other lipids. 
Exon: the sequences that are represented in the mature RNA.
G-protein Coupled Receptor: cell surface receptor that associates with an 
intracellular trimeric GTP-binding protein (G protein) after receptor activation by an 
extracellular ligand. 
Intron : intervening sequences that are removed when the primary transcript is 
processed to give the mature RNA.
Locus: is the position on a chromosome at which the gene for a particular trait 
resides. 
Phosphatidylinositol 4,5- Bisphosphate: an inositol phospholipid which is present 
in small amounts in the inner half of the plasma membrane lipid bilayer. G-protein 
coupled receptors mainly act through this pathway.
Polymorphism: refers to the simultaneous occurrence in the population of genomes 
showing allelic variations. 
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Pressure natriuresis: an increase in arterial pressure of only a few mm Hg that 
doubles the output of salt. 
Regulatory sequence: DNA sequence to which a gene regulatory protein binds to 
control the rate of assembly of the transcriptional complex at the promoter. 
Reporter Gene: a coding unit whose product is easily assayed. It may be connected 
to any promoter of interest so that expression of the gene can be used to assay 
promoter function.
Transcriptional Factors: proteins that help to position RNA polymerase correctly on 
promoter, aid in pulling apart the two strands of DNA to allow for transcription to 
begin, and release RNA polymerase from the promoter into the elongation mode once 
transcription has begun.
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Appendix B ─ Review of Literature
Hypertension is considered to be a primary risk factor for the development of 
CVD, and it has been reported that the relationship between blood pressure and CVD 
risk is continuous, consistent and independent of other risk factors (19). The influence 
of hypertension goes beyond the spectrum of CVD since it is also responsible for 
contributing to the incidence of stroke, heart failure and kidney disease (19). Vasan et 
al. recently reported on data from the Framingham Heart Study in which it was found 
that the residual lifetime risk for developing hypertension in middle-ag d and elderly 
individuals was 90% (153). It has been reported that for individuals between the ages 
of 40-70 years with blood pressure in the ranges of 115/75 to 185/115 mm Hg, each 
20 mm Hg or 10 mm Hg incremental increase in SBP or DBP, respectively, was 
associated with a doubling of the risk of developing CVD (19; 92). Thus, 
hypertension continues to be a disease associated with aging and poses a great public 
health burden (153). 
Many physiological systems are involved in the regulation of blood pressure 
and therefore there are potentially many avenues for disregulation of blood pressure. 
For example, the RAAS has generated great interest because it is intimately related to 
the function of the kidney, the long-term regulator of blood pressure (54; 55; 60). 
Thus, the primary focus of this literature review is to discuss the involvement of the 
RAAS, specifically aldosterone, in the regulation of blood pressure and its possible 
contributions to the etiology of hypertension. Recently, hypertension has been shown 
to have a substantial genetic component. Therefore, this review will also focus on the 
–344C/T single nucleotide polymorphism (SNP) of the CYP11B2 gene in light of 
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preliminary evidence suggesting that the variant is associated with hypertension as 
well as with variability in aldosterone levels. Furthermore, aerobic exercise has been 
recognized as a lifestyle modification that c n be prescribed alone or in conjunction 
with other antihypertensive therapies as an effective overall strategy for the 
prevention and treatment of hypertension (1; 19). Therefore, there will be a discussion 
of the effect of aerobic exercise training on the hypertensive phenotypes blood 
pressure, Na+ excretion, and aldosterone levels, and also on the interaction between 
genetics and exercise in the treatment of hypertension.
Renin-Angiotensin-Aldosterone-System
The RAAS is an essential and intimate partne  in the kidney’s regulation of 
fluid homeostasis and blood pressure. The RAAS should not only be thought of as a 
system that exerts its influence on the kidney, but also as a system that is born within 
the kidney. The kidney is considered to be one of the most complex and necessary 
organs within the body, and its ability to regulate fluid homeostasis and blood 
pressure comes from the millions of functional units, called nephrons, that lie within 
it  (138). Each nephron contains key vasculature, such as the afferent and efferent 
arterioles, and tubular elements, such as the loop of Henle, proximal, distal, and 
collecting tubules, that can be influenced by variables of the RAAS to elicit change in 
fluid homeostasis and eventually blood pressure (138). 
The RAAS includes renin, angiotensinogen, angiotensin I (ang I), ang  II, and 
aldosterone (54). Renin, an enzyme, is responsible for the activation of the RAAS. It 
is stored in its inactive form, prorenin, in the juxtaglomerulosa (JG) cells of the 
afferent and efferent arterioles that feed into the network of capillaries called the 
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glomerulus (54; 138). Reductions in blood pressure and blood volume stimulate the 
conversion of prorenin to renin (54). 
Numerous factors can contribute to the renin release; however thre  
mechanisms are thought to have the greatest influence: intrarenal baroreceptors, 
sympathetic nervous system, and macula densa receptors (60). The intrarenal 
baroreceptors, located in the JG cells, influence renin release by responding to 
changes in vascular wall tension and transmural pressure (30; 60). A second 
mechanism of renin release is the through activation of the sympathetic nervous 
system (SNS) (54; 60). The kidney is highly innervated by the SNS; specifically, 
there is exclusive adrenergic innervation of the afferent and efferent arterioles leading 
to the glomerulus (33). The SNS can directly influence renin release by stimulating 
beta2 adrenergic receptors, located on the JG cells, when there is a reduction in blood 
pressure, or an acute change in blood volume (33; 54). Renin release can also be 
indirectly stimulated via activation of alpha-adrenergic receptors, which leads to an 
increase in Na+ reabsorption in the proximal tubules of the kidney (60). The increase 
in Na+ reabsorption results in a reduction of Na+ chloride (Na+Cl-) delivery to the 
macula densa leading to renin release (32). The third mechanism involves the macula 
densa, which is a cluster of specialized cells located in the early portion of the distal 
tubule and in very close proximity to the JG cells of the afferent and efferent 
arterioles (60). The macula densa stimulates the release of renin by sensing changes 
in Na+Cl- concentration to the distal tubule (54). A decrease in arterial pressure can 
cause a decrease in glomerula  filtration rate (GFR), resulting in a reduction in flow 
rate through the loop of Henle and an increase in Na+Cl- reabsorption in the ascending 
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limb of the loop (54). The consequent increase in Na+ re bsorption by the ascending 
limb reduces the Na+Cl- concentration that passes the macula densa and thereby 
initiates a signal from the macula densa to the afferent and efferent arteriole 
stimulating the release renin from the JG cells (54; 60). The release of renin leads to 
ang II release, which causes efferent arteriole vasoconstriction (54). Combined with a 
simultaneous reduction in afferent arteriole resistance, GFR and arterial pressure 
increases (54). 
Once released, renin is not responsible for bringing about the physiological 
effects that aids in the regulation of blood pressure. Rather, renin initiates the steps 
needed to produce ang II, one of the vasoactive substances of the RAAS (54). Renin 
splits the substrate angiotensinogen (a plasma protein produced in the liver) to ang I, 
a 10 amino acid peptide (54). Once released, ang I circulates in the blood, however it 
has a very weak vasoconstrictive effect and therefore causes no physiological change 
in the vasculature (54). Despite this weak effect, ang I is important because it is the 
precursor peptide that is converted to the 8 amino acid peptide ang II, by angiotensin 
converting enzyme (ACE), which is produced in the endothelium of the lung blood 
vessels (54). 
There are two physiological pathways by which ang II can affect blood 
pressure.  The first pathway is via the vasculature, in which the presence of ang II in 
the blood leads to the vasoconstriction of arterioles, increased total peripheral 
resistance and eventually increased arterial pressure (54). Ang II also acts on the 
veins causing mild vasoconstriction to increase venous return (54). The first pathway 
of action by ang II is considered an acute method of increasing blood pressure (54). 
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The second pathway by which ang II affects blood pressure is through its influence on 
the kidney and is considered to be a slower, but more powerful method of increasing 
blood pressure (54). Ang II acts on the renal vasculature and renal tubules to increase 
Na+ and water reabsorption, which over hours to days will lead to an increase in 
blood pressure  (54). Ang II is also responsible for stimulating the release of 
aldosterone, the final component of the RAAS, and is also known to aid in the 
kidney’s regulation of blood pressure (54). 
Renal-Fluid-Feedback-System and Pressure Natriuresis 
Before introducing aldosterone and its influence on blood pressure regulation, 
it is important to have a general understanding of how aldosterone and ang II function 
within the kidney to aid in the long-term regulation of blood pressure. The 
maintenance of mean blood pressure is reliant on the maintenance of fluid 
homeostasis, in which equilibrium is achieved between fluid input and fluid output 
(54; 55; 60). The kidney is the organ solely responsible for fluid homeostasis and 
because of this it is referred to as the long-term regulator of blood pressure (54) . The 
kidney regulates blood pressure over the long-term via the renal fluid-feedback 
system (RFFS) (60). In the event of an increase or decrease in blood pressure due to 
changes in fluid volume, it is through the RFFS, that the kidney rectifies these 
changes and returns blood pressure to normal levels (54; 60).
The primary component of the RFFS that allows the kidneys to regulate fluid 
volume and blood pressure is the pressure-natriuresis mechanism (53; 54; 60; 61). 
This mechanism demonstrates the effect that blood pressure has on urinary Na+ and 
water excretion (55). In healthy individuals mean blood pressure is approximately 
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100 mm Hg, this is the single precise pressure considered to be the equilibrium 
pressure point (55). At the equilibrium pressure point, net fluid intake and renal fluid 
output are in equilibrium (55). The kidney continuously functions to maintain the 
equilibrium pressure point (55). Due to this fine regulation of fluid homeostasis, even 
a slight increase in blood pressure above the equilibrium pressure point causes the 
kidney to increase Na+ and water excretion to decrease fluid volume (54; 60). When 
fluid loss exceeds fluid intake, extracellular fluid volume will decrease and blood 
pressure will return to the equilibrium pressure point (55; 60). In the case of a 
reduction in blood pressure below the equilibrium pressure point, the kidneys increase 
water and Na+ reabsorption to increase extracellular fluid volume, which returns 
blood pressure to the equilibrum pressure point (55; 60). The RFFS is not responsible 
for regulating the moment-to-moment changes in blood pressure, but rather it is 
responsible for regulating blood pressure over the long-term (53; 60).
The kidney’s ability to make such fine adjustments to fluid volume and 
arterial pressure is reliant on variables of the RAAS such as aldosterone and ang II 
(60). Therefore, aldosterone and ang II are considered to be integral components of 
the RFFS that increase renal Na+ and water reabsorption (60).
Aldosterone and the Kidney
Similar to ang II, aldosterone is another component of the RAAS that can 
elicit physiological changes in the kidney that aid in the regulation of arterial 
pressure. Unlike ang II, aldosterone is not an amino acid peptide; it s a
mineralocorticoid that is released from the zona glomerulosa, a region within the 
adrenal gland (54). The renal tubules are one of the areas targeted by aldosterone 
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(54). The initial precursor of aldosterone is cholesterol, and with the aid of several 
enzymes, cholesterol is converted to several different steroid hormones, one of them 
being aldosterone (54). The steps in the biosynthesis of aldosterone from cholesterol 
occur mainly in the mitochondria and the endoplasmic reticulum of the zona 
glomerulosa cells (54). In one of the final steps of aldosterone biosynthesis, 
corticosterone is converted to aldosterone by the enzyme aldosterone synthase 
(P450c11AS) (54).
There are several mechanisms, such as changes in osmolarity in the 
extracellular fluid, that regulate aldosterone biosynthesis, but the most important 
regulators are K+ ion concentration, and ang II levels in the blood (54; 138). An 
increase in K+ concentration in the extracellular fluid is known to stimulate 
aldosterone biosynthesis  (138). WhenK+ levels are elevated, aldosterone 
biosynthesis increases leading to K+ secretion into the renal tubules, and an elevation 
in K+ excretion (138). Additionally, with the increase in K+ secretion into the renal 
tubules comes an increase in Na+ reabsorption by the renal tubules (138). The second 
important regulator of aldosterone biosynthesis is ang II (20). Located on the zona 
glomerulosa are ang II type I (AT1) receptors, and in times of reduced blood pressure 
and blood volume ang II levels will be elevated in the blood and will act on these G-
protein coupled receptors and stimulate the biosynthesis and release of aldosterone 
(20; 77; 137; 140). The net result is an increase in Na+ reabsorption and K+ secretion. 
The specific cellular mechanisms by which K+ and ang II regulate aldosterone 
biosynthesis will be discussed later in the section on the CYP11B2 (aldosterone 
synthase) gene. There is another adrenal stimulus that must be mentioned. Plasma 
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aldosterone levels can change based on a person’s posture (17). When an individual is 
supine, plasma aldosterone levels are lower and range from 
20-230 pg/ml, and when an individual is upright, plasma aldosterone levels are higher 
ranging from 40-600 pg/ml (114). 
Once aldosterone is released it acts on the renal tubules; specifically the 
collecting tubules and to a lesser extent the distal tubules and collecting ducts (54). 
Aldosterone increases Na+ reabsorption in these specific regions of the renal tubules 
by acting on the epithelial cells, and to a greater extent, the principal cells (54; 138). 
Aldosterone easily diffuses across the tubular epithelia and principal cells, and binds 
to a cytoplasmic receptor (138). The aldosterone-rec ptor complex moves into the 
nucleus of the cell stimulating two pathways of action, one that elicits an acute 
response and one that is a slower response (138). The acute mechanism of action 
involves aldosterone stimulation of Na+ channels located on the apical end of the cell, 
to open (138). This leads to an influx of Na+ into the cells increasing the intracellular 
Na+ concentration (138). On the basolateral side of the cell there is increased activity 
of the Na+-K+ ATPase channels, which are Na+ and K+ antiport ion channels that 
pump Na+ out of the cell and K+ inside the cell (138). The r sult is an increase in Na+
reabsorption into the blood and secretion of K+ into the lumen of the renal tubules 
(138).  In the slower mechanism of action, when the aldosterone-receptor complex 
enters the nucleus, DNA transcription is initiated and specific portions of the DNA 
are induced to form several types of messenger RNA (mRNA) related to the process 
of Na+ and K+ transport (54; 138). The mRNA enters the cytoplasm and undergoes 
translation leading to protein synthesis (54). The proteins formed become me brane 
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transport proteins that are required for Na+ K+ and hydrogen transport across the cell 
membrane (54). In addition, some of the proteins are designated as specific enzymes, 
such as ATPase, needed for Na+-K+ ATPase activity, and luminal membrane proteins, 
a channel protein inserted into the apical end of the cell (54). The insertion of the 
luminal protein channels aids in the rapid diffusion of Na+ from the lumen of the 
renal tubule into the cell (54).
The end result of both mechanisms is that there is an increase in Na+
reabsorption into the blood and an increase in K+ secretion into the urine. The 
increased Na+ reabsorption in the extracellular fluid does not necessarily cause a very 
large increase in Na+ concentration in the extracellular fluid (54). The reason is that 
with the rise in Na+ concentration is a concomitant increase in water reabsorption, but 
the net result is an increase in extracellular fluid volume (54).
Based on aldosterone’s ability to create extracellular fluid volume adjustments
that affect blood pressure, aldosterone like ang II, is an integral component of the 
RFFS. Therefore, aldosterone and ang II are factors that function with the kidney to 
ensure that extracellular fluid volume remains relatively constant despite disturbances 
in body fluid homeostasis (60). 
Aldosterone and Essential Hypertension
Despite aldosterone’s necessary role in the kidney’s long-term regulation of 
blood pressure, if consistently elevated over a few days aldosterone can cause an 
individual to become hypertensive (54). A mechanism for aldosterone to cause 
hypertension is that when aldosterone levels are elevated over a few days there is an 
increase in extracellular fluid volume and blood pressure (54). An increase in 
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extracellular fluid volume of 5-15% can cause a 15-25 mm Hg increase in blood 
pressure (54). Based on the pressure-natriuresis mechanism, the elevation in blood 
pressure is necessary to increase Na+ and water excretion, reducing extracellular fluid 
volume (54). The result is the restoration f balance between fluid intake and fluid 
output in which the rate of gain of salt and water will be zero, despite the excess of 
aldosterone. However, the elevation in blood pressure necessary to restore fluid 
balance will cause the individual to become hypertensive (54).
High levels of aldosterone secretion are known to cause a secondary form of 
hypertension called primary aldosteronism, which is usually due to a small tumor of 
the zona glomerulosa cells (54). Even though the etiology of essential hypertension is 
considered to be polygenic, in some individuals it is possible that a slight dysfunction 
in certain physiological systems, such as the RAAS, can influence the development of 
hypertension. Due to aldosterone’s Na+ retaining effect, there is the potential for 
consistent elevations in aldosterone levels, within a normal level  (20-600 pg/ml) 
(112), to contribute to the development of hypertension.
Guyton, one of the developers of the RFFS and the pressure-natriuresis 
theory, explained that only slight elevations in extracellular fluid volume are needed 
to cause shifts in the renal-function curve (i.e. the pressure natriuresis mechanism ) 
that can lead to hypertension (55). The example given by Guyton involved 
hypertensive patients being treated with spironolactone, a medication given to block 
the influence of steroid hormones, such as aldosterone (132). The patients stopped 
taking spironolactone for 1-2 weeks, which resulted in a  20-4 % increase in plasma 
volume and a rise in arterial pressure to their initial untreated hypertensive levels 
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(132). The patients remained off of their spironolactone, and over the following 
weeks plasma volume reduced to normal levels, but surprisingly there was no 
reduction in arterial pressure (132). Guyton explained that to compensate for the 
small amount of fluid retention that was occurring due to aldosterone, the equilibrium 
pressure point was shifted and reset to a higher mean arterial pressure (55). This was 
necessary so that equilibrium between fluid intake and output could be re-established 
in light of increased fluid retention. 
The main point of Guyton’s example was to illustrate that hypertension in 
some individuals could be due to an upward shift in the equilibrium pressure point 
that results from small but consistent elevations in Na+ retention (55). The Na+
retention experienced by some hypertensives may be the result of slight alterations in 
aldosterone biosynthesis and/or other mechanisms that impact renal Na+ handling 
(55). 
There is evidence of elevated plasma aldosterone levels among hypertensive 
individuals. In studies that have compared mild and severe hypertensives to matched 
normotensives, it was found that plasma aldosterone levels were significantly higher 
among the hypertensives compared to the normotensives (23; 44; 73; 74; 95). It is 
important to note that in these studies plasma aldosterone levels of both the 
hypertensives and normotensives were well within the normal range, but the 
hypertensives displayed significantly greater levels. For example, Garcia et al. 
reported average plasma aldosterone levels of 198 pg/ml among hypertensives and 
147 pg/ml among normotensives (73). Cortes et al. found that average plasma 
aldosterone levels were 116 pg/ml among hypertensives and 99 pg/ml among 
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normotensives, again demonstrating the same phenomenon as in the Garcia study 
(23). Additionally, hypertensives have been reported to show a significant decrease in 
the metabolic clearance rate of aldosterone, and a positive correlation between resting 
mean arterial pressure and plasma aldosterone levels (44; 95). Therefore, it is possible 
that the elevated plasma aldosterone levels displayed by the hypertensives contribute 
to the maintenance of a hypertensive state (73).
Normally, plasma aldosterone is negatively correlated with urinary Na+
excretion. This has been confirmed among normotensives but not among 
hypertensives (73). Garcia et al. suggested that the lack of correlation between plasma 
aldosterone and urinary Na+ excretion among the hypertensives may represent some 
type of disturbance in aldosterone biosynthesis that may or may not be directly linked 
to changes in Na+ regulation (27; 69; 149). 
Aldosterone’s response to an adrenal stimulus, such as salt loading and ang II 
infusion has been shown to differ between hypertensives and normotensives. Ishii et 
al. reported that after 4 days of salt loading, the reduction in plasma aldosterone levels 
that occurred among hypertensives was significantly less than normotensives (71). 
This was indicative of blunted suppression of aldosterone biosynthesis among the 
hypertensives. Ishii et al. suggested that the blunted aldosterone response displayed 
by the hypertensives may be the result of altered adrenal cortex sensitivity to 
circulating ang II (71). In normotensives, Na+ loading reduces the sensitivity of the 
adrenal cortex to ang II (109), this results in the suppression of aldosterone 
biosynthesis. Some hypertensives may experience dysfunction in adrenal 
responsiveness, in which the sensitivity of the adrenal cortex to ang II is not 
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suppressed under Na+ loaded conditions (71). There are studies that have 
demonstrated that hypertensives may display alterations in adrenal responsiveness to 
ang II infusion. Kisch et al. reported that hypertensives had a significant increase in 
plasma aldosterone levels at lower ang II infusion rates compared to normotensives 
(83). It was concluded that hypertensives demonstrated enhanced adrenal 
responsiveness to ang II infusion (83). Schlaich et al. also reported that normotensives 
with a family history of hypertension displayed a hyper-r sponsiveness to ang II 
infusion (133). Williams et al. also found that hypertensive patients placed on a 200 
mEq Na+ diet had a greater increase in plasma aldosterone in response to infused ang 
II compared to normotensives (157). 
There is evidence to support that among some hypertensives, plasma 
aldosterone levels are significantly elevated and have a distribution range that is 
wider than that of normotensives (73). From the available data, it appears that 
consistent elevation in plasma aldosterone within a normal range may contribute to 
the development and maintenance of hypertension.  
Ethnicity and Age Effects on Aldosterone Levels 
Ethnic Differences: It has been determined that there are some ethnic 
differences in PRA, and plasma levels of ang II and aldosterone. Specifically, this has 
been observed when comparing individuals of African descent and Caucasians. It has 
been reported that under basal and stimulated conditions, individuals of African 
descent have suppressed PRA, and plasma  ang II and aldosterone levels (40; 64; 
128). A review by Sagnella et al. explains that the reports of differences in RAAS 
function among those of African descent and Caucasians first appeared in the 1960s 
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when a study by Helmer and Hudson reported lower PRA among hypertensives of 
African descent compared to hypertensive Caucasians (65). In reviewing studies that 
compared PRA between hypertensive and normotensives of African descent and 
hypertensive and normotensive Caucasian , Sagnella et al. reported that on average 
hypertensives and normotensives of African descent had PRA that was 50% lower 
than Caucasian hypertensives and normotensives (128). However, Sagnella reported 
that there appeared to be a wide range of variability in PRA among hypertensives and 
normotensives of African descent, and therefore a large proportion of these 
individuals may have had PRA that was in the same range as Caucasians (128). 
Therefore, lower PRA among those of African descent continues to be a topic of 
debate. 
Ethnic differences in plasma aldosterone levels have also been investigated in 
normotensive and hypertensives of African descent and Caucasians. Studies have 
demonstrated that there appears to be some suppression of plasma and urinary 
aldosterone levels in normotensive and hypertensives of African descent when 
compared to Caucasians (40; 64; 115; 116). One study by Pratt et al. measured 
urinary and plasma aldosterone levels in children of African descent and Caucasian 
children (115). Urinary aldosterone levels were lower in the children of African 
descent compared to Caucasian children (115). In addition, there were no differences 
in Na+ excretion between the two groups, but the children of African descent did have 
lower K+ levels, which was indicative of lower K+ intake (115). Since K+ levels can 
affect aldosterone biosynthesis (20), lower K+ intake may have contributed to the 
lower aldosterone biosynthesis, leading to less aldosterone excreted in the urine. Pratt 
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et al. suggested that the children of African descent could have had a lower degree of 
responsiveness to K+, and this could have accounted for the lower urinary aldosterone 
excretion (115). Regardless of these suggestions, when controlling for K+ intake, 
aldosterone excretion was still lower in the children of African descent (115). Not 
only were urinary aldosterone levels different between the two groups, but plasma 
aldosterone levels were also lower among the children of African descent (115). The 
study by Pratt et al. indicates that there are possible ethnic differences in plasma and 
urinary aldosterone levels among children of African descent children. Due to the use 
of healthy children and lack of  control of Na+ nd K+ intake, it is difficult to make a 
definitive conclusion that the same ethnic differences in aldosterone levels observed 
in the children also occur in adulthood and contribute to the development 
hypertension (115).
There have been studies performed in adult normotensives and hypertensives 
investigating ethnic differences in plasma aldosterone levels. Fisher et al. conducted a 
study in which hypertensives and normotensives of African descent and Caucasian 
hypertensives and normotensives were placed on a standardized Na+ and K+ intake of 
10 mmol/d and 100 mmol/d, respectively (40). Under basal conditions, plasma 
aldosterone levels were the same between normotensives of African descent and 
Caucasian normotensives and between hypertensives of African descent and 
Caucasian hypertensives, but plasma aldosterone levels were lower among all 
hypertensives compared to normotensives (40). The responsiveness of plasma 
aldosterone to a change in posture differed between the two hypertensive ethnic 
groups in which the increase in plasma aldosterone levels when going from the supine 
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to the upright position were smaller in hypertensives of African descent compared to 
Caucasian hypertensives (40). In addition, upon infusion of ang II, which stimulates 
aldosterone secretion, hypertensives of African descent had lower plasma aldosterone
levels compared to the Caucasians hypertensives (40). Normotensives of African 
descent and Caucasian normotensives did not display these same differences (40).
This study by Fisher et al. suggested that among normotensives of African 
descent and Caucasian normotensives there were no differences in plasma aldosterone 
levels under basal and stimulated conditions (40). Additionally, the differences in 
plasma aldosterone levels that occurred between normotensives and hypertensives 
were independent of ethnicity (40), The ethnic differences occurred within the 
hypertensive group, and were not uncovered until postural changes and ang II were 
used to stimulate aldosterone biosynthesis (40). These findings may have 
demonstrated that possible ethnic differences in aldosterone biosynthesis may only be 
apparent among hypertensives and under conditions that stimulate the synthesis and 
release of aldosterone (40).
He et al. investigated the change in PRA, and plasma aldosterone and ang II 
levels in response to alterations i  Na+ intake in hypertensives of African descent and 
hypertensive Caucasians (64). Under basal conditions in which patients consumed 
their usual unregulated diet, plasma aldosterone and ang II levels were not different 
between individuals of African descent and Caucasians, but PRA was lower among 
individuals of African descent compared to Caucasians (64). Following their usual 
dietary period, the patients were placed on a 5 day high Na+ diet (350 mmol/day) 
followed by a 5 day low Na+ diet (10 mmol/day) (64). The investigators found that 
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the individuals of African descent had a greater reduction in blood pressure and a an 
attenuated increase in PRA, plasma ang II, and plasma aldosterone levels compared to 
Caucasians (64). Normally, a large reduction in Na+ intake, such as the one in this 
study, would stimulate an increase in PRA and plasma ang II and aldosterone levels 
to prevent a large fall in blood pressure (64). He et al. concluded that the 
hypertensives of African descent might have suppressed PRA, ang II and aldosterone 
allowing for a greater fall in blood pressure compared to Caucasians (64).  Therefore, 
it is possible that plasma aldosterone levels are less likely to differ among 
hypertensives of African descent and hypertensive Caucasians under basal conditions, 
but under conditions in which aldosterone biosynthesis is stimulated, ethnic 
differences are more likely to be uncovered. 
Age: Hypertension is a disease associated with aging, and this in part may be 
related to alterations within the systems that regulate blood pressure as individuals 
age. Therefore, it is conceivable that the RAAS would experience a decline in 
responsiveness and activity as individuals’ age. In general, it has been reported that 
after the second decade of life there is a steady decline in PRA that becomes 
pronounced between 40 and 60 years of age (24; 106; 130; 154). A similar decline 
with age has also been shown in many studies that have investigated the effect of age 
on plasma and urinary aldosterone levels (24). Crane et al. investigated the change in 
the RAAS with each decade of life and found that when individuals were on an 
unrestricted Na+ intake there was a progressive reduction in urinary aldosterone 
excretion rate from the 2nd to 7th decade of life (24). Additionally, urinary aldosterone 
excretion was 46% lower among those in the 7th decade compared to those in the 2nd
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decade (24). In regards to plasma aldosterone levels, studies have reported age- elated 
effects occurring under conditions that would stimulate aldosterne biosynthesis 
(130; 154). For example, plasma aldosterone levels appeared to be suppressed in 
older individuals, when they experienced postural changes or Na+ and volume 
depletion (130; 154). 
It appears that with age there is a general decline in RAASactivity, but 
specifically, there is a possible decline in adrenal responsiveness and the mechanisms 
responsible for the secretion of aldosterone.   
Heritability of Blood Pressure, and Hypertensive Phenotypes 
Blood pressure and the physiological variables involved in the regulation of 
blood pressure have been shown to have a genetic component (90). Williams et al. 
combined data from 5 heritability studies (12; 38; 39; 63; 76) and  reported that 
genetic factors have a stronger influence on the determination of an individual’s 
resting blood pressure than shared environment (159). Williams et al. also reported 
that among these studies, resting blood pressure correlations were higher among 
related family members compared to non-related family members from a shared 
environment (12; 38; 39; 63; 76; 159). For example, among genetically related 
individuals, such as parent-offspring, the correlations were reported to be 0.18 and 
0.16 for resting SBP and DBP, respectively (12; 38; 39; 63; 76; 159). Spouse pair 
correlations have been reported to be as low as 0.08 and 0.06 for resting SBP and 
DBP, respectively (12; 38; 39; 63; 76; 159). Additional family aggregation studies 
have investigated the heritability of resting blood pressure among parent-offspring, 
sibling-sibling and monozygotic (MZ) and dizygotic (DZ) twins (52; 103). The 
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family aggregation values for these relationships have ranged from 0.25-0.68 and 
0.41-0.58 for SBP and DBP, respectively (12; 38; 39; 52; 63; 76; 103). These 
heritability and family aggregation studies provide evidence that the establishment 
and regulation of an individual’s resting blood pressure is partly genetically 
determined. 
Essential hypertension differs from other monogenic forms of hypertension, 
such as primary aldosteronism or Liddle’s syndrome because it is polygenic, meaning 
that there may be a multitude of genes that contribute to its development (90; 159). 
Early debate about the genetics of essential hypertension occurred between two 
researchers, Pickering and Platt (144). Pickering suggested that essential hypertension 
was polygenic and was not due to a single loci mutation (90; 110). Platt believed that 
essential hypertension was a monogenic, single loci, autosomal mutation that 
followed Mendelian inheritance (111). Years of research have weakened Platt’s 
argument and provided support for Pickering’s argument that essential hypertension 
is indeed a multifactoral disease, involving the interaction of multiple genes, and is 
not due to a single loci mutation that follows Mendelian inheritance (90). The 
technique of simple segregation analysis has been used to help delineate whether the 
pattern of inheritance of hypertension fits that which would be predicted by a single-
locus model, and there has been limited evidence to demonstrate that essential 
hypertension follows such a pattern of inheritance (90). It has been suggested, 
however, that there may be rare subgroups of families in which the pattern of 
inheritance of hypertension can be predicted by a single-loci, but this has been 
difficult to detect (90). 
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Given the complex genetic etiology of hypertension, there are not many 
studies that have been able to clearly demonstrate its pattern of inheritance. In 
general, studies have reported on the heritability of blood pressure and/orthe 
phenotypes associated with the regulation of blood pressure. There are some studies 
that have reported on the family aggregation of hypertension by investigating family 
history (70). For example, Williams et al. reported, based on unpublished data, that 
70% of individuals who developed hypertension before the age of 55 had a positive 
family history of hypertension, which included having siblings and/or parents with 
hypertension (158). It has also been reported that young individuals with a positive 
family history of hypertension had a four-times greater risk of developing 
hypertension compared to those with no family history of hypertension (70; 158). 
As mentioned earlier, because hypertension is a heterogeneous trait, it has 
been difficult for studies to demonstrate genetic linkage (158). Therefore, researchers 
have focused their attention on the heritability of intermediate hypertension 
phenotypes in which genetic linkage is thought to be more evident (158). The 
Cardiovascular Genetics Research Clinic at the University of Utah studied the  
heritability of intermediate phenotypes that may contribute to the development of 
hypertension in 98 pedigrees with a family history of hypertension (156). They 
reported individuals with lower urinary excretion of kallikrein, a potent vasodilator 
(54), were two-times more likely to have a first-degree relative with hypertension 
(11). In addition, those with a family history of hypertension were found to have an 
increase in intraerythrocytic Na+ concentration and Ouabin binding sites, which 
reflected the number of Na+-K+-ATPase pumps on the surface of red blood cells (62). 
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An increase in both phenotypes (intraerythrocytic Na+ concentration and Ouabain 
binding sites) (11; 62), reflected a possible increase in renal tubular Na+ reabsorption 
that could have contributed to the development of hypertension. Williams et al. 
suggested that two or three of these traits in combination with specific environmental 
factors could explain the occurrence of essential hypertension in sme individuals 
(156). 
Additional studies have investigated the heritability of other intermediate 
phenotypes that may contribute to hypertension. In family aggregation studies it has 
been reported that among individuals with hypertensive first-degree relatives, plasma 
renin levels were higher and their ability to excrete a Na+ lo d was lower compared to 
those with normotensive first-degree relatives (50). There is also evidence of 
heritability with respect to aldosterone excretion and plasma aldosterone l vels.
Manatunga et al. reported that among young, (6-17 years), MZ and DZ twins, the 
interclass correlation coefficient for aldosterone excretion was 0.69 and 0.29, 
respectively, which was indicative of strong heritability (99). Additionally, 
Manatunga et al. found that among siblings of African descent, the interclass 
correlation for aldosterone excretion was 0.51, again indicative of strong family 
aggregation (99). Grim et al. reported that plasma aldosterone levels under basal 
conditions and in response to volume expansion were heritable among monozygotic 
and dizygotic twins (51). Additionally, it was found that urinary K+ and fractional 
Na+ excretion showed significant genetic variation under volume expanded 
conditions (51). Grim et al. concluded that the renal regulation of Na+ and K+
excretion, as well as homeostasis, may be partly influenced by heritability (51); 
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therefore, it can be suggested that disregulation of these phenotypes can aggregate 
among families and contribute to the incidence of hypertension that occurs among 
related individuals.  Kotchen et al. demonstrated that among hypertensive African 
descent sib-pairs, the response of indices of renal clearance to a norepinephrine 
stimulus and the PRA response to changes in posture were heritable (88). 
Furthermore, a family aggregation study among individuals of African descent 
investigated the heritability of salt sensitivity and found that SBP, DBP, and mean 
arterial blood pressure (MAP) responses to a change in Na+ load were heritable, 
suggesting a genetic component to salt sensitivity (143). 
Evidence of the heritability of blood pressure and the phenotypes that 
influence it establishes the precedence that the level of blood pressure is a 
heterogeneous trait in which its regulation may be the result of the interaction of 
multiple genes. The assumption can be made that the development of hypertension 
may be partly due to genetic variation within different pathways that regulate blood 
pressure. Therefore, in researching the genetics of hypertension, it is important to use 
these physiological pathways as a guide in determining what genes may be important 
in the investigation of hypertension. 
CYP11B2 Gene and Aldosterone Biosynthesis
The CYP11B2 gene, also known as the aldosterone synthase (AS) gene, is 
responsible for aldosterone biosynthesis, and therefore attention has been focused on 
its possible contribution to the development of hypertension. CYP11B2 stands for 
cytochrome P450, family 11, subfamily B, polypeptide 2, and encodes for a member 
of the cytochrome P450 superfamily of enzymes, P450c11AS (4). The P450c11AS 
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enzyme, also called AS, is a monooxygenase that has 18-hydroxylase and 11-beta 
hydroxylase activity, both of which are necessary for catalyzing the synthesis of 
aldosterone (4; 26; 81)
The CYP11B2 gene is located on the long arm of chromosome 8q, contains 9 
exons and 8 introns, and was first discovered by Kawamoto and colleagues (81). It 
was suspected to be a less active gene closely related to the CYP11B1 gene, which is 
involved in glucocorticoid production (81). Even though both the CYP11B1 and 
CYP11B2 genes were found to have exon sequences that were 93% identical, they 
differed significantly in their promoter region (81). The CYP11B2 gene was found to 
encode an enzyme that had both 18-hydroxylase and 11-beta-hydroxylase activity 
(81), whereas the CYP11B1 gene only encoded for the 11-beta-hydroxylase enzyme 
(81). Therefore, it was determined that the CYP11B2 and CYP11B1 genes, though 
closely related, were two separate genes that produced two separate enzymes (81). 
CYP11B2 encoded for an enzyme that catalyzed the synthesis of mineralcorticoids, 
while CYP11B1 encoded for an enzyme that catalyzed the synthesis of 
glucocorticoids (81). 
Aldosterone biosynthesis occurs in two phases, an acute phase and a chronic 
phase (21). The acute phase occurs within minutes and involves the transfer of 
cholesterol (the initial precursor to aldosterone) to the mitochondria of the 
glomerulosa cells (21). This process is partly regulated by intracellular calcium 
(Ca2+), calmodulin (CaM), and calcium/calmodulin-dependent kinases (CaMK) (21). 
CaM is a multipurpose intracellular Ca2+ receptor that mediates many Ca2+-related 
intracellular processes (5). While CaMK are responsible for the phosphorylation of 
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proteins involved in the signaling pathways stimulated by Ca2+ (5). Both CaM and 
CaMK are also important factors in the chronic phase of aldosterone biosynthesis 
which involves the signaling cascade necessary for regulating CYP11B2 gene 
expression (21).
In the chronic phase, aldosterone biosynthesis is regulated by CYP11B2 gene 
expression (21). There have been recent discoveries in the last few years that have 
uncovered possible steps in the regulation of CYP11B2 expression. One being that 
there are two main physiological regulators, ang II and K+ (20). Ang II and K+ can 
directly act on the adrenal gland and lead to an increase in CYP11B2 mRNA and 
protein levels (21). The suggested mechanism by which ang II and K+ regulate 
CYP11B2 gene expression involves the increase in intracellular Ca2+ levels (20). 
When plasma ang II levels become elevated, ang II will binds G-protein coupled AT1
receptors located in the adrenal glomerulosa cells (137). This leads to the intracellular 
activation of phospholipase-C (PL-C), a plasma membrane bound enzyme, which 
hydrolyzes phosphatidylinositol bisphosphate (PIP2), an inositol phospholipid, to 
inositol triphosphate (IP3) (5; 117). IP3, is a small water soluble molecule that leaves 
the plasma membrane, diffuses through the cytosol and then binds to IP3 gated Ca
2+ 
channels (5). The binding of IP3 to the Ca
2+ channels leads to the release of Ca2+ and 
to an increase in intracellular Ca2+ concentration (5; 20; 117). K
+ stimulates the 
release of Ca2+ by causing the depolarization of the plasma membrane of the adrenal 
glomerulosa cells (117). The depolarization leads to the activation of voltage-
sensitive Ca2+ channels and the release of Ca2+, which causes an increase intracellular 
Ca2+ concentration (20). Clyne et al. found that the increase in intracellular Ca2+ 
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concentration leads to an increase in CYP11B2 gene expression, confirming that 
intracellular Ca2+  concentration has a very important role in the induction of 
CYP11B2 (20).
The mechanism by which Ca2+ influences CYP11B2 gene expression is 
through the CaM-CaMK cascade (21). It is suggested that both CaM and CaMK are 
important in the induction of CYP11B2 by ang II and K+ (21). Condon et al., through 
the use of H295R adrenocortical cells transfected with luciferase reporter constru ts 
driven by CYP11B2 5’-flanking DNA, demonstrated that when two separate 
inhibitors for CaM and CaMK were used, expression of CYP11B2 by ang II and K+
was inhibited (21). The regulation of the CYP11B2 by ang II and K+ via the Ca+-
CaM-CaMK signaling pathway requires important gene regulatory elements located 
within the CYP11B2 gene. Within the 5’ flanking region of the CYP11B2 gene is a 
cis-regulatory element, a region within the promoter where the transcription factor 
CaMKI-295 binds and influences transcriptionof CYP11B2 (20; 21). The cis-
regulatory element is located between –64 and –347 bp, and when this region is 
deleted, CYP11B2 gene expression by CaMKI-295 decreases significantly (21). In 
addition, there is a second important regulatory region ide t fied at position –71/-64 
bp, called the cAMP response element (CRE) (21). Both Clyne and Condon identified 
this region as essential for regulation of CYP11B2 transcription by ang II, K+, and 
cAMP (20; 21). Mutations in this region have been found to block CAMKI and ang II 
stimulated gene expression (20; 21). The CYP11B2 CRE has been shown to bind 
transcription factors such as CRE-binding (CREB) protein and members of activating 
transcription factors (ATF-1 and ATF-2) (21). Condon et al. suggests that once the 
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Ca2+-CaM- CaMKI cascade is activated by ang II, and  K+, CaMKI phosphorylates 
CREB and ATF-1, which could increase their ability to enhance transcription of the 
CYP11B2 gene (21). 
Once the CYP11B2 gene product, P450c11AS, has been produced it is 
responsible for the two terminal steps in the conversion of corticosterone to 
aldosterone (18-hydroxylation and 18-methyloxidation) (26). The molecular steps 
responsible for the expression of CYP11B2 are intricate and continue to be 
elucidated. Due to the fact that the CYP11B2 is essential in aldosterone biosynthesis, 
it is possible that mutations in the regulation of this gene may contribute to chronic 
elevations in aldosterone levels and Na+ reabsorption, which may be important in the 
etiology of hypertension. 
CYP11B2 –344C/T Polymorphism and the Association with Hypertension
The CYP11B2 gene has recently been proposed as a hypertension candidate 
gene based on its involvement in aldosterone biosynthesis. Mutations in the 
CYP11B2 gene or abnormalities in the regulatory factors of the gene have been 
shown to lead to aldosterone related disorders (102)  Based on this evidence, 
researchers have investigated whether less severe mutations in different regions of the 
CYP11B2 gene could possibly contribute to the development of hypertension (14).  
For example, the –344C/T promoter polymorphism of the CYP11B2 gene, 
occurs in the core sequence of a regulatory element called Ad4, a nuclear receptor 
half-site consisting of a sequence of base pair repeats (10). Regulatory elements are 
vital in the regulation of the initiation of transcription by RNA polymerase (5). There 
are specific regulatory proteins, such as activator proteins that bind to the regulatory 
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elements called enhancer elements (5). Once bound, the activator proteins greatly 
enhance the initiation of transcription by attracting, modifying, and positioning RNA 
polymerase and other transcription factors onto the promoter (5). The specific 
activator protein that binds to the Ad4 element is a monomeric orphan nuclear 
receptor protein called steroidogenic factor-1 (SF-1) (10). An orphan nuclear receptor 
protein, such as SF-1, remains in an inactive state until the binding of an unknown 
hydrophobic signal molecule, once activated SF-1 binds to Ad4 (5). It has been
reported that the Ad-4 is essential for the coordinated development and function of 
the adrenal gland, and that SF-1 is required for full expression of many other 
cytochrome P450 genes (10; 104). Therefore, it could be suggested that a mutation in 
the Ad4 region, such as the -344C/T SNP, could alter the binding of SF-1 and 
consequently gene expression. 
White and Slutsker have reported that the presence of the C allele of the 
–344C/T polymorphism causes SF-1 to bind four times as tighter on a molar basis  
compared to the presence of the T allele (155). These findings were confirmed by 
Bassett et al. in which it was demonstrated, using an electrophoretic mobility shift 
assay, that the C allele bound SF-1 tighter than the T allele (10). Despite suggestions
that the binding of SF-1 to Ad4 was necessary for CYP11B2 expression, molecular 
studies by Bassett et al. determined that the binding of SF-1 to Ad4 was not essential 
for the expression of CYP11B2 (10). By cotransfecting H295R cells with reporter 
constructs containing the 5’ flanking DNA of the CYP11B2, CYP11A1, CYP11B1 
and CYP17 with an expression plasmid containing the coding region for SF-1, Basset 
et al. found that the expression of the CYP11B2 gene was significantly less compared 
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to the other CYP genes (10). In addition, with increasing SF-1 concentration 
CYP11B2 gene expression continued to decrease (10). Therefore, based on the 
findings of Bassett et al., the binding of SF-1 to Ad4 does not appear to be necessary 
for the expression of CYP11B2 (10; 20). Additionally, Bassett et al. investigated 
whether the C or T allele associated SF-1 binding affected gene expression, but found 
that regardless of the allele, the presence of SF-1 did not affect CYP11B2 gene 
expression (10).
Together, these findings indicate that the Ad4 site is a functional regulatory 
element that binds SF-1 and  therefore influences the expression of such CYP genes 
as CYP11A1, CYP11B1, and CYP17, but this is not true for CYP11B2 (10). It 
appears that even though SF-1 binds to the CYP11B2 Ad4 site in the same manner as 
the other CYP genes, SF-1 is not involved in the regulation of CYP11B2 transcription 
(10). Thus, there is some evidence that the –344C/T polymorphism may not be a 
functional mutation, which may be a surprising conclusion in light of the studies 
reporting an association between the –344C/T polymorphism and hypertension, and 
variations in both plasma and urinary aldosterone levels (14; 29; 66; 114; 147). 
One recent study by Henderson et al. found that the population attribut ble 
risk of hypertension associated with the presence of the T allele was 37.4% among 
African descent males and 27.7% among African descent females (66). These 
findings were further supported by Tiago et al., in which the association between the 
–344C/T polymorphism and ambulatory and office blood pressure was investigated in 
hypertensives of African descent (147). Ambulatory and office SBP was higher 
among those with the T allele (147). In addition there was reduced nocturnal decline 
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in SBP among those with the T allele (147). The association between the –344C/T 
polymorphism and blood pressure has also been investigated in the Caucasian 
hypertensive population. Both Davies et al. and Brand et al. found a higher frequency 
of the T allele among hypertensives compared to controls (14; 29). Staessen et al. 
demonstrated that in a European Caucasian population of both hypertensives and 
normotensives, an increase in relative risk of hypertension was associated with the T 
allele, and the CC genotype was associated with the lowest SBP and DBP (141). 
There is a possibility that the association between the –344C/T 
polymorphism and hypertension may be age-dependent. Russo et al. demonstrated 
that the T allele was associated with the age- ssociated increase in DBP in Caucasian 
males (127). Furthermore, in the majority of the studies that have shown an 
association between the T allele and hypertension the participants have had a mean 
age of 40 years and higher (14; 29; 89; 141; 147). It is well accepted that 
hypertension is a disease associated with aging, however it can also be suggested that 
there are some genes polymorphisms that exert a greater influence on blood pressure 
as one ages.
Most investigations of the -344C/T polymorphism and blood pressure have 
examined Caucasians, while there are only a limited number of studies that have used 
other populations. The T and C allele frequencies of hypertensives of African descent 
were reported to be .78 and .22, respectively (163). Among Japanese hypertensives, 
the T and C allele frequencies were similar to hypertensives of African descent, .66 
and 0.34, respectively (151). By comparison, the T allele frequency is reportedly 
lower (.52) and the C allele higher (.47) among Caucasian hypertensives (163).
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Not all studies have found that the T allele is associated with hypertension, it 
is possible that ethnic differences in the -344C/T allele frequencies may contribute to 
the inconsistent findings among studies. For example, studies in Japanese 
hypertensives have demonstrated thate C allele appears to be more frequent than in 
normotensive Japanese controls (145; 151). Tamaki et al. compared the frequency of 
the TT and TC+CC genotypes in Japanese hypertensives, and controls and found that 
the frequency of the TC+CC genotype was significantly greater in the hypertensives 
than normotensives, 52.2% and 43.2% respectively (145). In addition, when 
investigating 24 hour ambulatory blood pressure in the same Japanese hypertensives, 
it was found that the TC+CC genotype group was classified as nondippers, meaning 
that they had a blunted nocturnal decline (145). Similarly, Tsukada et al. also reported 
that the frequency of the C allele was higher among Japanese hypertensives compared 
to normotensives (151). In contrast, Matsubara et al. reported that the nocturnal 
decline in blood pressure was greater among the CC genotype compared to those 
carrying the T allele in community dwelling Japanese, suggesting that the T allele 
was associated with a blunted nocturnal decline in blood pressure (100). Furthermore, 
studies by Kato et al. and Tsujita et al. reported no association between the –344C/T 
polymorphism and hypertension in the Japanese hypertensive populations (79; 150). 
Possible explanations for the conflicting findings among these studies may tem from 
heterogeneity among the Japanese population used. The study by Matsubara reported 
using community dwelling Japanese, but did not specify whether or not these 
individuals were hypertensive or normotensive (100). Tsukada et al. mentioned that 
the differences between their findings and those of Kato et al. may actually be related 
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to geographic environmental differences in the Japanese that were examined in their 
study (151). The population in the Tsukado study was from rural and suburban 
districts, whereas the Japanese group studied by Kato was mostly from the city 
(Tokyo) (151). Such distinctions are important since the Japanese from the rural 
environment have been found to ingest more Na+ th n those from the urban 
environment; therefore, the difference in results between the two studies may have 
been related to gene-environment interactions, in which one specific genotype 
association may have developed over generations due to specific dietary habits (151). 
There have been discrepancies in regards to the association between the 
–344C/T polymorphism and hypertension among other populations as well. Zhu et 
al., found that there was no association between –344C/T polymorphism and 
hypertension between Caucasians and individuals of African descent (163). These 
findings differed from the previously mentioned studies that investigated the 
association within Caucasian populations and populations of African descent (14; 29; 
66; 141; 147). It is difficult to discern why Zhu et al. did not find a genotype 
association with BP, despite having a robust sample size. Possible differences in 
study design could have contributed to the lack of findings. 
Available literature provides evidence that the –344C/T polymorphism is 
associated with blood pressure and hypertension. It is known that there can be 
substantial interindividual variability in intermediate phenotypes related to the 
development of hypertension, such as plasma aldosterone and renal Na+ h ndling. 
Variation in these intermediate phenotypes may be partially attributed to genetic 
variation. The CYP11B2 –344C/T polymorphism has been found to be associated 
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with plasma and urinary aldosterone and Na+ excretion. Pojoga et al. investigated the 
association between the –344C/T polymorphism and plasma aldosterone lev ls in 
Caucasians with mild to moderate hypertension (114). Plasma aldosterone levels were 
measured after participants completed an overnight fast and were supine for 90 
minutes (114). It was determined that the C allele was associated with greater plasma
aldosterone levels. There was a C allele dosage effect in which plasma aldosterone 
levels were highest among the CC genotype group, intermediate among the TC 
genotype group and lowest among the TT genotype group (114). It is important to 
note that the greater plasma aldosterone levels in C allele carriers were well within 
normal range and were not considered to be at pathologic levels consistent with 
secondary forms of hypertension, such as hyperaldosteronism. Pojoga et al. reported 
that normal supine plasma aldosterone levels range from 20-230 pg/ml and upright 
values range from 40-600 pg/ml (112). Therefore, the point should be taken that the
–344C/T polymorphism may account for the slight elevations in plasma aldosterone 
levels that are within a normal range, and due to aldosterone’s Na+ retaining qualities, 
this could contribute to the development of hypertension.
There have been only a few other studies that have investigated the 
association between the –344C/T polymorphism and plasma or urinary aldosterone 
levels (14; 29; 163) . Brand et al. reported that the T allele was associated with 
elevated serum aldosterone levels in normotensives(14). These results may have 
differed from Pojoga et al. study because the hypertension status of the participants 
was different.  Pojoga studied hypertensives and Brand et al. studied normotensives 
(14; 114). Zhu et al. investigated the association between the –344C/T polymorphism 
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and plasma aldosterone levels in hypertensives of African descent and Caucasian 
hypertensives (163). No association was found between the –344C/T polymorphism 
and plasma aldosterone levels in either population. This could have been due to the 
difference in the methods used to obtain plasma aldosterone. Zhu et al. obtained 
blood samples while participants were seated, however they did not report the amount 
of time that the participants were seated, whether the participants were fasted, or the 
time of day blood samples were obtained (163) . Aldosterone is sensitive to changes 
in body position and diet and can differ based on the time of day the blood sample is 
obtained (17).Therefore, lack of control of these variables could have contributed to 
the lack of association between the -344C/T polymorphism and plasma aldosterone 
levels in the Zhu et al. study. 
The association between urinary aldosterone levels, Na+ excretion and the 
-344C/T polymorphism has also been investigated. Davies et al. reported that the T 
allele was associated with higher urinary aldosterone excretion rates compared to 
those with the C allele; however, the hypertensive status of the participants was not 
indicated. Due to aldosterone’s influence on renal Na+ handling, some studies have 
investigated the association between the –344C/T polymorphism and urinary Na+
excretion (31). Delles and colleagues conducted a study in young men with mild 
hypertension and found that after one week of an oral Na+ oad, those with the TT 
genotype had a greater increase in 24-hour urinary Na+ excretion compared to those 
with the CC genotype (31). Additionally, hypertensives with the TT or TC genotype 
were found to decrease serum aldosterone levels to a greater extent compared to those 
with the CC genotype (31) . The greater increase in Na+ excretion in the TT genotype 
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group in addition to the suppression of serum aldosterone levels indicated that T 
allele carriers demonstrated a normal response to an increase in Na+ load. Whereas, 
those with the CC genotype experienced an altered response in which the reduced 
Na+ excretion was an indication of Na+ retention that may have resulted from reduced 
suppression of aldosterone biosynthesis. 
The association of the C allele with elevated plasma aldosterone levels and 
reduced Na+ excretion is somewhat perplexing in light of the fact that in many 
studies, it was the T allele not the C allele that was associated with hypertension. It is 
logical to think that because the T allele is associated with hypertension, it may also 
be associated with an elevation in the hypertension-related phenotype, such as plasma 
aldosterone, which can contribute to an elevation in blood pressure. This pattern has 
been demonstrated with other hypertension candidate gene polymorphisms, such as 
the AGT M235T polymorphism, in which in some studies the T allele was associated 
with both hypertension and elevated plasma angiotensinogen levels (75; 160). 
Based on the relationship between aldosterone and renal Na+ handling, a 
few studies have investigated the association between the –344C/T polymorphism 
and salt sensitivity of blood pressure (15; 80; 113). These studies did not find an 
association between the –344C/T polymorphism and salt sensitivity (15; 80; 113). 
The reason for this could be: 1) the heterogeneity in Na+ loading protocols used to 
measure salt sensitivity, 2) the criteria for categorizing someone as salt sensitive is 
not consistent among studies, 3) the CYP11B2 gene may be one of many genes that 
influences blood pressure responsiveness to changes in a Na+ load, and the effect of a 
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single polymorphism such as the –344C/T may not be sufficient to significantly 
influence this phenotype. 
The evidence thus far demonstrates that the –344C/T polymorphism shows 
an association with hypertension and plasma aldosterone levels. These results are 
somewhat surprising based on findings that the Ad4 regulatory site, where the
-344C/T polymorphism occurs and SF-1 binds, has been found to be nonfunctional 
(10; 20). Consequently, there have been questions about whether the –344C/T 
polymorphism can cause alterations in aldosterone synthase tran cription that may 
influence aldosterone biosynthesis and eventually blood pressure. It has been 
suggested that although the Ad4 site is not necessary for CYP11B2 transcription, the 
–344C/T polymorphism may still influence transcription based on the allele-
associated differences in SF-1 binding (147). As mentioned earlier, the C allele is 
associated with tighter binding of SF-1 compared to the T allele (10). Therefore, 
when the C allele is present, the result may be tighter binding of SF-1 to the Ad4 site 
making SF-1 unavailable to bind to other functional regulatory sites that influence 
CYP11B2 transcription (14; 94; 147). The result is that the C allele is associated with 
reduced transcription of CYP11B2 and reduced aldosterone biosynthesis. In contrast, 
the presence of the T allele would cause SF-1 to bind less tightly to Ad4, freeing it up 
to bind to functional sites that would influence transcription of CYP11B2 and 
increase aldosterone biosynthesis, and over time, elevate blood pressure (14; 94; 147). 
Linkage disequilibrium may be another explanation for the association 
between the –344C/T polymorphism and hypertension and plasma and urinary 
aldosterone levels. Linkage disequilibrium occurs when two alleles at different loci 
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occur together within an individual more often than would be predicted by random 
chance (123). Indeed, a few CYP11B2 polymorphisms have been found to be in 
linkage disequilibrium with the –344C/T polymorphism. Thus, the –344C/T 
polymorphism may be a marker for a functional mutation or mutations that result in 
phenotypic differences. The K173R and the intron 2 conversion polymorphisms have 
been found to be in linkage disequilibrium with –344T/C polymorphism (14; 29; 155; 
163). The intron 2 conversion polymorphism results from the intron 2 of CYP11B2 
being replaced by the intron 2 of CYP11B1 (14; 155). The genotypes for the intron 2 
conversion are -/-, meaning both alleles have no conversion, -/+ means one allele has 
the conversion, and +/+ means both alleles have the conversion (163).  Zhu et al. 
found that Caucasian hypertensives had a greater frequency of the TT+/+ haplotype 
(163). However, these same results were not found in the population of African 
descent. The author suggested that the two polymorphisms may not be in linkage 
disequilibrium in this population of African descent (163). Similarly, Davies and 
colleagues found that among Caucasian hypertensives and normotensives, the 
-344C/T and intron 2 conversion polymorphisms were in linkage disequilibrium and 
that the T and + allele frequencies were greater among the hypertensives compared to 
the normotensives (29). 
In summary, there is evidence indicating that the -344C/T polymorphism is 
associated with hypertension. The majority of the studies report a T allele association, 
but there are some that report a C allele association. The reason for such 
discrepancies has not been clearly delineated but may be the result of differences in 
the study population or study design. Similarly, studies that have investigated the 
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-344C/T polymorphism’s association with plasma and urinary aldosterone levels are 
few and the findings are mixed. There is some evidence that this lack of consistency 
could be due to the non-functional effect of the -344C/T polymorphism. That is, the 
binding of SF-1 to the Ad4 site where the -344C/T polymorphism occurs, may not be 
essential for CYP11B2 gene expression. More studies are needed to clarify the 
association of the -344C/T polymorphism with both hypertension and plasma 
aldosterone levels, not only in Caucasian , but also in other ethnic groups where 
available data are limited.
Effectiveness of Aerobic Exercise Training on Hypertension
As previously mentioned, hypertension is considered to be a major public 
health burden in which 90% of individuals over the agof 50 are at risk for 
developing the disease (153). As a result of hypertension being a major risk factor for 
the development of CVD, there is a continuous effort to increase public and 
practitioner awareness about nonpharmacologic treatments that will reduce and 
control blood pressure in those afflicted with hypertension. In 1997, the Sixth Report 
of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure (1) was released with recommendations for the treatment of 
hypertension in individuals diagnosed as having high-normal or stages 1-3 
hypertension. It was recommended that lifestyle modification, such as increasing 
physical activity, independent of antihypertensive therapy, be the first line of 
treatment for those with high-normal blood pressure (130-139/85-89) or Stage 1 
hypertension (140-159/90-99) (1). In 2003, the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
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Pressure (19) was released with an updated recommendation for the treatment of 
hypertension. In this report, there were some slight changes in which the category of 
high-normal was abolished and the new category, pre-hypertension, (comprised of 
individuals with blood pressures between 120-139/80-89), was created (19). 
According to JNC VII, life-style modification, independent of antihypertensive 
medications, is recommended as first-line therapy in the treatment of hypertension for 
pre-hypertensive individuals (19). For those with stage 1 or 2 hypertension (stage 2 ≥
160/100), lifestyle modification in conjunction with antihypertensive medications is 
recommended. JNC VI and VII provide the gold standard for the treatment of 
hypertension, therefore the inclusion of physical activity as a therapeutic modality, 
speaks to its effectiveness and importance in the control of hypertension.
In 2000, Hagberg, Park and Brown reviewed all available studies that had 
been published on the effectiveness of aerobic exercise training on hypertension (59).
Of the studies that were reviewed, there were 74 groups of patients with hypertension, 
76% significantly decreased SBP with aerobic exercise training (59). Of the 73 
groups of patients with diastolic hypertension, 81% significantly decreased DBP with 
aerobic exercise training (59). Hagberg et al. were able to demonstrate that from all 
available studies that investigated the effect of aerobic exercise training on 
hypertension, a significant proportion reported hypertensive patients reducing blood 
pressure with aerobic exercise training (59). 
The effectiveness of aerobic exercise training to reduce blood pressure is not a 
haphazard science in which any given exercise intensity and duration will elicit 
beneficial results. Rather, the same specificity that is used when prescribing an 
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antihypertensive medication to a hypertensive patient is required when developing an 
exercise prescription for a hypertensive patient. Research has shown that an 
individual’s exercise intensity and duration does affect the magnitude of blood 
pressure reduction. Hagberg et al. reported that in aerobic exercise training studies in 
which intensities were set below 70% of maximal oxygen consumption (VO2 max), 
which is considered a low to moderate exercise intensity, hypertensive individuals 
had a 50% greater reduction in SBP, and a slightly greater reduction in DBP, 
compared to aerobic exercise training studies that used exercise intensities greater 
than 70% VO2 max (59). Roman et al. reported that among females with Stage 1 or 2 
Hypertension, those who exercised for 12 months at 70% of maximal heart rate had 
significant reductions in SBP and DBP of 20 and 18 mm Hg, respectively (125). 
However, when they exercised for 12 months at a high intensity over 70% of 
maximal heart rate, there was no significant reduction in blood pressure (125). 
Hagberg et al. demonstrated that among hypertensives, 9 months of aerobic exercise 
training at a low intensity of 50% of VO2 max, significantly reduced in both SBP and 
DBP by 20 and 11- 2 mm Hg, respectively. In contrast, the hypertensives that trained 
for 9 months at a higher intensity of 70-85% VO2 max, only significantly reduced 
their DBP (58). Other studies have also supported these results (34; 72; 135; 148; 
152). The findings that low to moderate inte sity exercise is as effective or even more 
effective at reducing blood pressure in a hypertensive population compared to high 
intensity exercise, demonstrate that the majority of individuals can achieve adequate 
reductions in blood pressure without being overwhelmed by unattainable exercise 
expectations. Also, as stated by Hagberg et al., with lower intensity exercise, 
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individuals are more likely to adhere to exercise expectations without experiencing 
injury and/or extreme physical exhaustion (59). 
The length of time it takes for reductions in blood pressure to occur when 
hypertensives undergo an aerobic exercise training protocol is additionally important. 
It is reported that average reductions in SBP and DBP of 9.8 mm Hg and 
8.4 mm Hg, respectively, can occur within the first 1-10 weeks of aerobic exercise 
training (59). Kohno et al. reported a 6 mm Hg and 4 mm Hg reduction in SBP and 
DBP, respectively, after 3 weeks of aerobic exercise training (86). Others studies such 
as Kiyonaga et al. reported sign ficant reductions of  18 mm Hg and 10 mm Hg in 
SBP and DBP, respectively, after 10 weeks of aerobic exercise training in Japanese 
hypertensives (84). Urata et al. and Sasaki et al. also reported reductions in SBP and 
DBP of approximately 12-13 mm Hg and 4-5 mm Hg, respectively after 10 weeks of 
aerobic exercise training (131; 152). Therefore, within a relatively short amount of 
time aerobic exercise training can cause considerable reductions in both SBP and 
DBP among hypertensives. 
Despite the significant reductions that can occur in both SBP and DBP after 
only a few weeks, evidence indicates that extending exercise training an extra 11-20 
weeks or more can elicit further reductions in SBP, but the same has not been 
reported for DBP (59). Hagberg et al. found that after 3 months of aerobic exercise 
training, there was an 11-12 mm Hg and an 8 mm Hg reduction in SBP and DBP, 
respectively, and after an additional 6 months of aerobic exercise training there was a 
further decrease in SBP by 8-9 mm Hg and DBP by 4 mm Hg (58). Kiyonaga et al. 
found that an additional 10 weeks of aerobic exercise training further reduced SBP 
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and DBP by 3 and 4 mm Hg, respectively (84). Additionally, Motoyama et al. 
demonstrated that after 3 months of aerobic exercise training, SBP and DBP 
decreased by 15 and 9 mm Hg, respectively (105). After an additional 6 months of 
aerobic exercise training SBP continued to decrease, but DBP did not change any 
further (105). 
The prevalence of hypertension increases in all aging populations independent 
of ethnicity. However, the prevalence and severity of hypertension and the blood 
pressure response to antihypertensive therapies can differ among ethnic groups. In the 
case of aerobic exercise training, there appears to be some differences among ethnic 
groups in blood pressure response. Caucasians have been one of the primary 
ethnicities studied in the area of aerobic exercise training and hypertension studies, 
and it has been demonstrated that they reduce blood pressure with aerobic exercise 
training (56). There have been a few studies on blood pressure response to aerobic 
exercise training in hypertensive Asian-Pacific Islanders, mainly Japanese (84; 86; 
131; 152). This population has shown significant reductions in blood pressure in 
response to aerobic exercise training (84; 86; 131; 152). Additionally, it has been 
found that blood pressure reduction can be slightly higher among Asian-Pacific 
Islanders hypertensives compared to Caucasian hypertensives (56).
Individuals of African descent have an increased prevalence and severity of 
hypertension. Despite this, very few studies have investigated the blood pressure 
response to aerobic exercise training in hypertensives of African descent. Over the 
past few years this has slowly changed, as more studies have either included 
hypertensives of African descent or used hypertensives of African descent 
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exclusively. Brown et al, investigated the change in blood pressure in response to a 
short-term aerobic exercise training protocol among females of African descent with 
hypertension (16). There was no significant reduction in blood pressure, which may 
have been the result of the 7 day training protocol not being long enough to elicit a 
significant blood pressure response (16). Dubbert et al. included hypertensives of 
African descent in a 12 week aerobic exercise training study and found that they 
significantly reduced SBP and DBP, and that the reductions were no different from 
the Caucasian hypertensives in the study (34). Kokkinos et al. found that SBP and 
DBP decreased approximately 7 and 5 mm Hg, respectively in male hypertensives of 
African descent that were placed on a 16 week aerobic exercise training program 
(87). In the first 16 weeks of training, the men remained on medication, but after 
being tapered off of the medication and continuing with aerobic exercise training, the 
reduction in blood pressure remained the same (87). There have even been aerobic 
exercise training studies that included hypertensive children of African descent, and it 
was found that blood pressure was significantly reduced with aerobic exercise 
training (28; 36). More studies including hypertensives of African descent are needed 
to validate that aerobic exercise training is an effective mode of treatment, but from 
the limited available data, it appears that hypertensives of African descent may 
respond to training as well as hypertensive Caucasians. 
In regards to age-related responses to aerobic exercise training, there have not 
been many studies that have clearly investigated whether one age group is more 
responsive to reducing blood pressure with aerobic exercise training compared to 
another. In the review by Hagberg et al., it was found that middle-aged hypertensives, 
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(41-60 years) had greater and more consistent reductions in blood pressure compared 
to older and younger patients (59). Hagberg et al. suggested that their findings be 
interpreted with caution because the number of older and younger patients, in the 
studies that they reviewed was much less than the middle-aged group. There has been 
one study by Ishikawa et al. that did compare the response of blood pressure between 
hypertensives that were 30-49 years and 50-69 years of age (72). After 4 and 8 weeks 
of aerobic exercise training, significant age related differences were associated with 
the blood pressure reductions, in which smaller reductions were seen within the older 
age group (72). Additionally, investigations that have studied hypertensive 
individuals over 60 years of age have also reported significant reductions in blood
pressure with aerobic exercise training (58; 135). Therefore, from the limited 
available data it appears that most age groups reduce their blood pressure with 
aerobic exercise training, but possibly middle-aged hypertensives experience slightly 
greater and more consistent reductions in blood pressure (59).
The response of hypertensive phenotypes, such as Na+ excretion and plasma 
aldosterone, to aerobic exercise training is as important as the response of blood 
pressure to aerobic exercise training. Since plasma aldosterone can alter renal Na+
handling, ultimately leading to shifts in blood pressure, the investigation into whether 
plasma aldosterone levels and urinary Na+ excretion change with aerobic exercise 
training may help identify the mechanisms that contribute to the training-induced 
reductions of blood pressure. Unfortunately, there have been very few studies that 
have investigated the change in plasma aldosterone levels and urinary Na+ excretion 
with aerobic exercise training. From the few studies that are available, there is some 
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variability in the response of plasma aldosterone and urinary Na+ excretion to aerobic 
exercise training. One study in normotensives demonstrated that after 16 weeks of 
training, individuals achieving the greatest work capacity experienced the greatest 
reduction in plasma aldosterone levels (67). Another study by Braith et al. reported a 
50 pg/ml reduction in plasma aldosterone levels of heart failure patients in response 
to 16 weeks of aerobic exercise training (13). Not all studies have found a reduction 
in plasma aldosterone levels with aerobic exercise training; Kohno et al. found no 
reduction in plasma aldosterone levels in Japanese hypertensives after 3 weeks of 
aerobic exercise training (86). Urata et al. also reported a non-significant reduction in 
serum aldosterone concentration in Japanese hypertensives after 10 weeks of aerobic 
exercise training (152). Findings from kohno et al., and urata et al., may have been a 
consequence of the length of training being shorter than e other studies that reported 
significant reductions in plasma aldosterone levels (86; 152). The reduction in plasma 
aldosterone levels with aerobic exercise training can ultimately be beneficial because 
it can lead to a reduction in Na+ reabsorption that may be contributing to an 
individual’s hypertensive state.
Urinary Na+ excretion can also change with aerobic exercise training in 
hypertensives. Kiyonaga et al. reported a significant 44 mEq/d increase in Na+
excretion after 10 weeks of aerobic exercise training in Japanese hypertensives (84). 
Brown et al. also reported a significant 37 mEq/d increase in urinary Na+ excretion 
after short-term aerobic exercise training in hypertensive females of African descent 
(16). Similar to plasma aldosterone, the response of urinary Na+ excretion to aerobic 
exercise training is variable. Several studies that measured urinary Na+ excretion 
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before and after aerobic exercise training found no significant change (34; 58; 86; 
152). 
Overall, aerobic exercise training has proven to be an effective mode of 
treatment for hypertension. Individuals with hypertension can expect to experience 
reductions in blood pressure within the first few weeks of aerobic exercise training, 
and at an intensity that is realistic and manageable for those hypertensives that are 
transitioning from a sedentary to active lifestyle 
Heritability of Blood Pressure Response to Aerobic Exercise Training
Blood pressure and heart rate (HR) response to stimuli such as aerobic 
exercise training can vary among individuals. There has been a modicum of research 
in regards to whether these phenotypic responses may be heritable. Most of the 
available literature has focused on the heritability of cardiovascular phenotypic 
responses to acute bouts of exercise (18; 139). In the past few years, the HERITAGE 
Family Study has produced the only body of research to investigate the influence of 
genetics on the response of cardiovascular phenotypes to aerobic exercise training (6; 
121). A HERITAGE study by Rice et al. reported that among 98 Caucasian families 
placed on a 20-week aerobic exercise training program, maximal heritabilities were 
18% and 24% for SBP and HR, respectively (121). When the sample was divided into 
individuals with high blood pressure and normotensives, among those with high 
blood pressure, maximal heritabilities were 20% and 36% for SBP and HR responses 
to aerobic exercise training, respectively (121). In the normotensives, the heritabilities 
for SBP and HR responses to aerobic exercise training were not sig ificant (121). 
Additionally, for the entire sample the DBP response to aerobic exercise training was 
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not heritable (121). An et al. reported on the heritability of exercise blood pressure 
and HR among 99 sedentary normotensive Caucasian families that were placed on the 
same aerobic exercise training protocol as the participants in the Rice et al. study (6; 
121). An et al. found significant heritabilities of 34% and 29% for HR at 50 W and 
60% of VO2 max, respectively. In regards to blood pressure, a significant heritability 
of 22% was found for SBP at 50 W (6). There were no significant findings in regards 
to exercise DBP. The limited data indicates that among family aggregation studies, 
there appears to be heritability in the SBP response to aerobic exercis  training (6; 
121). Unfortunately, the family aggregation studies have not been able to demonstrate 
heritability of DBP. Even though there is a strong likelihood that there is genetic 
involvement in the blood pressure response to aerobic exercise training in both 
normotensive and hypertensive populations, being that there is limited data, more 
research in the area of heritability of such cardiovascular phenotypes as blood 
pressure and their response to aerobic exercise training is warranted. 
Gene-Exercise Interactions and Hypertension
Numerous studies have demonstrated that aerobic exercise training is an 
effective mode of reducing blood pressure in hypertensive individuals. Despite these 
positive results, there continue to be some hypertensives that may experience no 
change or an increase in blood pressure with aerobic exercise training. This 
variability in blood pressure response continues to occur regardless of the 
standardization of aerobic exercise training protocol and controlling for factors such 
as dietary differences, weight, age, and ethnicity; all of which can contribute to 
variability in blood pressure response to aerobic exercise training. As a consequence, 
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a few researchers have begun to investigate whether genetic differences can account
for the unexplained interindividual variability in the blood pressure response to 
aerobic exercise training.
The current body of literature that has investigated the influence of genetics 
and blood pressure response to aerobic exercise training, has mainly involved the 
ACE I/D and AGT M235T polymorphisms (57; 119; 120; 161). Gene polymorphisms 
of the RAAS have been researched thoroughly in regards to whether they contribute 
to hypertension development (25; 68; 75; 107; 126). The ACE I/D polymorphism has 
shown a weak association with blood pressure, but the D allele has been related to 
higher plasma ACE levels, compared to the I allele, which could impact blood 
pressure (43; 122). The AGT 235T allele has been associated with increased blood 
pressure and plasma AGT levels (75; 160). The in depth investigation into whether 
these specific gene polymorphism are associated with hypertension has greatly 
influenced the area of gene-exercise research as it relates to hypertension. From the 
limited number of studies, it appears that both the ACE D and the AGT 235T alleles 
are associated with a non-significant reduction in blood pressure with aerobic 
exercise training compared to those with the ACE I and AGT  M235 alleles (57; 119; 
120; 161)
Hagberg et al. were one of the first to investigate the association between the 
ACE I/D polymorphism and blood pressure response to aerobic exercise training in a 
hypertensive population (57). The genotype groups were divided into II+ID and DD, 
and after 9 months of aerobic exercise training it was found that both the II + D and 
DD genotype groups had significantly lowered their systolic blood pressure (-10 mm 
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Hg, -5 mm Hg, respectively), but the reduction in the II+ID  genotype group was 
significantly greater than the DD (57). The II+ID genotype group had significantly 
lowered their DBP (-10 mmHg), whereas the DD genotype group did not (57). The 
II+ID group’s reduction in DBP was significantly greater than the DD genotype 
group (57).
These findings were further confirmed in a study by Zhang et al. in which 
Japanese hypertensives were placed on an aerobic exercise training protocol. All 
participants exercised for 10 weeks (161). The I allele carriers experienced a 
significant -9.5 mm Hg change in SBP and a -4.8 mm Hg change in DBP, 
respectively after 4 weeks of exercise training (161). The DD genotype group 
experienced a significant -5.5 mm Hg change in SBP after 4 weeks of exercise 
training and no significant change in DBP (161). Following 10 weeks of aerobic 
exercise training both SBP and DBP were significantly reduced among the I allele 
carriers but not among the DD genotype groups (161).
Both Hagberg et al. and Zhang et al. found that the I allele carriers 
experienced a reduction in SBP and DBP, whereas the D allele carriers were 
associated with less of a reduction in blood pressure or no reduction at all (57; 161). 
Possibly the elevated ACE levels that have been associated with the D allele could 
contribute to a lack of blood pressure response to aerobic exercise training (43; 122). 
Because ACE levels were not measured in these two studies it is difficult to speculate 
whether this could be true. 
The AGT M235T polymorphism has been studied in association with blood 
pressure response to aerobic exercise training. Rankinen et al. investigated the 
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association between the M235T polymorphism and resting blood pressure and 
submaximal exercise blood pressure in Caucasian normotensives (119). Following 20 
weeks of aerobic exercise training, significant genotype associations were found only 
with submaximal DBP and exclusively in men (119). The MM and MT genotype 
groups significantly reduced their submaximal DBP by 3.7 and 3.5 mm Hg, 
respectively; whereas the TT genotype group experienced a 0.4 mm Hg reduction in 
submaximal DBP (119). There was n interactive effect between the ACE I/D and the 
M235T polymorphisms, in which individuals with the TT and the II genotype 
experienced a reduction in submaximal DBP, but individuals with the TT genotype 
and the ID or DD genotype experienced no change in submaximal DBP (119).
From these finding it is apparent that the TT genotype, which is normally 
associated with a higher blood pressure, is also associated with a lack of reduction in 
exercise blood pressure, whereas the MM and MT genotypes are associated with a 
reduction in submaximal exercise blood pressure. Rankinen et al. suggested that the 
lack of reduction in submaximal blood pressure in the TT genotype group could have 
been due to elevated AGT levels that have been associated with the TT genotype 
(119). Rankinen et al. further suggested that elevated AGT levels might have 
indirectly counter-acted the exercise induced-vasodilation that occurs with training 
(119). Additionally, the lack of reduction in submaximal exercise blood pressure that 
occurred among those with both the AGT 235 TT and ACE DD genotype may have 
been the result of elevated AGT and ACE levels that could have caused physiological 
changes that prevented a reduction in blood pressure with aerobic exercise training 
(119). 
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A recent study by Rauramaa et al. investigated the association of the AGT 
M235T polymorphism with change in blood pressure over a six year period in 
individuals that performed unsupervised exercise during this period and those that did 
not (120). The study was composed of older normotensive and hypertensive men. 
Those that exercised during the six years and had the MM genotype, experienced an 
increase in seated SBP of 1 mm Hg, whereas those that had the MM genotype, but did 
not exercise, increased their seated SBP by 14 mm Hg (120). In regards to seated 
DBP, those that exercised and had the MM genotype reduced their DBP by 6.2 mm 
Hg (120). Among the men that had the MM genotype, but did not exercise, DBP 
increased by 2.8 mm Hg after 6 years (120). Additionally, among thoseat xercised 
and had the MM genotype, supine DBP decreased, but this was not observed in those 
with the MM genotype that did not exercise (120). No reductions in blood pressure 
were reported among those with the TT genotype (120).
Rauramaa et al. suggest d that the MM genotype, among those that exercised, 
was associated with the attenuation of the age-related increase in SBP and DBP (120). 
It was further suggested that the lack of blood pressure reduction among those with 
the TT genotype could be due to the elevated AGT levels that have been associated 
with the T allele, a possible indication of over stimulation of RAAS (120). This over-
stimulation of the RAAS could have accounted for the lack of blood pressure 
response among those with the TT genotype (120). Whereas, because the MM 
genotype has been associated with lower AGT levels, a possible indicator elevated 
extracellular fluid volume, exercise may be more effective in reducing blood pressure 
by increasing Na+ and fluid excretion (120).
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Both Rankinen et al. and Rauramaa et al. provide evidence that the AGT 
M235 allele shows an association with aerobic exercise training- duced reductions in 
blood pressure among normotensives and hypertensives (119; 120). Both studies did 
not have very stringent criteria in regards to what BP was considered to be 
normotensive and hypertensive. Possibly with more control in these studies, the 
associations may have been even stronger. The interactive effect between the AGT 
M235T and ACE I/D polymorphism was a very significant finding because it 
demonstrated that the genes of the RAAS may influence resting blood pressure and 
the blood pressure response to aerobic exercise training. Lastly, both studies could 
have benefited from the measurement of plasma ACE and AGT levels to determine if 
there were genetic associations between baseline and after-tr ining levels of these two 
phenotypes. 
In regards to the CYP11B2 –344C/T polymorphism, there are no studies to 
date that have investigated its association with hypertension with respect to aerobic 
exercise training, but a recent study may provide support for a possible gene- xercise 
interaction. A genome-wide linkage study conducted by Rankinen et al. recently 
reported significant linkage between the change in SBP at 50% VO2max after 20 
weeks of aerobic exercise training and chromosomal region 8q21 in Caucasians 
(118). In individuals of African descent there was suggestive linkage between 
baseline DBP at 80% VO2max and the same 8q21 region (118). What makes these 
findings noteworthy is that the 8q21 region is the location of CYP11B2 (118). Such 
findings help to establish the precedence for gene-exercise interactions involving the 
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–344C/T polymorphism and blood pressure along with other hypertension-related 
phenotypes.
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Appendix C ─ Detailed Methods
This current study was a part of the larger Gene Exercise Research Study 
(GERS) conducted at the University of Maryland, College Park. GERS is a National 
Institutes of Health funded study, in which the main objectiv  is to investigate genetic 
and exercise interactions on hypertension. 
Recruitment
 Participants were recruited from the College Park, Maryland and the District 
of Columbia metropolitan areas, via advertisements in newspapers, radio public 
service announcements, direct mail and health fairs. Potential participants who were 
interested in the study were instructed to call the GERS office at the University of 
Maryland in order to receive additional information about the study and to undergo an 
initial telephone screening.  
Telephone Screening
The telephone screening began with an overview of the study to provide 
potential participants information about the study obligations and the time 
commitment required. Potential participants were excluded if they were not between 
the ages of 50-75 years, had a body mass index (BMI) greater than 37 kg/m2, and had 
any form of cardiovascular disease (CVD), liver disease and pulmonary disease, 
diabetes, or orthopedic conditions that would impair their ability to exercise. Females 
were excluded if they were not post-menopausal for more than 2 years. For those that 
were post-menopausal, they were asked to maintain their hormone replacement status 
for the entirety of the study. Potential participants were asked whether or not they had 
hypertension and to estimate their resting blood pressure. Those using more than 2 
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antihypertensive medications were excluded. Potential participants were asked about 
their current physical activity level, those exercising more than 2 times per week for 
more than 20 minutes were considered to be physically active, and were excluded. 
Once an individual met the initial study inclusion criteria, they were scheduled for an 
orientation visit, and a consent form, health history and physical activity 
questionnaire were mailed to the individual.
Orientation and Informed Consent 
The orientation meeting was held at the GERS facilities. The orientation was 
directed by one of the Principal Investigators, and during this visit all participants 
provided their written informed consent. In addition, participants toured the facilities 
and had their casual blood pressure measured. Screening Visit 1 was then scheduled 
for all participants who signed consent forms. 
Screening Visit 1
Participants arrived at the Physiology of Exercise Laboratory having fasted for 
12 hours in order to undergo a 2-hour post-prandial glucose tolerance test. The post-
prandial glucose tolerance test required participants to drinka10 oz,75 g dextrose 
load (Fisherbrand). Blood samples were obtained for blood chemistries and to 
conduct DNA analyses. Participants were excluded if they exhibited a fasting blood 
glucose > 126 mg/dl or blood glucose greater than 200 mg/dl at 2 hours. Participants 
were excluded if they had a GFR < 60 ml/min/1.73 m2, which was estimated using the 
Modification of Diet in Renal Disease (MDRD) equation, and serum creatinine levels 
>1.5 mg/dl, both ensured that they did not have evidence of renal disease. During the 
2-hour visit, height and weight were measured to verify BMI. In addition, three casual 
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blood pressure measurements were obtained on each arm. Participants with an 
average SBP < 120 or >159 mm Hg and/or DBP <80 or >99 mm Hg were excluded 
from the study. During this visit, participants were scheduled for their second 
screening visit.
Screening Visit 2
During the second screening visit, participants underwent a physical 
examination by a physician and performed a physician supervised graded exercise 
test (Bruce protocol) to screen for CVD. During the treadmill test, ECG, blood 
pressure, and heart (HR) were measured before the test, at the end of each stage, and 
every two minutes for 6 minutes after the test. The test was terminated upon the onset 
of cardiovascular signs and/or symptoms, or when the participants could no longer 
continue. Subjects were included in the study if they did not exhibit any 
cardiovascular signs or symptoms and had less than a 2mV ST segment depression 
(2). 
Dietary Stabilization/Medication Tapering
Dietary and weight changes are known to independently contribute to changes 
in blood pressure (9; 42; 49). In order to control for such effects, all participants were 
required to be weight stable and follow a standardized diet to determine the 
independent effects of aerobic exercise training on plasma aldosterone levels, sodium 
excretion, and blood pressure. Participants attended a 6-week dietary class two times 
per week, which was taught by a Registered Dietician. The participants followed the 
American Heart Association (AHA) Step I diet (50- 5% of calories from 
carbohydrates, 30-35 % from fat, 20-25% from protein, 350 mmol/day of cholesterol, 
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and 3g/day of salt) for the entirety of the study. The participants were weighed once 
per week at the beginning of each dietary session, and were required to stay within 
5% of their study entry body weight throughout the study. The participants completed 
a 7-day food record to ensure they were adhering to the diet. Participant’s diet records 
were analyzed using the Nutritionist IV software. 
All participants using antihypertensive medications were tapered off of their 
medications during the 6-week dietary period with written approval from their 
physician. During each dietary session, blood pressure was measured on each 
participant to ensure they stayed within the required range of 120-159/ 80-99 mm Hg. 
Participants were instructed to measure their blood pressure several times per week 
outside of the dietary classes and to maintain a log of their blood pressure values. 
Weekly telephones calls were made to the participants to ensure that their blood 
pressure remained within the required range. Participants with SBP < 120 or >159 
mm Hg and/or DBP <80 or >99 mm Hg consistently during the 6-week dietary period 
were excluded from the study.
Baseline Testing
Casual Blood Pressure
Casual blood pressures were determined  all participants on three separate 
baseline testing days. Participants were instructed to sit for 15 minutes with their feet 
flat on the floor. Three blood pressure measurements were recorded on each arm 
within two minutes of each other. The average of the casual blood pressure 
measurements taken on three separate baseline testing days were used as the primary 
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outcome variable in the data analysis. In the event that casual blood pressure 
measurements wer only taken on two separate baseline testing days, these values 
were averaged and used as the primary outcome variable in the data analysis. 
24-hour Urine Collection
Participants underwent a 24-hour urine collection to measure Na+ and K+
excretion. The participants were given 2 urine collection bottles in which to collect 
their urine over the 24-hour period, starting the morning they picked up the containers 
(7am-9am) and ending after their first urination of the morning. They w realso given 
a cooler filled with ice to keep the urine cold. Participants returned the urine
containers the following morning. The urine was processed at the Hypertension and 
Exercise Physiology Laboratory and sent to Quest Diagnostics Laboratories for 
analysis (CLIA license 21D0218877).  
Maximal Oxygen Consumption (VO2max)
To develop an exercise prescription specific for each participant and to assess 
their cardiovascular fitness, participants performed a physician supervised VO2max 
test. Participants began exercising on a tre dmill at an intensity equivalent to 70% of 
the peak HR they achieved during their screening exercise test. Participants were 
fitted with a mouthpiece and a nose clip to collect the expired air necessary to 
measure oxygen consumption. The grade was increased 2% every 2 minutes, and 
ECG, HR and blood pressure were measured every 2 minutes during the test and 
every 2 minutes for 6 minutes after the test. The test was stopped when participants 
could no longer continue or upon onset of cardiovascular signs and/or symptoms (2). 
Oxygen uptake was measured using a computerized on-line VO2 system including a 
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gas analyzer (Mass Spectrometer MGA-1100, Marquette Electronics Inc., 
Milwaukee, WI) and a bi-directional turbine flow meter (Ventilation Measurement 
Module VMM-2, Interface Associates, Aliso Viejo, CA). VO2maxwas measured 
continuously, and to ensure that a true VO2max was achieved two of the three criteria, 
(RER > 1.1, HR > [220-age], and <150 ml/min increase in VO2 during the last two 
minutes of the test), wer  met.    
Body composition
Changes in percent body fat may act as a confounding variable when 
measuring the independent effect of exercise training on blood pressure and sodium 
excretion (9; 46-49; 78; 129). Therefore, participants were transported to the 
Baltimore VA Medical Center to undergo dual energy X-ray absorptiometry (DEXA) 
to assess any body composition changes that occurred during the 6-month exercise 
training period. Participants were instructed to fast for the 12 hours prior to the start 
of the test. 
Measurement of Aldosterone 
Blood samples for the measurement of plasma aldosterone were collected 
before the start of the oral glucose tolerance test (OGTT). Participants were instructed 
to undergo a 12-hour fast prior to blood sample collection, and because cold and pain 
medications such as antihistamines, ibuprofen, and acetaminophen, can alter 
aldosterone levels, participants were instructed to exclude these items for the 48 hours 
before the OGTT (17).  Aldosterone levels also vary by body position, therefore the 
blood samples were collected while the participants were supine for approximately 20 
minutes (142). Blood samples were collected in EDTA (ethylene diamine tetra-acetic 
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acid) tubes and centrifuged at 3000 rpm for 20 minutes at 4°C, and the plasma was 
aliquoted into 1.5 ml microtubes and stored at –20°C (85).
Plasma aldosterone levels were measured by a competitive binding 
radioimmunoasay (RIA). The RIA is based on competition between aldosterone in the 
sample, and a fixed amount of the aldosterone labeled with the radioisotope 125I to 
bind to a limited quantity of the antibody specific for aldosterone (3). Once the 
system has reached equilibrium, free aldosterone (both labeled and unlabeled) is 
separated from the aldosterone that is bound to the antibody (3). The number of 
counts of 125I labeled aldosterone is measured with the use of a gamma counter (3). 
The greater the number of counts of 125I, the lower the aldosterone concentration is in 
the sample, whereas the lower the number of counts of 125I labeled, the greater the 
aldosterone concentration is in the sample. 
The125I kit used to measure plasma aldosterone levels in each sample was a 
100 tube Coat-A-Count Aldosterone kit manufactured byDiagnostic Products 
Corporation. The Coat-A-Count procedure is a solid phase radioimmunoassay, in 
which the antibodies specific for aldosterone are immobilized to the wall of a 
polypropylene tube (DPC). Four plainpolypropylene tubes, in which there were no 
antibodies attached to the wall of the tubes, were labeled NSB (non-specific binding) 
in duplicate and T (total activity) in duplicate. The NSB tubes measured non-specific 
non-immunological binding of 125I and the T tubes measured total activity of the 125I.
Fourteen coated tubes were designated for the calibrators (standards) in which there 
were 7 known aldosterone concentrations (A-G) that were run in duplicate. The 
concentration (pg/ml) for calibrator A was 0, B was 25, C was 50, D was 100, E was 
120
200, F was 600 and G was 1200. The remaining coated tubes were designated for 
participants’ samples and controls, which were all run in duplicate.  
The first step of the RIA required the reconstitution of the 7 calibrators, which 
required adding 6.0 ml of deionized water to the A calibrator. This was followed by 
adding 3.0 ml of deionized water to calibrators B through G. These steps were done 
approximately 30 minutes prior to use of the calibrators. During this same time 
period, 6.0 ml of deionized water was added to three controls. While the calibrators 
and the controls sat for 30 minutes, the samples were brought from the freezer to 
thaw. Once the calibrators had been reconstituted, 200 µl of the zero calibrator A was 
pipeted into each NSB and A tube. This was followed by pipeting 200 µl of the 
calibrators B through G into their respective tubes. Once all calibrators had been 
pipeted into their corresponding tubes, 200 µl of each sample and control were also 
pipeted into their respective tubes. Approximately 10 minutes prior to all samples and 
controls being pipeted into their respective tubes, the 125I was reconstituted by adding 
110 ml of deionized water. Once the deionized water was added, the reconstituted 125I 
was set aside for approximately 10 minutes. Prior to adding the 125I, the vial was 
gently inverted to ensure thorough mixing. 
After all the samples and controls had been added, 1.0 ml of the 125I was 
added to every tube. It was required that this process be done within a 10 minute 
period. After the addition of the 125I, each tube was capped and all tubes were 
vortexed. The samples then incubated for 18-20 hours at room temperature.
Following the incubation period, the caps were removed from the tubes and 
the liquid from each tube, except for the T tubes, was poured into the radioactive 
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waste container. This was followed by striking each tube against an absorbent pad, 
several times, to remove excess moisture. The tubes were then taken to the gamma 
counter (Beckman 5500) in which the number of counts in each tube was detected. 
Calculations were used to convert counts to concentrations.Plasma aldosterone levels 
were expected to be between 20-230 pg/ml (112).
Genotyping
Genotyping was performed at the Physiological Genomics Laboratory in the 
Department of Kinesiology at the University of Maryl nd, College Park. DNA was 
extracted from whole blood samples using techniques described by Miller (101). 
DNA amplification was performed by polymerase chain reaction  (PCR), with the use 
of the CYP11B2 (-344T/C) forward primer 5’- AGG-GTG-TAC- CTG- TGT-CAG-
GGC A-3’ and the CYP11B2 (344T/C) reverse primer 5’-CCT-CTC-CTT-TCT-
CCA-GGG-CTG A-3’. The PCR was performed at a denaturing temperature of 95°C 
for 5 minutes, followed by 35 cycles at 95°C for 30 seconds, 53°C for 30 seconds, 
72°C for 30 seconds and 72°C for 5 minutes. Digestion was performed with the use 
of the Hae III enzyme and TT homozygotes were detected at 186 base pairs (bp), CT 
heterozygotes were detected at 186, 115, and 71 bp, and CC homozygotes were 
detected at 115 and 71 bp.
Exercise Training
Participants underwent a 6 month supervised aerobic exercise training 
intervention, which was held at the Wellness Research Laboratory. An exercise 
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prescription was developed for each participant by using the Karvonen formula, target 
HR = [(max HR-resting HR) x desired %] + resting HR. The participants were given 
a wrist heart rate monitor (Model 6124, Polar Electro, Canada), which allowed them 
to monitor their prescribed heart rate. Participants were expected to exercise 3 days a 
week throughout the 6 month period. Intensity and duration were increased gradually 
during the first few weeks of aerobic exercise training. During the first week of 
exercise training, the participants exercised for 20 minutes at 50% of heart rate 
reserve (HRR). Exercise duration was increased gradually by 5 minutes per week 
until the participants were exercising for 40 minutes. At the 6th week, exercise 
intensity was increased by 5% of their HRR every week until they were exercising at 
70% of HRR. The increases in intensity and duration occurred only when participants 
completed their current intensity for three consecutive exercise sessions without any 
cardiovascular signs or symptoms. The gradual increase in exercise intensity and 
duration was used to prevent excessive fatigue and injury, which could reduce 
participant adherence (59). Seated blood pressures were measured at the beginning 
and end of each exercise training session. Blood pressure was measured once while 
participants were exercising. The participants recorded their blood pressure, heart 
rate, weight and exercise duration in a logbook provided for them. These log books 
were analyzed to ensure that the participants were adhering to their exercise 
prescription. Once the participants completed their 10th week of exercise training, 
they were asked to add 45-60 minutes of unsupervised exercise at <70% of HRR to 
their current exercise prescription. 
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Final Testing
Upon completion of the 6-month aerobic exercise training protocol, 
participants repeated all tests performed at baseline. This included casual blood 
pressure measurement, 24-hour urine collection, VO2max, body composition, and 
plasma aldosterone measurement. The participants continued exercising until all final 
tests were completed. The final tests were performed aft r participants provided a 7-
day food record to ensure dietary compliance, and 24-36 hours after their regular 
exercise session.
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Appendix D ─ Aldosterone Radioimmunoassay Prot col
Materials Required
Materials 
100 polypropylene antibody coated 
tubes
Tubes coated with aldosterone specific 
antibodies. Allows for unlabeled and labeled 
aldosterone to bind to the side of the tube.
4 uncoated polypropylene tubes Tubes used to measure non-specific 
immunological binding of aldosterone and the 
total counts of aldosterone.
7 Aldosterone calibrators
A = 0 pg/ml            E = 200 pg/ml
B = 25 pg/ml          F = 600 pg/ml
C = 50 pg/ml         G = 1200 pg/ml
D = 100 pg/ml
Calibrators are 7 known concentrations of 
aldosterone, which are necessary to determine 
the standard curve that is used to identify the 
aldosterone concentrations of the unknown 
samples. 
125I Aldosterone Aldosterone labeled with an 125I tracer. It 
competes with an unknown amount of 
aldosterone in the samples to bind to antibodies 
located on the inside of the tubes.
Tri-level, human serum-based 
immunoassay controls
Three known aldosterone concentrations that 
are run in each assay as quality controls.
Deionized water
Used to reconstitute the calibrators and the 125I 
Aldosterone 
Gamma counter Used to measure 125I counts in each tube. The 
number of counts is used to calculate 
aldosterone concentration in the samples.
100 µl and 1000 µl Gilson pipettes
10 ml and 50 ml graduated 
cylinders
The 100 µl and 1000 µl pipettes are used for 
the measurement of samples, calibrators, 
controls and 125I Aldosterone.







Not reconstituted: 4ºC refrigerator
Reconstituted:-20 ºC freezer
6.0 ml of deionized 
water to calibrator A
3.0 ml of deionized 
water to calibrators 
B-G 
Tri-level controls Not reconstituted: 4ºC refrigerator
Reconstituted:-20 ºC freezer
6.0 ml of deionized 
water to each control
125I Aldosterone Not reconstituted: 4ºC refrigerator
Reconstituted: 4ºC refrigerator




A. Organize tube set up on spread sheet. A second spread sheet is needed to 
organize tube placement for the gamma counter.
B. Thaw samples.
C. Reconstitute calibrators 30 minutes prior to use. Add 6.0 ml of deionized water 
to calibrator A and 3.0 ml of deionized water to calibrators B-G.
D. Reconstitute tri-level controls 30 minutes prior to use. Add 3.0 ml of deionized 
water to controls 4, 5 and 6.
E. Label 2 tubes NSB and 2 tubes T. Label 7 tubes A-G in duplicate. Label the 
remaining tubes with the appropriate sample and controls numbers in duplicate. 
Place the tubes in the appropriate order in the tube rack. 
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2. Addition of Calibrators, Samples and Controls
    A. Pipet 200 µl of calibrator A, which has zero concentration, into each NSB tube. 
B. Pipet 200 µl of calibrator A into each A tube.
C. Pipet 200 µl of each of the remaining calibrators, B-G, into their respective
  tubes.
D. Pipet 200 µl of the samples and controls into their respective tubes.
3. 125I Aldosterone Preparation and Addition
A. Reconstitute the 125I Aldosterone by adding 110 ml of deionized water to the
vial. Let it stand for 10 minutes prior to use.
B. Once calibrators, samples, and controls have been added, pipet 1000 µl of the 
reconstituted 125I Aldosterone into every tube. This must be done within a 10 
minute period.  
C. Place tops on all tubes and vortex each tube. 
4. Incubation and Decanting
    A. Incubate tubes for 18-20 hours at room temperature (15-28 ºC). 
B. All visible moisture must be removed from each tube except for the T tubes. 
Remove the tops from each tube one at a time and dump contents into the 
radioactive waste container. Vigorously strike the tubes on absorbent pads to 
remove all remaining moisture. 
5. Reading125I Countswith the Gamma Counter
A. The tubes must be placed into the gamma counter within 2- 3 hours after 
decanting.
   B. After decanting the tops of each tube must be placed back on. 
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   C. Transfer tubes to the appropriate gamma counter racks, by referring to the       
gamma counter placement spreadsheet. 
   D. Place each rack in the gamma counter and switch the gamma counter to 
automated. Each tube will be counted for 1 minute. 
6. Converting Counts to Concentration
   A. To obtain the net counts for each tube, the average counts per minute of the 
duplicates must be obtained. Net counts = average counts per minute – average 
NSB counts.
   B. To obtain the Percent 125I bound to the tubes the net counts for tube A, also 
known as the maximum binding tube must be used. 
Percent bound = (Net counts ÷ Net MB counts) x 100
C. Take the natural log (LN) of the known concentrations for calibrators B-G. 
   D. Take the logit (% bound/1-% bound)   of the % bound of all tubes.
   E. Run a regression with the logit of the % bound and the LN for calibrators B-G. 
The logit of the % bound will be the predictor and the LN for the calibrator 
concentrations will be the dependent variable.
   F. Obtain the slope (b) and the intercept (a) from the regression. The regression 
equation will be: y= a + b(x), where x will be LN (% bound/1-% bound) for all of 
the samples and controls.
  G. The sum of the regression equation will be in log form therefore the inverse log 
of the sum must be performed in order to obtain the aldosterone concentration into 
pg/ml.
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Appendix E − Human Subjects Approval and Consent Form
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CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY
Project Title: ACE genotype, blood pressure, and exercise training in 
hypertensives
I state that I am over 18 years of age and wish to participate in a program of 
research being conducted by Dr. James Hagberg in the Department of Kinesiology, 
University of Maryland.
The purpose of this study is to determine the role that genetics may play in 
determining how my blood pressure changes with exercise training. This research 
project will require visits to University of Maryland College Park and the Baltimore 
VA Medical Center. The specific tests, their requirements, and time commitments are 
described below. 
I already completed a telephone interview that determined that I am not 
physically active, 50 - 75 years of age, not a diabetic, have no evidence of lung 
disease, have an appropriate body weight for my height, and have no other medical 
problems that would keep me from exercising vigorously. It is also probable that I 
have a blood pressure that is in the Prehypertensive or Stage 1 hypertension range 
(Systolic blood pressure: 120 – 159; Diastolic blood pressure: 80 – 99). Furthermore, 
if I am a woman, I must be postmenopausal, defined as no menstrual cycles for at 
least the last 2 years. I understand that if I am a woman and change my hormone 
replacement therapy regimen during the study, my participation in the study will be 
terminated. 
The Flow Chart on the next page indicates the different testing sessions and 
time required by this study. I understand that if I qualify and complete this study my 
total involvement will last approximately 9 months. Two of the testing visits are 
performed at the Baltimore VA Medical Center. I understand that I will also be asked 




I understand that I will complete 1 Orientation and 2 initial screening visits. 
For my first visit, the study will be explained to me, my medical history will be 
reviewed, and I will provide my written iformed consent. This visit will last about 
60 minutes. On my first screening visit, I will report to the laboratory in the morning 
after an overnight fast and a blood sample will be drawn for blood chemistries and for 
isolation of my DNA. I will have my height, weight, and blood pressure measured. I 
understand that I may be excluded from the study if this initial blood sample shows 
elevated levels of glucose or creatinine in my blood. A blood sample will also be 
drawn 2 hours after I drink a sugar solution. This visit will last about 2 ½ hours. I 
understand that a total of 3 tablespoons of blood will be drawn during this visit. I 
understand that I will be excluded from the study at this point if I have a low red 
blood cell count, evidence of kidney or liver disease, evidence of diabetes, or if my 
blood pressure is too high or too low.  
I understand that if I remain qualified to this point, I will undergo a treadmill 
exercise test to determine if I have heart disease. A physical examination will precede 
the exercise test. I will have my resting blood pressure measured. I will then complete 
a test on an exercise treadmill where the treadmill speed and grade will increase every 
3 minutes until I cannot continue or symptoms of heart disease develop. Blood 
pressure, heart rate, and electrocardiogram (electrical activity of my heart) will be 
recorded before, during, and after the test. During this test I will have a noseclip on 
my nose and I will breathe through a mouthpiece so that the air that I breathe out can 
be analyzed. I understand that this visit will last about 1 hour and that I will be 
excluded from the study at this point if I have evidence of heart disease.
I understand that if I meet these requirements to enter the study and if I am 
taking medications to control my blood pressure, I give my permission for my private 
physician to be contacted to obtain their approval for me to stop taking these 
medications for the remainder of this study. I understand that I will be slowly 
withdrawn from these medications according to the plan my physician provides and 
that my blood pressure will be measured weekly for the remainder of the study. I also 
understand that if my blood pressure is too high (Systolic blood pressure: >159; 
Diastolic blood pressure: >99) for three consecutive weeks at any time during the 
study, I will be excluded from further participation in the study and referred back to 
my physician. If I am in the exercise training portion of the study, I understand that if 
this happens I will complete all Final Testing (see below) and then be referred back to 
my physician. I also understand that a physician from the University of Maryland 
School of Medicine is directly involved in this study and that he can be contacted for 
any medical questions, but only as they concern my involvement in this study. 
I understand that if I meet these requirements to enter the study, I will undergo 
6 weeks of instruction in the principles of an American Heart Association low-fat and 
low salt diet and must follow this diet for the remainder of this study. This program 
consists of two 40 minute classes each week for the 6 week duration of the program. 
During the final 3 weeks of this dietary program, I understand that I will have my 
blood pressure measured weekly for 3 weeks. I understand that my blood pressure 
must average in the range of 120 – 159 for systolic or 80– 99 for diastolic blood 
pressure for me to continue in the study.
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After this I will undergo Baseline Testing that includes the following tests that 
will be completed in 7 testing sessions (5 at the University of Maryland, College Park 
and 2 at the Baltimore VA Medical Center). I will have blood drawn on 2 occasions 
from a vein in my arm in the morning after an overnight fast to measure my 
cholesterol levels; these visits will each last about 20 minutes. I understand that a 
maximum of 2 tablespoons of blood will be drawn during these visits. I understand 
that I will also undergo a second exercise test on a treadmill to measure my 
cardiovascular fitness. This test will start at 70% of the highest heart rate achieved on 
my first exercise test and the treadmill grade will increase by 2% every 2 minutes. 
Blood pressure, heart rate, and electrocardiogram will be monitored before, during, 
and after the test. The test will bestopped when I can no longer continue. During this 
test I will have a noseclip on my nose and I will breathe through a mouthpiece so that 
the air that I breathe out can be analyzed. I understand that this visit will last about 1 
hour. I also understand that my dietary habits will be measured by having me record 
for 7 days all of the food items that I eat. I understand that I will collect my urine for 
24 hours in a container that must be refrigerated so that the amount of salt I eat in my 
diet can be measured; I also understand that my blood pressure will be monitored 
throughout this 24 hour period with a cuff around my upper arm and a “Walkman-
size” controller worn at my waist. I also understand that I will undergo a 3 hour 
glucose tolerance test where I will come to the laboratory in the morning after an 
overnight fast, have a small catheter inserted in an arm vein for blood sampling, and 
have blood samples drawn before and for every 30 minutes after I drink a glucose 
solution. Additional samples will be drawn before this test to measure hormone levels 
in my blood that affect my blood pressure, immunological (disease-fighting), and 
blood clotting systems. I understand that a maximum of 7 tablespoons of blood will 
be drawn for this portion of the study. I understand that on another occasion after an 
overnight fast, I will have blood samples drawn before and every 30 minutes for 4 
hours after drinking 1- 2 cups of a high-fat liquid meal. These blood samples also will 
be drawn through a small catheter inserted into my arm vein. The high-fat meal is 
made of heavy whipping cream with small amounts of chocolate, sugar, and 
powdered milk and tastes like a rich chocolate shake.I understand that 10 tablespoons 
of blood will be drawn during this test and will be used to measure how my body 
absorbs and uses fat from a meal and how my blood clotting, and substances that 
affect hunger are affected by a fat meal. Before and after I drink the high-fat meal, I 
understand that I will breath through a mouthpiece while my nose is closed-off with a 
nose clip and the air that I breath out will be collected and used to determine how 
much fat I use for energy while sitting at rest. I also understand that I will complete a 
test that takes about 1 hour to measure the blood flow in my ar  at rest and 
immediately after stopping my arm blood flow for 5 minutes with the use of a blood 
pressure cuff. I understand that all of these tests listed above will be done at the 
University of Maryland College Park.
I understand that on a visit to Baltimore on a separate day, I will have my 
kidney function measured at the Clinical Research Unit, Division of Nephrology, 
University of Maryland at Baltimore after an overnight fast. Before the test, I will 
drink 17 ounces of water over a 30-minute period. A Registered Nurse will then insert 
a small needle into veins in both of my arms. One line will be used to give the study 
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medications and the other will be used to draw blood samples. Before the study drugs 
are given, I will provide a urine sample and a 0.7 ounce blood sample. During the test 
I will remain in a seated position except for when I provide urine samples. 
Next, I will receive the study medications, para- minohippurate and 
iothalamate, which are markers used for estimating kidney function. Para-
aminohippurate (5mg/kg body weight) and iothalamate (434 mg) will be given over 
five minutes. Then I will receive an additional small dose of para-aminohippurate and 
iothalamate by a slow, continuous infusion so that I will have the necessary amounts 
in my blood.  Four blood samples (~0.7 ounces) will be drawn over the next 2½ hours 
and I will be asked to collect my urine every ½ hour for the next 2½ hours. This test 
will take approximately 3 hours. A total of 1.4 ounces of blood will be drawn during 
this test. I understand that I will undergo this test twice, once before and once after 6 
months of aerobic exercise training. I understand that the amount of fat I have around 
my waist will be measured with a CAT scan while I lie quietly on a table. Another 
study will be done to measure my total body fat mass and total body muscle mass 
while I lie quietly on a table. I also understand that if I have elevated blood 
cholesterol levels, I will have blood samples drawn before and after a substance that 
temporarily stops blood from clotting is injected into my arm vein. The blood samples 
will be used to measure chemicals that affect my blood cholesterol levels. A total of 4 
tablespoons of blood will be drawn at this visit. I understand that I will remain in the 
VA Medical Center for 2 – 3 hours after this test to make sure that all bleeding is 
stopped. I also understand that these tests will be done at the VA Medical Center in 
Baltimore. I understand that each of these visits will require approximately 4 – 5 
hours including travel time. 
I understand that the maximum total amount of blood that will be drawn 
during this Screening and Baseline Testing is 28 tablespoons over 2 – 3 months. This 
is approximately 90% of the amount of blood that is typically drawn during a single 
blood donation. 
I understand that after completing this testing, for 6 months I will complete 3 
exercise sessions each week supervised by study personnel. I understand that I will be 
instructed on appropriate warmup and stretching exercises to perform prior to each 
exercise training session. I will be taught to measure my heart rate and to use heart 
rate monitors to control how hard I am exercising. The first training sessions will 
consist of 20 minutes of light exercise. The amount of exercise and how hard I 
exercise will increase gradually until I am completing 40 minutes of moderate 
intensity exercise every session. Exercise modes include walk/jogging, stairstepping, 
and cycle, cross-country ski, and rowing ergometry. I will be asked to add a 45-60 
minute walk to my exercise program on weekends after the first 10 weeks of the 
exercise program. I understand that this is not designed as a weight loss program and 
that if I lose more weight than expected from the amount of exercise that I complete, I 
will be counseled by a dietitian against restricting how much food I eat. I will also be 
asked to complete food records during the exercise training program and if major 
dietary changes have occurred, I will also be counseled by a dietitian to resume my 
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original dietary habits. I understand that I may also be asked to collect my urine for 
24 hours during the exercise training portion of the study. 
I understand that after completing 6 months of exercise training, I will have 
everything reevaluated that was measured before I began the exercise program. I 
understand that during this 4 weeks of Final Testing a maximum of 28 tablespoons of 
blood will be drawn; this is approximately 90% of the amount of blood that is 
typically drawn during a single blood donation.
I understand that if I qualify for this study that my DNA will be isolated from 
my blood and analyzed at a number of sites for differences in DNA that may affect 
how my blood pressure changes with exercise training. I understand that some of my 
DNA wil l also be frozen for future studies. However, these studies can only analyze 
my DNA at sites that might affect how my 
blood pressure, cholesterol levels, glucose and insulin levels, bone density, body 
composition, immunology (disease-fighting), and cardiovascular and blood clotting 
systems change with exercise training.
All information collected in this study is confidential, and my name will not 
be identified at any time. I understand that my DNA (genetic material) will be sent to 
collaborating genetics laboratories that are part of this study and that a sample of my 
DNA will be kept in the University of Maryland Department of Kinesiology 
laboratories. I also understand that samples of my blood will be sent to other 
collaborating laboratories for other blood measurements. I understand, however, that 
my DNA and blood samples sent to these laboratories will be identified only by a 
numeric code and that only investigators at the University of Maryland College Park 
will know whose name is associated with each coded number. I further understand 
that the list of names and codes will be retained at the University of Maryland 
College Park for up to 25 years. 
I understand the following risks are associated with my participation in this 
study. (1) The risk of maximal exercise testing is approximately 1 nonfatal event in 
10,000 tests and 1 fatal cardiac event in 70,000 tests. Risks will be minimized by 
having the test administered by a physician and personnel trained in such tests and 
emergency procedures. I will be screened with a resting electrocardiogram and a 
physical examination prior to this test. An emergency cart with the necessary drugs 
and a cardiac defibrillator will be present at all testing sessions. (2) There is minimal 
risk of bruising and infection associated with blood drawing. These risks will be 
minimized by using sterile techniques and by having experienced personnel draw all 
blood samples. (3) The risk of the body composition testing is the exposure to X-rays. 
The amount of X-ray exposure for this test is the same as that occurring during 30 
minutes of any activity outside in the sun. (4) There is some risk associated with the 
elevated blood pressure that I have and some risk associated with stopping the 
medications I take to control my blood pressure. However, a 12 month lifestyle 
change program including diet and exercise is part of the medical recommendations 
for blood pressure control for individuals with levels of blood pressure similar to 
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mine. In addition, I understand that my blood pressure will be monitored weekly and 
that this exceeds the blood pressure follow-up guidelines recommended for 
physicians. I also understand that if my blood pressure is too high for three 
consecutive weeks anytime during the study, my participation in the study will be 
discontinued and I will be referred back to my private physician. 
I also understand that a physician associated with this project is available to deal with 
concerns related to my participation in this study. (5) The risk associated with the 
CAT scan to measure abdominal fat is the exposure to X-rays. The X-ray exposure is 
less than the maximum radiation dose individuals are permitted to be exposed to each 
year in their occupation. (6) There are no risks associated with the 24 hour urine 
collection. (7) The only risks associated with the measurement of the hormones in my 
blood that affect my blood pressure are those associated with blood drawing. (8) The 
risks associated with the glucose tolerance test and high fat meal are those related 
again to blood sampling, the possibility that my blood sugar may go too low levels at 
the end of the test, and the possibility of an upset stomach, primarily a stomach ache, 
after drinking the glucose or high-fat meal. I understand that I will be given a juice 
drink and small snack to minimize the chances of my blood glucose levels decreasing 
too much. (9) There are no 
risks associated with the genetic testing because I will not be provided with these 
results. (10) The risk of exercise training is the possibility of a heart attack or other 
cardiovascular event. A large physical activity center reported that 1 nonfatal 
cardiovascular event occurred in 1.7 million walk/jogging miles. These risks will be 
minimized because I will undergo a cardiovascular evaluation before beginning 
exercise training. Exercise sessions will be supervised by experienced personnel 
trained in emergency procedures. An emergency cart with the necessary drugs and a 
cardiac defibrillator will be present at all supervised exercise training sessions. (11) If 
I have elevated blood cholesterol levels, I understand that the risk associated with the 
test requiring the injection into an arm vein of a substance that temporarily stops 
blood clotting is bleeding. This risk will be minimized by excluding peopl  with 
bleeding disorders, peptic ulcers, or other blood disorders from the study. The risk is 
further minimized by placing a bandage on the intravenous access site after the blood 
sampling and observing the subject for 2 – 3 hours. (12) The risks associated with the 
tests to assess kidney function are low as these are routine clinical tests. The risks are 
the side effects of the compounds put into my blood to assess kidney function; side 
effects include nausea, vomiting, facial flush, a generalized feeling of warmth, and 
allergic reactions. The risks are also those associated with blood drawing. These risks 
are minimized by administering these tests in a hospital setting with nurses 
experienced with these methods administering the test, so that if I should experience 
these side effects, medical personnel and equipment are readily available to respond 
and treat these symptoms. (13) The risks associated with the 24 hour blood pressure 
recording are the possibility of sleep disturbances in about 2% of volunteers. (14) The 
risks associated with the measurement of the blood flow in my arm are the result of 
stopping blood flow to the arm for 5 minutes. This causes substantial discomfort that 
ceases shortly after the blood pressure cuff is removed. I understand that if I can not 
tolerate the discomfort, this test will be terminated immediately on my request.  
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I understand that this study is not designed to help me personally, but may 
help the investigators to determine whom exercise might benefit the most. I 
understand that I am free to ask questions or to withdraw from participation at any 
time without penalty. I understand that I will earn $50 at the completion of Baseline 
Testing after the dietary stabilization period. I also understand that I will earn another 
$50 after 3 months of exercise training if I complete at least 90% of my exercise 
training sessions. I also understand that I will earn another $100 after completing 90% 
of my training sessions for 6 months and all final testing. I understand that that the 
total amount that I earn will be paid to me at the completion of my participation in the 
study. I understand that if my participation in the study has to be terminated because I 
change my hormone replacement therapy regimen, I will only be paid for the portion 
of the study that I have already completed, that is, which of the stages above that I 
have completed.
In the event of a physical injury resulting from participation in this study, I 
understand that immediate medical attention is available at the Washington Adventist 
Hospital or the Baltimore VA Medical Center. However, I understand that the 
University of Maryland does not provide any medical or hospitalization coverage for 
participants in this research study nor will the University of Maryland provide any 
compensation for any injury sustained as a result of participation in this research 
study except as required by law.
Principal Investigator: James Hagberg, PhD, Department of Kinesiology, HLHP 
Building, University of Maryland, College Park, MD 20742- 611, telephone 301-
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405-2487.
_________________________________           __________________
Subject’s signature Date
_________________________________           __________________
Witness Date 
_________________________________           ___________________
Investigator Date
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Appendix F − Statistical Tables
Descriptive Statistics for the Total Population
Descriptive Statistics
66 50 75 58.03 .68 5.488
66 149.9 191.8 170.040 1.159 9.4131
61 19.80 38.20 28.7492 .4945 3.86181
39 21.10 37.90 27.7615 .5503 3.43677
57 54.49 132.99 76.0515 1.8817 14.20664
61 .50 1.50 1.0131 .0253 .19788
57 20.50 55.50 37.0088 1.1802 8.91021
29 18.60 52.80 35.4414 1.7888 9.63278
57 32569.00 69315.00 48826.81 1422.9041 10742.69
31 33934.00 76286.00 50562.65 2325.9715 12950.46
57 110.70 162.50 131.2526 1.3878 10.47778
34 111.10 155.00 130.9912 1.9787 11.53767
53 72.40 102.00 85.2434 .8477 6.17157
33 70.30 99.70 83.8758 1.2142 6.97491
60 29.00 300.00 111.7333 7.1606 55.46594
37 49.00 365.00 124.2703 9.6818 58.89239
60 25.00 127.60 62.1350 3.1190 24.15958
37 35.40 149.00 68.1649 3.8332 23.31658
60 638.00 3970.00 2001.8500 102.0043 790.12157
37 590.00 4267.00 2196.8108 144.3167 877.84391
61 6.00 233.00 82.2951 7.0718 55.23264
37 18.00 132.00 75.0541 5.4572 33.19467
59 17.00 35.10 23.9475 .5860 4.50132
38 18.40 38.70 28.0716 .8856 5.45938
59 .99 3.68 2.0079 .0727 .55805
38 1.41 4.07 2.3274 .1074 .66231
61 53.60 110.90 83.6016 1.7297 13.50946































Statistic Statistic Statistic Statistic Std. Error Statistic
N Minimum Maximum Mean Std.
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Effects of Aerobic Exercise Training in the Total Population
Paired Samples Statistics
28.3923 39 3.58332 .57379
27.7615 39 3.43677 .55032
37.0138 29 9.31388 1.72954
35.4414 29 9.63278 1.78876
48797.03 29 12362.11545 2295.587
49137.76 29 12052.79282 2238.147
131.8441 34 10.75992 1.84531
130.9912 34 11.53767 1.97869
84.0576 33 6.51426 1.13399
83.8758 33 6.97491 1.21418
118.6757 37 54.84780 9.01692
124.2703 37 58.89239 9.68185
65.7189 37 25.17532 4.13880
68.1649 37 23.31658 3.83322
2104.3514 37 871.95875 143.34914
2196.8108 37 877.84391 144.31665
94.7027 37 61.55705 10.11992
75.0541 37 33.19467 5.45717
24.5684 38 4.97682 .80735
28.0716 38 5.45938 .88563
2.0824 38 .59258 .09613
2.3274 38 .66231 .10744
84.2333 39 13.54154 2.16838





















































.6308 1.17050 .18743 .2513 1.0102 3.365 38 .002
1.5724 2.31746 .43034 .6909 2.4539 3.654 28 .001
-340.7241 1732.66609 321.74802 -999.7951 318.3468 -1.059 28 .299
.8529 7.99050 1.37036 -1.9351 3.6410 .622 33 .538
.1818 5.83376 1.01553 -1.8867 2.2504 .179 32 .859
-5.5946 42.82293 7.04005 -19.8725 8.6833 -.795 36 .432
-2.4459 25.39045 4.17416 -10.9115 6.0197 -.586 36 .562
-92.4595 667.46476 109.73053 -315.0033 130.0844 -.843 36 .405
19.6486 55.43576 9.11358 1.1654 38.1319 2.156 36 .038
-3.5032 2.54691 .41316 -4.3403 -2.6660 -8.479 37 .000
-.2450 .21304 .03456 -.3150 -.1750 -7.089 37 .000
1.8692 3.33515 .53405 .7881 2.9504 3.500 38 .001
BMI_B - BMI_FPair 1
TFAT_B - TFAT_FPair 2
LBW_B - LBW_FPair 3
SBP_B - SBP_FPair 4
DBP_B - DBP_FPair 5
NA_B - NA_FPair 6
K_B - K_FPair 7
TV_B - TV_FPair 8
PA_B - PA_FPair 9
VO2REL_B - VO2REL_FPair 10
VO2AB_B - VO2AB_FPair 11








t df Sig. (2-tailed)
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Regression in the Total Population
Predictor: change plasma aldosterone (PA)

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGSBPb. 
Predictor: change in plasma aldosterone


































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHDBPb. 
Predictor: change in plasma aldosterone


































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGNAb. 
Ethnic Differences Independent t-test
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Group Statistics
33 58.36 5.846 1.018
28 57.36 5.215 .986
33 172.728 10.0371 1.7472
28 166.571 8.2479 1.5587
31 28.6484 4.13738 .74310
25 29.2760 3.66507 .73301
23 28.6739 3.54121 .73839
13 26.9462 3.00600 .83371
31 75.3135 11.79692 2.11879
26 76.9313 16.84087 3.30277
31 .9871 .17840 .03204
26 1.0577 .20430 .04007
32 35.7063 9.15807 1.61893
20 40.0300 8.50047 1.90076
16 33.5000 7.78486 1.94621
11 39.9455 10.57964 3.18988
32 50741.03 12153.69697 2148.490
20 45916.30 9113.49231 2037.839
17 54263.29 13389.73938 3247.489
12 45736.50 12192.49608 3519.670
31 132.1581 10.31997 1.85352
21 129.4810 9.90735 2.16196
21 130.5762 9.15319 1.99739
10 134.0800 13.40786 4.23994
28 84.9214 7.09002 1.33989
20 86.0550 4.91630 1.09932
21 83.8095 7.86619 1.71654
9 84.0222 6.08169 2.02723
31 114.1290 57.70254 10.36368
25 108.8400 55.96404 11.19281
22 131.9091 68.97750 14.70605























































.130 .720 .704 59 .484 1.01 1.430 -1.855 3.868
.710 58.835 .480 1.01 1.417 -1.829 3.842
3.541 .065 2.587 59 .012 6.156 2.3796 1.3949 10.9180
2.629 58.950 .011 6.156 2.3414 1.4711 10.8418
.025 .875 -.593 54 .555 -.6276 1.05762 -2.74801 1.49279
-.601 53.486 .550 -.6276 1.04379 -2.72075 1.46552
.067 .797 1.481 34 .148 1.7278 1.16660 -.64305 4.09857
1.551 28.608 .132 1.7278 1.11369 -.55135 4.00687
.803 .374 -.425 55 .672 -1.6178 3.80594 -9.24504 6.00950
-.412 43.651 .682 -1.6178 3.92397 -9.52780 6.29225
.002 .969 -1.393 55 .169 -.0706 .05069 -.17218 .03099
-1.376 50.120 .175 -.0706 .05130 -.17364 .03244
.173 .680 -1.702 50 .095 -4.3238 2.54085 -9.42720 .77970
-1.732 42.770 .091 -4.3238 2.49677 -9.35974 .71224
2.255 .146 -1.827 25 .080 -6.4455 3.52798 -13.71148 .82057
-1.725 17.238 .102 -6.4455 3.73672 -14.32096 1.43005
5.213 .027 1.525 50 .133 4824.7312 3163.1244 -1528.59 11178.05
1.629 48.208 .110 4824.7312 2961.2156 -1128.53 10777.99
.142 .710 1.751 27 .091 8526.7941 4869.5746 -1464.75 18518.34
1.781 25.163 .087 8526.7941 4788.9731 -1333.04 18386.62
.049 .825 .933 50 .356 2.6771 2.87061 -3.08867 8.44290
.940 44.264 .352 2.6771 2.84774 -3.06116 8.41539
4.925 .034 -.856 29 .399 -3.5038 4.09454 -11.87807 4.87046
-.748 13.147 .468 -3.5038 4.68686 -13.61769 6.61007
1.777 .189 -.616 46 .541 -1.1336 1.83977 -4.83683 2.56969
-.654 45.978 .516 -1.1336 1.73315 -4.62226 2.35512
.416 .524 -.072 28 .943 -.2127 2.94838 -6.25218 5.82678
-.080 19.562 .937 -.2127 2.65635 -5.76171 5.33631
.000 .983 .346 54 .731 5.2890 15.30500 -25.39565 35.97371
.347 52.136 .730 5.2890 15.25401 -25.31848 35.89655
.977 .330 .684 33 .499 14.3706 21.00214 -28.35855 57.09981




























































































t-test for Equality of Means
145
Group Statistics
31 70.2290 23.21049 4.16873
25 50.8040 22.17180 4.43436
22 68.8909 19.87396 4.23714
13 69.1000 30.02788 8.32823
31 2154.5484 830.14400 149.09826
25 1828.1600 753.87873 150.77575
22 2395.3636 893.83372 190.56599
13 1957.3846 744.22975 206.41219
28 106.6071 64.18107 12.12908
28 62.2143 36.79710 6.95400
20 81.4000 31.02868 6.93822
14 61.2143 33.41851 8.93147
30 24.8167 5.01694 .91596
24 22.2417 3.04301 .62115
22 29.2414 5.12297 1.09222
13 25.8536 5.79773 1.60800
30 2.1559 .66651 .12169
24 1.8026 .37370 .07628
22 2.5360 .66099 .14092
13 2.0280 .62367 .17297
21 -2.8857 6.17003 1.34641
10 3.6000 9.93714 3.14240
21 -.2857 6.04998 1.32021
9 -1.2778 5.36884 1.78961
22 9.0000 39.00916 8.31678
13 3.5385 43.97464 12.19637
20 -37.6000 65.02421 14.53985

















































2.824 .099 3.176 54 .002 19.4250 6.11666 7.16187 31.68820
3.192 52.415 .002 19.4250 6.08620 7.21448 31.63558
.745 .394 -.025 33 .980 -.2091 8.41930 -17.33828 16.92010
-.022 18.315 .982 -.2091 9.34414 -19.81621 19.39803
.471 .496 1.523 54 .134 326.3884 214.28068 -103.219 755.99528
1.539 53.194 .130 326.3884 212.04626 -98.88627 751.66304
.234 .632 1.486 33 .147 437.9790 294.73171 -161.657 1037.615
1.559 29.096 .130 437.9790 280.92951 -136.504 1012.462
9.562 .003 3.175 54 .002 44.3929 13.98116 16.36233 72.42339
3.175 43.019 .003 44.3929 13.98116 16.19754 72.58818
.004 .950 1.809 32 .080 20.1857 11.15825 -2.54290 42.91433
1.785 26.757 .086 20.1857 11.30974 -3.02981 43.40123
8.906 .004 2.208 52 .032 2.5750 1.16617 .23491 4.91509
2.327 48.795 .024 2.5750 1.10672 .35073 4.79927
.197 .660 1.801 33 .081 3.3877 1.88141 -.44001 7.21551
1.743 22.848 .095 3.3877 1.94387 -.63493 7.41042
11.165 .002 2.319 52 .024 .3533 .15236 .04762 .65908
2.460 47.099 .018 .3533 .14362 .06444 .64226
.245 .624 2.242 33 .032 .5080 .22657 .04709 .96901
2.277 26.536 .031 .5080 .22311 .04988 .96621
.909 .348 -2.238 29 .033 -6.4857 2.89820 -12.41320 -.55823
-1.897 12.419 .081 -6.4857 3.41870 -13.90661 .93518
.045 .834 .425 28 .674 .9921 2.33605 -3.79313 5.77725
.446 17.056 .661 .9921 2.22389 -3.69875 5.68288
.494 .487 .382 33 .705 5.4615 14.30247 -23.63705 34.56013
.370 22.922 .715 5.4615 14.76212 -25.08196 36.00504
3.871 .058 -1.886 32 .068 -35.2429 18.68380 -73.30051 2.81480








































































































Mean Std. Deviation N
Levene's Test of Equality of Error Variancesa
Dependent Variable: PA_F
.242 1 31 .626
F df1 df2 Sig.
Tests the null hypothesis that the error variance of
the dependent variable is equal across groups.
Design: Intercept+BMI_F+ETHNa. 
Tests of Between-Subjects Effects
Dependent Variable: PA_F
7158.358a 2 3579.179 3.890 .031 .206
74.099 1 74.099 .081 .779 .003
2643.419 1 2643.419 2.873 .100 .087













of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .206 (Adjusted R Squared = .153)a. 
2. 1=cauc; 2=AD
Dependent Variable: PA_F
80.009a 6.832 66.056 93.963




Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated at the following
values: BMI_F = 27.6515.
a. 
148
Covariate: final 24-hour K + excretion


















Mean Std. Deviation N
Levene's Test of Equality of Error Variancesa
Dependent Variable: PA_F
2.260 1 30 .143
F df1 df2 Sig.
Tests the null hypothesis that the error variance of
the dependent variable is equal across groups.
Design: Intercept+K_F+ETHNa. 
Tests of Between-Subjects Effects
Dependent Variable: PA_F
9340.944a 2 4670.472 5.407 .010 .272
3603.220 1 3603.220 4.171 .050 .126
4348.090 1 4348.090 5.034 .033 .148













of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .272 (Adjusted R Squared = .221)a. 
2. 1=cauc; 2=AD
Dependent Variable: PA_F
82.480a 6.745 68.684 96.275




Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated at the following
values: K_F = 70.2875.
a. 
149
Dependent T-test in Caucasians
Paired Samples Statistics
29.0913 23 3.62716 .75631
28.6739 23 3.54121 .73839
35.6750 16 8.39964 2.09991
33.5000 16 7.78486 1.94621
52095.81 16 13336.25719 3334.064
52886.88 16 12525.30740 3131.327
133.4619 21 11.10029 2.42228
130.5762 21 9.15319 1.99739
84.0952 21 7.39618 1.61398
83.8095 21 7.86619 1.71654
122.9091 22 63.70984 13.58298
131.9091 22 68.97750 14.70605
71.0727 22 23.35927 4.98021
68.8909 22 19.87396 4.23714
2226.9545 22 944.06177 201.27464
2395.3636 22 893.83372 190.56599
119.0000 20 70.33828 15.72812
81.4000 20 31.02868 6.93822
25.4136 22 5.16013 1.10014
29.2414 22 5.12297 1.09222
2.2605 22 .63592 .13558
2.5360 22 .66099 .14092
88.2391 23 13.77038 2.87132





















































.4174 .66309 .13826 .1307 .7041 3.019 22 .006
2.1750 2.19621 .54905 1.0047 3.3453 3.961 15 .001
-791.0625 1822.23140 455.55785 -1762.06 179.9361 -1.736 15 .103
2.8857 6.17003 1.34641 .0771 5.6943 2.143 20 .045
.2857 6.04998 1.32021 -2.4682 3.0396 .216 20 .831
-9.0000 39.00916 8.31678 -26.2957 8.2957 -1.082 21 .291
2.1818 23.65306 5.04285 -8.3054 12.6690 .433 21 .670
-168.4091 698.67437 148.95788 -478.1840 141.3658 -1.131 21 .271
37.6000 65.02421 14.53985 7.1677 68.0323 2.586 19 .018
-3.8277 2.54126 .54180 -4.9545 -2.7010 -7.065 21 .000
-.2755 .21243 .04529 -.3697 -.1814 -6.084 21 .000
1.3000 2.01855 .42090 .4271 2.1729 3.089 22 .005
BMI_B - BMI_FPair 1
TFAT_B - TFAT_FPair 2
LBW_B - LBW_FPair 3
SBP_B - SBP_FPair 4
DBP_B - DBP_FPair 5
NA_B - NA_FPair 6
K_B - K_FPair 7
TV_B - TV_FPair 8
PA_B - PA_FPair 9
VO2REL_B - VO2REL_FPair 10
VO2AB_B - VO2AB_FPair 11








t df Sig. (2-tailed)
150
Univariate Analysis in Caucasians: 
Covariate: baseline plasma aldosterone




Mean Std. Deviation N
Tests of Between-Subjects Effects
Dependent Variable: CHGPA
64758.542a 1 64758.542 74.835 .000 .806
18648.897 1 18648.897 21.551 .000 .545












of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .806 (Adjusted R Squared = .795)a. 
Grand Mean
Dependent Variable: CHGPA
-37.600a 6.578 -51.419 -23.781
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated
at the following values: PA_B = 119.0000.
a. 
Regression in Caucasians
Predictor: baseline plasma aldosterone


































Predictors: (Constant), PA_Ba. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), PA_Ba. 
Dependent Variable: CHGPAb. 
Regression Caucasians
Predictor: baseline SBP


































Predictors: (Constant), SBP_Ba. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), SBP_Ba. 
Dependent Variable: CHGSBPb. 
Regression Caucasians
Predictor: change in plasma aldosterone


































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGSBPb. 
Predictor: change in plasma aldosterone


































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHDBPb. 
Predictor: change in plasma aldosterone


































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGNAb. 
Dependent t-test in individuals of African descent
Paired Samples Statistics
27.9692 13 3.50366 .97174
26.9462 13 3.00600 .83371
40.3273 11 10.19148 3.07285
39.9455 11 10.57964 3.18988
44390.18 11 11018.55958 3322.221
43879.73 11 10863.43736 3275.450
130.4800 10 9.95945 3.14945
134.0800 10 13.40786 4.23994
85.3000 9 4.83580 1.61193
84.0222 9 6.08169 2.02723
114.0000 13 37.80873 10.48625
117.5385 13 39.81963 11.04398
57.3538 13 28.46450 7.89463
69.1000 13 30.02788 8.32823
2002.0769 13 774.31738 214.75700
1957.3846 13 744.22975 206.41219
63.5714 14 34.54476 9.23248
61.2143 14 33.41851 8.93147
22.3154 13 3.57301 .99098
25.8536 13 5.79773 1.60800
79.4923 13 12.17685 3.37725


















































1.0231 1.80377 .50028 -.0669 2.1131 2.045 12 .063
.3818 2.11840 .63872 -1.0413 1.8050 .598 10 .563
510.4545 1370.37304413.18302-410.17461431.0837 1.235 10 .245
-3.6000 9.93714 3.14240 -10.7086 3.5086 -1.146 9 .281
1.2778 5.36884 1.78961 -2.8491 5.4046 .714 8 .496
-3.5385 43.97464 12.19637 -30.1121 23.0351 -.290 12 .777
-11.7462 28.40242 7.87742 -28.9096 5.4173 -1.491 12 .162
44.6923 584.67945162.16090-308.6260 398.0106 .276 12 .788
2.3571 29.94766 8.00385 -14.9341 19.6484 .295 13 .773
-3.5382 2.55077 .70746 -5.0796 -1.9968 -5.001 12 .000
2.9385 5.06993 1.40615 -.1253 6.0022 2.090 12 .059
BMI_B - BMI_FPair 1
TFAT_B - TFAT_FPair 2
LBW_B - LBW_FPair 3
SBP_B - SBP_FPair 4
DBP_B - DBP_FPair 5
NA_B - NA_FPair 6
K_B - K_FPair 7
TV_B - TV_FPair 8
PA_B - PA_FPair 9
VO2REL_B - VO2REL_FPair 10








t df Sig. (2-tailed)
Univariate Analysis in individuals of African descent
Covariate: baseline plasma aldosterone 




Mean Std. Deviation N
Tests of Between-Subjects Effects
Dependent Variable: CHGPA
2580.522a 1 2580.522 3.411 .090 .221
1673.723 1 1673.723 2.212 .163 .156












of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .221 (Adjusted R Squared = .156)a. 
Grand Mean
Dependent Variable: CHGPA
-2.357a 7.351 -18.374 13.660
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated
at the following values: PA_B = 63.5714.
a. 
157
Regression in individuals of African descent
Predictor: baseline plasma aldosterone

































Predictors: (Constant), PA_Ba. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), PA_Ba. 
Dependent Variable: CHGPAb. 
158
Univariate Analysis in individuals of African descent
Covariate: baseline 24-hour Na+ excretion




Mean Std. Deviation N
Tests of Between-Subjects Effects
Dependent Variable: CHGNA
6631.897a 1 6631.897 4.402 .060 .286
6636.698 1 6636.698 4.405 .060 .286












of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .286 (Adjusted R Squared = .221)a. 
Grand Mean
Dependent Variable: CHGNA
3.538a 10.766 -20.156 27.233
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated
at the following values: NA_B = 114.0000.
a. 
Regression in individuals of African descent
Predictor: baseline 24-hour Na+ excretion


































Predictors: (Constant), NA_Ba. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), NA_Ba. 
Dependent Variable: CHGNAb. 
Univariate Analysis in individuals of African descent
Covariate: change in 24-hour Na+ excretion




Mean Std. Deviation N
Tests of Between-Subjects Effects
Dependent Variable: CHDBP
100.424a 1 100.424 5.400 .053 .435
24.116 1 24.116 1.297 .292 .156












of Squares df Mean Square F Sig.
Partial Eta
Squared




-1.278a 1.437 -4.677 2.121
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated
at the following values: CHGNA = 4.0000.
a. 
161
Independent T-test in the Caucasian TT vs. TC+CC Group
Group Statistics
1=TT:2 
TC+CC N Mean Std. Deviation
Std. Error 
Mean
1.00 13 56.08 4.663 1.293AGE
2.00 18 60.11 6.398 1.508
1.00 13 28.9077 4.71301 1.30715BMI_B
2.00 16 28.3938 4.03410 1.00852
1.00 9 29.1111 2.35502 .78501BMI_F
2.00 14 28.0286 4.40951 1.17849
1.00 12 74.6192 14.36136 4.14577MDRD
2.00 18 74.8117 9.71508 2.28987
1.00 12 .9833 .18505 .05342SCR
2.00 17 1.0176 .16672 .04043
1.00 12 37.1250 8.91374 2.57318TFAT_B
2.00 18 33.5389 8.98581 2.11798
1.00 7 35.4286 6.15866 2.32775TFAT_F
2.00 8 30.3250 7.86670 2.78130














1.00 12 130.4417 11.12201 3.21065SBP_B
2.00 17 133.7176 10.39130 2.52026
1.00 8 130.4625 11.14014 3.93863SBP_F
2.00 12 130.2000 8.39740 2.42412
1.00 11 83.3727 8.83585 2.66411DBP_B
2.00 16 85.8375 5.95011 1.48753
1.00 8 86.1250 8.85676 3.13134DBP_F
2.00 12 82.6250 7.44765 2.14995
1.00 12 123.1667 65.67251 18.95802NA_B
2.00 17 107.9412 56.17881 13.62536
1.00 8 157.3750 86.89885 30.72338NA_F
2.00 13 122.6154 53.12805 14.73507
1.00 12 75.0333 20.31333 5.86395K_B
2.00 17 65.8059 26.04255 6.31625
1.00 8 73.6250 22.18447 7.84339K_F
2.00 13 68.2000 17.86342 4.95442
1.00 12 2371.3333 789.91062 228.02755TV_B
2.00 17 1984.4118 885.02380 214.64980
1.00 8 2400.6250 422.45133 149.35910TV_F
2.00 13 2368.6923 1133.80571 314.46113
1.00 11 119.0000 63.91870 19.27221PA_B
2.00 16 98.8125 67.11504 16.77876
162
1.00 8 98.2500 22.37186 7.90965PA_F
2.00 12 70.1667 31.62805 9.13023
1.00 13 24.4154 4.57381 1.26855VO2REL_B
2.00 15 25.6533 5.60202 1.44644
1.00 9 29.1222 4.81762 1.60587VO2REL_F
2.00 13 29.6392 5.31955 1.47538
1.00 13 86.2692 18.05526 5.00763WGT_B
2.00 16 87.5250 13.76302 3.44075
1.00 9 89.6667 12.86439 4.28813WGT_F
2.00 14 84.7500 14.25271 3.80920
1.00 8 -1.5000 5.78644 2.04581CHGSBP
2.00 12 -4.4083 6.26817 1.80946
1.00 8 3.3875 6.39563 2.26120CHDBP
2.00 12 -2.1083 4.68507 1.35246
1.00 8 -8.1250 29.58343 10.45932CHGK
2.00 13 4.4615 16.48077 4.57094
1.00 8 20.1250 45.57705 16.11392CHGNA
2.00 13 6.7692 32.60919 9.04416
1.00 8 -35.7500 57.78470 20.42998CHGPA
2.00 12 -38.8333 71.93158 20.76486
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Independent Samples Test
1.632 .212 -1.930 29 .063 -4.03 2.091 -8.310 .241
-2.031 28.988 .052 -4.03 1.987 -8.097 .029
.747 .395 .316 27 .754 .5139 1.62387 -2.81796 3.84584
.311 23.794 .758 .5139 1.65099 -2.89510 3.92298
.998 .330 .449 20 .659 .7188 1.60225 -2.62344 4.06104
.498 19.137 .624 .7188 1.44298 -2.29993 3.73753
1.289 .266 -.044 28 .965 -.1925 4.38321 -9.17110 8.78610
-.041 17.671 .968 -.1925 4.73613 -10.15601 9.77101
1.081 .308 -.522 27 .606 -.0343 .06576 -.16925 .10062
-.512 22.205 .614 -.0343 .06700 -.17318 .10455
.000 .989 1.074 28 .292 3.5861 3.33829 -3.25206 10.42429
1.076 23.866 .293 3.5861 3.33273 -3.29434 10.46657
.004 .950 .946 14 .360 3.5625 3.76488 -4.51237 11.63737
.946 13.884 .360 3.5625 3.76488 -4.51872 11.64372
.006 .940 -1.117 28 .274 -4865.5278 4357.5703 -13791.6 4060.550
-1.114 23.527 .277 -4865.5278 4368.5539 -13891.4 4160.334
.212 .653 -.178 14 .861 -1185.7500 6658.7061 -15467.3 13095.75
-.178 13.990 .861 -1185.7500 6658.7061 -15468.2 13096.71
.000 .983 -.812 27 .424 -3.2760 4.03242 -11.54982 4.99786
-.803 22.785 .430 -3.2760 4.08166 -11.72395 5.17199
.660 .427 .060 18 .953 .2625 4.36261 -8.90301 9.42801
.057 12.194 .956 .2625 4.62485 -9.79640 10.32140
1.859 .185 -.869 25 .393 -2.4648 2.83717 -8.30804 3.37850
-.808 16.160 .431 -2.4648 3.05126 -8.92796 3.99841
.226 .640 .956 18 .352 3.5000 3.66294 -4.19554 11.19554













































































t-test for Equality of Means
164
Independent Samples Test
.342 .563 .670 27 .508 15.2255 22.70801 -31.36749 61.81847
.652 21.378 .521 15.2255 23.34646 -33.27396 63.72494
.345 .564 1.145 19 .266 34.7596 30.36010 -28.78481 98.30404
1.020 10.274 .331 34.7596 34.07416 -40.88921 110.40844
1.597 .217 1.025 27 .314 9.2275 9.00174 -9.24260 27.69750
1.071 26.660 .294 9.2275 8.61864 -8.46710 26.92200
.137 .715 .617 19 .545 5.4250 8.79247 -12.97786 23.82786
.585 12.536 .569 5.4250 9.27713 -14.69265 25.54265
.191 .665 1.211 27 .236 386.9216 319.56272 -268.767 1042.610
1.236 25.413 .228 386.9216 313.16306 -257.519 1031.362
6.221 .022 .076 19 .940 31.9327 420.97358 -849.175 913.04051
.092 16.579 .928 31.9327 348.12920 -703.980 767.84588
.012 .913 .783 25 .441 20.1875 25.79379 -32.93580 73.31080
.790 22.346 .438 20.1875 25.55279 -32.75822 73.13322
1.711 .207 2.167 18 .044 28.0833 12.95789 .85981 55.30686
2.325 17.881 .032 28.0833 12.07988 2.69228 53.47439
1.642 .211 -.634 26 .532 -1.2379 1.95265 -5.25167 2.77577
-.643 25.925 .526 -1.2379 1.92390 -5.19314 2.71724
.692 .416 -.268 19 .792 -.6203 2.31480 -5.46522 4.22466
-.274 18.505 .787 -.6203 2.26688 -5.37352 4.13297
.114 .739 -.519 26 .608 -.1325 .25539 -.65742 .39250
-.516 24.897 .610 -.1325 .25657 -.66098 .39606
.008 .930 .329 19 .746 .0963 .29305 -.51703 .70970








































































t-test for Equality of Means
165
Independent Samples Test
.553 .464 -.213 27 .833 -1.2558 5.90528 -13.37241 10.86087
-.207 22.070 .838 -1.2558 6.07578 -13.85385 11.34231
.126 .726 .578 20 .570 3.3128 5.73358 -8.64722 15.27286
.583 17.873 .567 3.3128 5.68466 -8.63630 15.26195
.291 .596 1.047 18 .309 2.9083 2.77757 -2.92713 8.74380
1.065 16.003 .303 2.9083 2.73121 -2.88147 8.69814
.165 .689 2.224 18 .039 5.4958 2.47155 .30331 10.68836
2.086 11.932 .059 5.4958 2.63480 -.24851 11.24017
4.483 .048 -1.260 19 .223 -12.5865 9.98730 -33.49021 8.31713
-1.103 9.722 .297 -12.5865 11.41451 -38.11846 12.94538
1.018 .326 .784 19 .443 13.3558 17.03362 -22.29600 49.00754
.723 11.443 .484 13.3558 18.47851 -27.12408 53.83562
.340 .567 .101 18 .921 3.0833 30.48398 -60.96112 67.12779















































t-test for Equality of Means
166
Univariate Analysis in Caucasians TT vs. TC+CC Genotype Group
Covariate: baseline plasma aldosterone levels

















Mean Std. Deviation N
Levene's Test of Equality of Error Variancesa
Dependent Variable: CHGPA
3.273 1 18 .087
F df1 df2 Sig.
Tests the null hypothesis that the error variance of
the dependent variable is equal across groups.
Design: Intercept+PA_B+CY_CODEa. 
Tests of Between-Subjects Effects
Dependent Variable: CHGPA
67574.981a 2 33787.490 45.015 .000 .841
21180.470 1 21180.470 28.219 .000 .624
67529.347 1 67529.347 89.970 .000 .841













of Squares df Mean Square F Sig.
Partial Eta
Squared




-22.829a 9.782 -43.466 -2.191




Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated at the following
values: PA_B = 119.0000.
a. 
Univariate Analysis in Caucasians TT vs. TC+CC Genotype Group
Covariate: baseline SBP

















Mean Std. Deviation N
Levene's Test of Equality of Error Variancesa
Dependent Variable: CHGSBP
.004 1 18 .949
F df1 df2 Sig.
Tests the null hypothesis that the error variance of
the dependent variable is equal across groups.
Design: Intercept+SBP_B+CY_CODEa. 
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Tests of Between-Subjects Effects
Dependent Variable: CHGSBP
257.025a 2 128.512 4.853 .022 .363
184.176 1 184.176 6.956 .017 .290
216.424 1 216.424 8.173 .011 .325













of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .363 (Adjusted R Squared = .289)a. 
2. 1=TT:2 TC+CC
Dependent Variable: CHGSBP
-1.974a 1.827 -5.828 1.880




Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated at the following
values: SBP_B = 133.5500.
a. 
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Dependent T-test in Caucasian TC+CC Genotype Group
Paired Samples Statistics
28.8154 13 4.30443 1.19383
28.3923 13 4.36548 1.21077
32.7625 8 8.64621 3.05690
30.3250 8 7.86670 2.78130
55317.13 8 14539.27613 5140.410
56038.13 8 13493.80238 4770.780
134.6083 12 10.48735 3.02744
130.2000 12 8.39740 2.42412
84.7333 12 5.60817 1.61894
82.6250 12 7.44765 2.14995
115.8462 13 61.50860 17.05942
122.6154 13 53.12805 14.73507
63.7385 13 25.78984 7.15281
68.2000 13 17.86342 4.95442
1965.9231 13 1000.99679 277.62656
2368.6923 13 1133.80571 314.46113
109.0000 12 72.24453 20.85520
70.1667 12 31.62805 9.13023
25.2417 12 5.97760 1.72559
29.7425 12 5.54246 1.59997
2.2261 12 .64230 .18542
2.5347 12 .64394 .18589
87.6462 13 13.44189 3.72811





















































.4231 .48158 .13357 .1321 .7141 3.168 12 .008
2.4375 1.65178 .58399 1.0566 3.8184 4.174 7 .004
-721.0000 1367.38771 483.44456 -1864.16 422.1647 -1.491 7 .179
4.4083 6.26817 1.80946 .4257 8.3909 2.436 11 .033
2.1083 4.68507 1.35246 -.8684 5.0851 1.559 11 .147
-6.7692 32.60919 9.04416 -26.4748 12.9363 -.748 12 .469
-4.4615 16.48077 4.57094 -14.4208 5.4977 -.976 12 .348
-402.7692 579.71202 160.78319 -753.0857 -52.4528 -2.505 12 .028
38.8333 71.93158 20.76486 -6.8698 84.5365 1.870 11 .088
-4.5008 1.88344 .54370 -5.6975 -3.3042 -8.278 11 .000
-.3086 .18335 .05293 -.4251 -.1921 -5.830 11 .000
1.2923 1.41978 .39378 .4343 2.1503 3.282 12 .007
BMI_B - BMI_FPair 1
TFAT_B - TFAT_FPair 2
LBW_B - LBW_FPair 3
SBP_B - SBP_FPair 4
DBP_B - DBP_FPair 5
NA_B - NA_FPair 6
K_B - K_FPair 7
TV_B - TV_FPair 8
PA_B - PA_FPair 9
VO2REL_B - VO2REL_FPair 10
VO2AB_B - VO2AB_FPair 11








t df Sig. (2-tailed)
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Regression in Caucasian TT Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGSBPb. 
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Regression in Caucasian TT Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHDBPb. 
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Regression in Caucasian TT Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGNAb. 
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Regression in Caucasian TC+CC Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGSBPb. 
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Regression in Caucasian TC+CC Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHDBPb. 
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Regression in Caucasian TC+CC Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGNAb. 
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Independent T-test Among individuals of African descent in TT vs. TC+CC
Group Statistics
14 57.79 3.534 .944
12 57.08 6.694 1.932
12 28.1250 3.09578 .89368
12 29.9500 3.84767 1.11073
6 25.5833 1.99741 .81544
7 28.1143 3.36126 1.27044
13 73.8438 10.23172 2.83777
11 81.8227 23.01040 6.93790
13 1.0692 .11821 .03279
11 1.0455 .29449 .08879
11 36.6455 6.54788 1.97426
8 43.7375 9.64275 3.40923
6 35.1833 9.06651 3.70139
5 45.6600 10.11103 4.52179
11 45341.27 8227.06300 2480.553
8 46391.50 11271.96674 3985.242
6 43249.83 10191.83539 4160.799
6 48223.17 14433.68900 5892.529
12 128.8667 9.16667 2.64619
8 129.7625 11.99666 4.24146
6 128.0000 11.77268 4.80618
4 143.2000 11.11246 5.55623
11 85.2909 4.98065 1.50172
8 86.6750 5.20707 1.84098
5 81.4200 5.22178 2.33525
4 87.2750 6.07310 3.03655
13 126.1538 64.25450 17.82099
11 89.4545 41.77646 12.59608
6 110.1667 50.21719 20.50108




















































4.760 .039 .342 24 .736 .70 2.056 -3.540 4.945
.327 16.106 .748 .70 2.151 -3.855 5.260
.735 .400 -1.280 22 .214 -1.8250 1.42561 -4.78154 1.13154
-1.280 21.036 .214 -1.8250 1.42561 -4.78941 1.13941
4.553 .056 -1.611 11 .136 -2.5310 1.57124 -5.98922 .92732
-1.677 9.938 .125 -2.5310 1.50962 -5.89744 .83554
5.590 .027 -1.129 22 .271 -7.9789 7.06938 -22.63988 6.68212
-1.064 13.315 .306 -7.9789 7.49582 -24.13372 8.17596
7.439 .012 .268 22 .792 .0238 .08886 -.16050 .20805
.251 12.716 .806 .0238 .09465 -.18118 .22873
1.139 .301 -1.915 17 .072 -7.0920 3.70295 -14.90458 .72049
-1.800 11.571 .098 -7.0920 3.93961 -15.71113 1.52704
.000 .987 -1.813 9 .103 -10.4767 5.77970 -23.55127 2.59793
-1.793 8.208 .110 -10.4767 5.84353 -23.89263 2.93930
.729 .405 -.235 17 .817 -1050.2273 4460.0634 -10460.1 8359.684
-.224 12.193 .827 -1050.2273 4694.1769 -11260.0 9159.535
2.080 .180 -.689 10 .506 -4973.3333 7213.4699 -21045.9 11099.28
-.689 8.993 .508 -4973.3333 7213.4699 -21293.2 11346.54
.463 .505 -.189 18 .852 -.8958 4.72844 -10.82992 9.03825
-.179 12.322 .861 -.8958 4.99923 -11.75675 9.96508
.186 .677 -2.042 8 .075 -15.2000 7.44228 -32.36192 1.96192
-2.069 6.863 .078 -15.2000 7.34650 -32.64201 2.24201
.539 .473 -.587 17 .565 -1.3841 2.35820 -6.35946 3.59128
-.583 14.821 .569 -1.3841 2.37579 -6.45329 3.68510
.245 .636 -1.558 7 .163 -5.8550 3.75827 -14.74189 3.03189
-1.528 6.019 .177 -5.8550 3.83067 -15.22116 3.51116
.987 .331 1.623 22 .119 36.6993 22.60747 -10.18573 83.58433
1.682 20.766 .108 36.6993 21.82313 -8.71558 82.11418
5.700 .036 -.601 11 .560 -13.6905 22.76750 -63.80142 36.42046























































































t-test for Equality of Means
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Group Statistics
13 47.3538 11.39339 3.15996
11 55.2727 31.38070 9.46164
6 52.4167 12.65487 5.16633
7 83.4000 33.95566 12.83403
13 1822.8462 607.52090 168.49598
11 1902.9091 926.38744 279.31632
6 1621.8333 545.02456 222.50534
7 2245.0000 806.91284 304.98439
14 63.6429 42.42932 11.33971
12 59.0000 33.01515 9.53065
6 37.0000 19.35975 7.90359
8 79.3750 30.44404 10.76359
12 22.1083 2.62902 .75893
12 22.3750 3.52294 1.01699
6 25.5833 4.25602 1.73751
7 26.0853 7.21090 2.72546
12 1.7345 .31795 .09178
12 1.8707 .42520 .12274
6 1.8498 .44893 .18328
7 2.1807 .74231 .28057
12 78.1417 8.54469 2.46664
12 83.6417 12.43612 3.59000
6 71.4833 6.78157 2.76856
7 80.9000 12.27341 4.63891
6 -1.2833 7.55630 3.08485
4 10.9250 9.04668 4.52334
5 -3.3200 5.03905 2.25353
4 1.2750 5.23155 2.61578
6 4.9167 18.97329 7.74581
7 17.6000 35.02551 13.23840
6 -9.1667 42.22519 17.23836
7 14.4286 45.62842 17.24592
6 -16.5000 29.11185 11.88486


























































6.391 .019 -.849 22 .405 -7.9189 9.32777 -27.26348 11.42572
-.794 12.228 .442 -7.9189 9.97536 -29.60839 13.77063
3.302 .097 -2.102 11 .059 -30.9833 14.73742 -63.42017 1.45350
-2.240 7.855 .056 -30.9833 13.83486 -62.98967 1.02300
1.081 .310 -.254 22 .802 -80.0629 315.05053 -733.438 573.31186
-.245 16.754 .809 -80.0629 326.20316 -769.064 608.93775
.346 .568 -1.600 11 .138 -623.1667 389.51300 -1480.48 234.14567
-1.651 10.513 .128 -623.1667 377.52365 -1458.81 212.47824
1.260 .273 .307 24 .761 4.6429 15.10728 -26.53705 35.82276
.313 23.811 .757 4.6429 14.81291 -25.94233 35.22804
1.614 .228 -2.972 12 .012 -42.3750 14.25623 -73.43665 -11.31335
-3.173 11.786 .008 -42.3750 13.35371 -71.52881 -13.22119
1.231 .279 -.210 22 .835 -.2667 1.26895 -2.89831 2.36498
-.210 20.352 .836 -.2667 1.26895 -2.91073 2.37739
6.208 .030 -.149 11 .884 -.5020 3.36559 -7.90956 6.90565
-.155 9.905 .880 -.5020 3.23220 -7.71312 6.70922
1.270 .272 -.888 22 .384 -.1362 .15327 -.45402 .18169
-.888 20.372 .385 -.1362 .15327 -.45550 .18317
3.842 .076 -.950 11 .363 -.3309 .34840 -1.09771 .43595
-.987 10.023 .347 -.3309 .33512 -1.07735 .41559
1.139 .297 -1.263 22 .220 -5.5000 4.35573 -14.53324 3.53324
-1.263 19.493 .222 -5.5000 4.35573 -14.60107 3.60107
1.309 .277 -1.667 11 .124 -9.4167 5.64824 -21.84835 3.01502
-1.743 9.577 .113 -9.4167 5.40227 -21.52605 2.69272
.476 .510 -2.321 8 .049 -12.2083 5.25900 -24.33561 -.08106
-2.230 5.700 .070 -12.2083 5.47512 -25.77838 1.36172
.007 .935 -1.337 7 .223 -4.5950 3.43623 -12.72040 3.53040
-1.331 6.444 .228 -4.5950 3.45264 -12.90428 3.71428
.401 .539 -.790 11 .446 -12.6833 16.05513 -48.02043 22.65377
-.827 9.478 .429 -12.6833 15.33795 -47.11512 21.74845
.568 .467 -.961 11 .357 -23.5952 24.54279 -77.61356 30.42309
-.968 10.910 .354 -23.5952 24.38407 -77.31831 30.12783
.144 .711 -1.624 12 .130 -24.7500 15.24260 -57.96077 8.46077

































































































t-test for Equality of Means
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Univariate Analysis in African descent TT vs. TC+CC
Covariate: baseline plasma aldosterone levels

















Mean Std. Deviation N
Levene's Test of Equality of Error Variancesa
Dependent Variable: CHGPA
1.839 1 12 .200
F df1 df2 Sig.
Tests the null hypothesis that the error variance of
the dependent variable is equal across groups.
Design: Intercept+PA_B+CY_CODEa. 
Tests of Between-Subjects Effects
Dependent Variable: CHGPA
6335.668a 2 3167.834 6.546 .013 .543
2566.653 1 2566.653 5.303 .042 .325
4235.453 1 4235.453 8.752 .013 .443













of Squares df Mean Square F Sig.
Partial Eta
Squared




-21.953a 9.168 -42.132 -1.774




Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated at the following
values: PA_B = 63.5714.
a. 
Univariate Analysis in African descent TC+CC
Covariate: baseline plasma aldosterone levels




Mean Std. Deviation N
Tests of Between-Subjects Effects
Dependent Variable: CHGPA
2992.085a 1 2992.085 9.610 .036 .706
660.950 1 660.950 2.123 .219 .347












of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .706 (Adjusted R Squared = .633)a. 
Grand Mean
Dependent Variable: CHGPA
-16.500a 7.204 -36.500 3.500
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated
at the following values: PA_B = 53.5000.
a. 
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Univariate Analysis in African descent TT
Covariate: change in BMI




Mean Std. Deviation N
Tests of Between-Subjects Effects
Dependent Variable: CHGNA
8298.154a 1 8298.154 9.894 .026 .664
7317.986 1 7317.986 8.725 .032 .636












of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .664 (Adjusted R Squared = .597)a. 
Grand Mean
Dependent Variable: CHGNA
14.429a 10.946 -13.709 42.566
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated
at the following values: CHGBMI = -1.6000.
a. 
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Dependent T-test Individuals of African descent TT Genotype Group
Paired Samples Statistics
25.9333 6 2.15932 .88154
25.5833 6 1.99741 .81544
35.3167 6 7.34586 2.99893
35.1833 6 9.06651 3.70139
43485.00 6 9850.52496 4021.460
43249.83 6 10191.83539 4160.799
129.2833 6 9.14799 3.73465
128.0000 6 11.77268 4.80618
84.7400 5 5.08360 2.27346
81.4200 5 5.22178 2.33525
119.3333 6 44.69750 18.24768
110.1667 6 50.21719 20.50108
47.5000 6 15.01666 6.13052
52.4167 6 12.65487 5.16633
1668.8333 6 384.75988 157.07756
1621.8333 6 545.02456 222.50534
53.5000 6 35.67492 14.56423
37.0000 6 19.35975 7.90359
22.1333 6 2.20151 .89876
25.5833 6 4.25602 1.73751
1.6140 6 .27134 .11077
1.8498 6 .44893 .18328
72.5000 6 7.68583 3.13773





















































.3500 .78166 .31911 -.4703 1.1703 1.097 5 .323
.1333 2.76164 1.12744 -2.7648 3.0315 .118 5 .910
235.1667 1065.39165 434.94432 -882.8933 1353.2266 .541 5 .612
1.2833 7.55630 3.08485 -6.6465 9.2132 .416 5 .695
3.3200 5.03905 2.25353 -2.9368 9.5768 1.473 4 .215
9.1667 42.22519 17.23836 -35.1460 53.4793 .532 5 .618
-4.9167 18.97329 7.74581 -24.8279 14.9946 -.635 5 .553
47.0000 628.41579 256.54967 -612.4819 706.4819 .183 5 .862
16.5000 29.11185 11.88486 -14.0510 47.0510 1.388 5 .224
-3.4500 2.38390 .97322 -5.9518 -.9482 -3.545 5 .016
-.2358 .17882 .07300 -.4235 -.0482 -3.230 5 .023
1.0167 2.19765 .89719 -1.2896 3.3230 1.133 5 .309
BMI_B - BMI_FPair 1
TFAT_B - TFAT_FPair 2
LBW_B - LBW_FPair 3
SBP_B - SBP_FPair 4
DBP_B - DBP_FPair 5
NA_B - NA_FPair 6
K_B - K_FPair 7
TV_B - TV_FPair 8
PA_B - PA_FPair 9
VO2REL_B - VO2REL_FPair 10
VO2AB_B - VO2AB_FPair 11








t df Sig. (2-tailed)
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Regression Among the Individuals of African descent: TT Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGSBPb. 
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Regression Among the Individuals of African descent: TT Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHDBPb. 
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Regression Among the Individuals of African descent: TT Genotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGNAb. 
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Regression Among the Individuals of African descent: TC+CCGenotype Group
Predictor: change in plasma aldosterone levels




























Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGSBPb. 
Mean Std. Deviation N
CHGSBP 10.9250 9.04668 4
CHGPA 2.2500 24.39091 4
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Regression Among the Individuals of African descent: TC+CCGenotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHDBPb. 
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Regression Among the Individuals of African descent: TC+CCGenotype Group
Predictor: change in plasma aldosterone levels

































Predictors: (Constant), CHGPAa. 
ANOVAb









Squares df Mean Square F Sig.
Predictors: (Constant), CHGPAa. 
Dependent Variable: CHGNAb. 
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